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Despite the high degree of similarities that bind humanity together as a species, 
considerable diversity exists between individual patients.1 All patients are indi-
viduals and often respond differently to identical treatments despite similar 
diagnosis.2 For instance in oncology, patients with similar histological features, 
stages and grades of cancer have a broad range of outcomes. Some patients 
may respond to treatment; others do not.3 This natural variation can be defined 
as variability. Unfortunately, the large part of this variability in treatment re-
sponse is often not readily predictable before treatment.2 The part of this varia-
bility that can be explained by certain patient characteristics is defined as pa-
tient heterogeneity. These patient characteristics may include demographics 
(e.g. age, gender, income), preferences (e.g. attitude, beliefs, risk tolerance) 
and clinical characteristics (e.g. disease severity, disease history, genetic 
profile).4 Patient heterogeneity should be distinguished from treatment hetero-
geneity, which refers to differences in the nature of the treatment (e.g. differ-
ences in treatment dose or technique). Patient heterogeneity is increasingly 
acknowledged in clinical practice through anticipating on predictable differences 
in treatment response and aiming to tailor treatments to individual patients 
based on this information.3,5 It is considered one of the great challenges for 21st 
century medicine to deliver effective therapies that are tailored to an individual6 
to enable so-called personalized medicine; ‘the right treatment for the right 
person’. The promise of personalized medicine is that it will improve treatment 
efficacy, reduce toxicity and minimize costs.7 This minimization of costs can be 
considered valuable in the light of the accelerating healthcare costs and the 
growing attention on costs of expensive novel medicines and technologies. 
Economic evaluations are increasingly employed to examine the costs of novel 
medicines and technologies in relation to its effects. Ideally this evaluation is 
based on all relevant evidence. Patient heterogeneity may affect different input 
parameters that are used in an economic evaluation: baseline risks, relative 
treatment effects, health state utility and resource utilization.4 Differences in unit 
costs, are more likely to result from differences between geographical regions 
and are thus unlikely to originate from differences between patients.4 Similarly 
as mentioned above for clinical practice, acknowledging patient heterogeneity in 
economic evaluations would be beneficial as it potentially improves the effec-
tiveness and/or efficiency of health care.4 Patient heterogeneity is, however, 
often neglected in economic evaluations.8 This thesis focuses on the role of 
patient heterogeneity in economic evaluation. We hypothesize that it is feasible 
and informative to acknowledge patient heterogeneity in economic evaluation. 
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Health technology assessment 
Western societies are facing dramatically increasing healthcare costs. This 
includes the skyrocketing costs of cancer care, which are mainly caused by the 
ageing population and costly new treatments.9,10 Considering these escalating 
costs, the subsequent rising insurance premiums and the finite healthcare 
budgets, available resources should be allocated as efficient as possible and 
choices between healthcare technologies have to be made. This implies re-
stricting reimbursement in the statutory package of insured care, to healthcare 
technologies that provide acceptable value for their money. Health Technology 
Assessments (HTA) is a field of research that aims to inform health policy 
makers in these decisions by examining the medical, economic, social and 
ethical implications of a medical technology in healthcare.11 In this context, a 
technology can be anything from preventive screening, pharmaceuticals, medi-
cal devices and surgical procedures to the organization of healthcare.11 Eco-
nomic evaluation is a frequently used tool for HTA to compare the costs and 
consequences of different healthcare technologies. These consequences or 
effects are often expressed in terms of Quality Adjusted Life Years (QALYs).12  
The QALY is a product of the quantity and the quality of life lived. It is a com-
bined measure that captures both life expectancy and generic health-related 
quality of life (HRQOL) in a single value. HRQOL is often measured using 
disease-specific measures such as the European Organization for Research 
and Treatment of Cancer, Quality of Life Questionnaire-C 30 (EORTC-QLQ-
C30). Although disease-specific measures of HRQOL are relevant for patients 
and physicians, their main disadvantage is the inability to compare HRQOL 
between different disease areas. In contrast, generic HRQOL can be compared 
in different disease areas. Generic HRQOL in terms of utility scores can be 
used to calculate QALYs. In this calculation life expectancy is corrected with 
quality weights, using utility scores, which are based on preferences for different 
outcomes and measured on an interval scale.12 Utility scores indicate the pref-
erence for a certain health state; the more preferable a health state, the more 
utility associated with it.12 These preferences can be measured from the pa-
tients’ perspective by inquiring how patients value their own health status or 
from the general public perspective based on the preferences of society. Direct 
or indirect methods can be used to elicit utility scores for certain health states. 
Direct methods are often complex and time consuming. Indirect methods to 
elicit utility scores might be preferred to bypass these disadvantages and to 
measure utility scores from a societal perspective.12,13 Indirect methods include 
multi-attribute health status classification systems using generic preference 
questionnaires. The EuroQol-5D questionnaire14 (EQ-5D) is the most frequently 
used multi-attribute health status classification system. The EQ-5D consists of 
questions regarding five dimensions of generic HRQOL (mobility, self-care, 
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usual activities, pain/discomfort and anxiety/depression).14 The answers to 
these questions can be combined to calculate utility scores using a scoring 
function based on the societal perspective. Calculated utility scores range from 
less than 0 (health state worse than death, severe problems in all five dimen-
sions), through 0 (death) to 1 (full health, no problems in all dimensions).14 
Ideally, economic evaluations consider all relevant evidence with regard to the 
costs and consequences and compare the full range of available treatment 
options. Meta-analyses are often necessary to satisfy these requirements and 
combine results from different studies or sources. For instance, meta-analysis 
can be used to synthesize available effectiveness data retrieved from multiple 
randomized controlled trials. Decision-analytical models can then act as an 
analytical framework to combine this evidence synthesis with other types of 
evidence such as quality of life data, data on resource use and unit prices.15 
Ultimately, all parameters in these model-based economic evaluations are 
based on a meta-analysis or other form of synthesis of available evidence.15 
Based on these data, decision-analytic models aim to reflect the course of a 
disease to compare the costs and consequences of competing interventions. 
More specifically, economic evaluations aim to inform two distinct but connected 
questions:16 
1. whether current evidence suggests that the new treatment is cost-effective 
compared to current practice and;  
2. whether further research into this matter would be worthwhile. 
 
The answer to the first question depends on the differences in costs and QALYs 
between the treatments of interest, and the amount of money that society is 
willing to pay per gained QALY. This amount is referred to as the ceiling ratio. 
This is illustrated with an example considering a new treatment that leads to an 
average gain in QALYs of 0.100 and is on average €10,000 more expensive 
compared with current practice. These average incremental outcomes are 
presented (diamond) in Figure 1.1. The diagonal line represents a ceiling ratio 
of €80,000 per QALY gained. This is the informal ceiling ratio for a high burden 
of disease in the Netherlands.17 As the diamond is above this ceiling ratio, this 
new treatment is not deemed cost-effective and should not be reimbursed 
based on this information. However, average cost-effectiveness estimates, as 
presented in Figure 1.1, are inevitably surrounded by uncertainty. As a result, it 
is possible that based on current information, the ‘wrong’ decision is being 
made. Therefore, it is essential to characterize uncertainty in economic evalua-
tions. This decision uncertainty is often incorporated in economic evaluations by 
reflecting the uncertainty in the input parameters of the economic evaluation 
representing that we do not know the exact estimates.15 The eclipse in Figure 
1.2 reflects this parameter uncertainty (or sampling uncertainty) surrounding the 
average cost-effectiveness. As illustrated in this Figure, there is a substantial 
probability that the ‘true’ cost-effectiveness estimate for the new treatment falls 
C H A P T E R  1  
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Figure 1.1: Incremental cost-effectiveness plane 
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Figure 1.2: Incremental cost-effectiveness plane with estimated parameter uncertainty 
surrounding the average cost-effectiveness 
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below the ceiling ratio and would thus be cost-effective. This decision uncertain-
ty is considered in the second question. The second question examines wheth-
er further research would be valuable to reduce the decision uncertainty and 
(re-)inform the reimbursement decision in the future. This can be quantified by 
using the expected value of perfect information analysis to assess the expected 
costs of available decision uncertainty. This is assessed by considering the 
certainty that the new treatment is cost-effective and the consequences if adopt-
ing the new treatment turns out to be the wrong decision (based on future 
information).15  
The two questions mentioned above are usually informed by presenting the 
average cost-effectiveness for a group of patients.12,18 Although parameter 
uncertainty is often considered in these economic evaluations (as in Figure 1.2), 
variability and patient heterogeneity, are frequently neglected in average cost-
effectiveness estimates and subsequent reimbursement and research deci-
sions.8 Neglecting these genuine differences between patients might mask 
important variations in cost-effectiveness.18,19 At the same time, as mentioned 
above, in clinical practice it is recognized that average outcomes may not apply 
to the individual patient.20,21 Thus, in contrast with individualized decisions in 
clinical practice, differences between individual patients are frequently neglect-
ed in economic evaluations and subsequent population-based reimbursement 
decisions.4,8 
Personalized reimbursement decisions 
Economic evaluations are often aimed to inform reimbursement decisions. 
Hence, neglecting patient heterogeneity in economic evaluations impacts the 
allocation of resources. This may lead to inefficiency if a treatment is not cost-
effective for certain subgroups while it is reimbursed for all patients. For in-
stance, in Figure 1.3, it becomes clear that the average cost-effectiveness 
estimate as presented in Figure 1.1 does not apply to all patients. In Figure 1.3 
the dots (females) and crosses (males) represent individual patients. As shown, 
the effectiveness and cost-effectiveness differs per individual patient. The 
diamond again represents the average cost-effectiveness. Based on average 
cost-effectiveness estimates for all patients, the new treatment might not be 
reimbursed for the total group, although there are subgroups of patients for 
whom it is expected to be cost-effective, potentially leading to a suboptimal 
allocation of available resources. 
Average population-based cost-effectiveness might also be suboptimal for 
reimbursement decisions if a treatment is not cost-effective for certain sub-
groups while these subgroups do receive this treatment since it is cost-effective 
on average. Again, this would lead to a suboptimal allocation of available re-
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sources. Therefore, a more individualized approach to the allocation of re-
sources by providing and/or restricting treatment reimbursement to subgroups 
of patients (instead of one decision for all), has the potential to increase popula-
tion health gains.18,19,22,23 For instance, as illustrated in Figure 1.3, the new 
treatment would be cost-effective on average for females (triangle below the 
ceiling ratio) while it is not on average cost-effective for males (triangle above 
the ceiling ratio). Therefore, reimbursing the new treatment for females and not 
for males would lead to a more optimal allocation of available resources than 
not reimbursing the new treatment for all patients. In this example, this would 
lead to improvements in terms of effectiveness (average QALY gain: 0.060) and 
cost-effectiveness (average net monetary benefit gain: €1,570). 
Next to these potential gains in terms of effectiveness and/or cost-effectiveness, 
acknowledging patient heterogeneity is considered one of the quality criteria for 
good practice in economic evaluations.24 Attempts have been made to 
acknowledge patient heterogeneity in economic evaluations by using stratified 
analysis,22 regression techniques,25-27 and/or estimating the expected value of 
individualized care.28 Despite these incentives, patient heterogeneity is fre-
quently neglected in current economic evaluations and subsequent policy 
decisions.8 This frequent neglect might in part be explained by a lack of guid-
ance how to acknowledge patient heterogeneity, the large demand of data 
associated with the analyses and ethical or equity concerns when excluding 
patient subgroups. Firstly, guidance seems to be lacking on how and when to 
acknowledge patient heterogeneity.4,18 Hence, there might be an important role 
for pharmacoeconomic guidelines. These pharmacoeconomic guidelines pro-
vide essential guidance how economic evaluations, with the purpose to support 
reimbursements decision-making, should be performed within a jurisdiction. 
Secondly, in addition to this lack of guidance, patient heterogeneity might be 
neglected because of the potentially large demand of data and the computa-
tional burden associated with the analysis. Also, from a decision-making per-
spective, the awareness of this large data demand may lead to a priori concerns 
on the quality of the evidence (e.g. concerns regarding type I errors). Prefera-
bly, the analyses are based on individual patient data.29 In case these data are 
absent, average outcomes of comparative effectiveness research can be used. 
Acknowledging patient heterogeneity in economic evaluation becomes chal-
lenging if comparative effectiveness research is lacking. As comparative effec-
tiveness research is often lacking in the early phase of new medical technolo-
gies, lacking data might impose a serious barrier to the acknowledgement of 
patient heterogeneity in (early) economic evaluations. Thirdly, ethical concerns 
may arise when acknowledging patient heterogeneity in policy decisions. For 
instance, ethical concerns may arise if a new treatment is effective and cost-
effective on average, but is not cost-effective for males. In this case, it is ques-
tionable whether it would be deemed ethical to discriminate between patients 
based on gender and to reimburse a treatment, which is effective for all pa-
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tients, only for females. Thus, it is open to discussion whether it is justified to 
withhold treatments from subgroups (e.g. males) for reasons of efficiency alone. 
These normative considerations and unawareness how to deal with them might 
lead to the neglect of patient heterogeneity. 
Innovative radiotherapy treatments 
Radiotherapy either alone or combined with other modalities such as chemo-
therapy and surgery, is an important and commonly used modality in the treat-
ment of cancer (40-50% of all cancer cases).30 In the past decade, innovations 
in radiotherapy planning and delivery have evolved rapidly. These technological 
advances provide unique opportunities to improve the precision and potentially 
also the effectiveness of radiotherapy. However, on the other hand these inno-
vations are also associated with rising costs.31,32 As a result, the costs of radio-
therapy and the total costs of oncology care are expected to accelerate while 
available resources are becoming restrained.9,10 Therefore, many countries 
require evidence on the cost-effectiveness of new treatments before a treatment 
is reimbursed in the statutory package of insured care.31 Evidence on the effec-
tiveness and cost-effectiveness of innovative treatments should ideally be 
retrieved from a randomized controlled trial to achieve the highest grade of 
evidence and firm recommendations.33 Although new oncology drugs are gen-
erally evaluated in randomized controlled trials, for innovative radiotherapy 
technologies this is more complex and as a result comparative studies are 
frequently lacking. Accordingly, innovative radiotherapy technologies are often 
rapidly introduced into clinical practice without performing comparative studies 
and while considerable uncertainty still exists about its effectiveness and cost-
effectiveness.31 This rapid introduction is often based on the presumption that 
dosimetric advantages will eventually lead to better treatment outcomes, as 
innovative radiotherapy technologies typically result in an improved dose distri-
bution or a more accurate dose delivery. Nevertheless, it is often uncertain to 
what extent the surrogate outcomes in terms of dosimetric advantages will 
eventually translate in better patient outcomes. Dose-response models, in terms 
of normal tissue complication probability (NTCP) and tumor control probability 
(TCP) models, can be helpful to translate these dosimetric advantages in clini-
cal outcomes.  
Another challenge is that innovative radiotherapy technologies often involve 
substantial investments costs in terms of equipment, quality assurance, and 
additional training of staff. These costs are to a large extend irreversible and 
thus cannot be recovered if the expected clinical benefit of the technology does 
not live up to its expectations. Therefore, assessing the costs of introducing 
novel radiotherapy technologies is more complicated than calculating the costs 
C H A P T E R  1  
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of medical drugs.31 Additionally, as mentioned above, technological advance-
ments frequently lead to substantially higher costs (e.g. particle radiotherapy, 
intensity-modulated radiotherapy and positron emission tomography for treat-
ment planning).34 As a result, with regards to the challenges associated with 
estimating the effectiveness and costs of innovative radiotherapy technologies, 
it is often unknown whether these rapidly introduced treatments represent good 
value for money. 
The technological advancements in radiotherapy are increasingly being used to 
strive towards individualized treatments instead of traditional treatment based 
on disease stage.30,35 These individualized treatment strategies require predic-
tion models or predictive tests to estimate which treatment is optimal for which 
patient. It might be challenging to attain these predictive models or tests when 
comparative effectiveness research is frequently lacking for novel radiotherapy 
technologies. Additionally, in case comparative effectiveness research is avail-
able, the body of knowledge related to average outcomes is typically much 
larger than for subgroup outcomes, which is required to explore patient hetero-
geneity.36 This evidence gap hinders the implementation of individualized treat-
ments and makes it challenging to acknowledging patient heterogeneity in cost-
effectiveness analysis considering innovative radiotherapy treatments. 
Dissertation objective 
The objective of this thesis was to examine recommendations and to explore 
methodology to acknowledge patient heterogeneity in economic evaluation 
(Figure 1.4). This objective was subdivided into two aims: 
1. To examine recommendations in pharmacoeconomic guidelines on ac-
knowledging patient heterogeneity in economic evaluations (Part I).  
2. To explore innovative methodology to acknowledge patient heterogeneity in 
economic evaluations in case a) comparative studies are lacking and; b) if 
individual patient data are available (Part II). 
 
Two case studies in the field of radiotherapy will be used to address the second 
aim. The first case study aims to acknowledge patient heterogeneity in econom-
ic evaluations in case comparative studies are lacking, as if often the case for 
novel radiotherapy technologies.31 The second case acknowledges patient 
heterogeneity in case comparative studies are available in terms of individual 
patient data from randomized controlled trials.  
G E N E R A L  I N T R O D U C T I O N  A N D  O U T L I N E  
 
19 
Dissertation outline 
Chapter 2 considers the first aim by reviewing and analyzing available national 
pharmacoeconomic guidelines on recommendations with regard to acknowledg-
ing patient heterogeneity in economic evaluations. 
The subsequent three chapters consider aim 2a by using a case study wherein 
proton and photon radiotherapy are compared for head and neck cancer. In 
Chapter 3, all available clinical and dosimetric evidence is synthesized to 
compare the effectiveness of proton and photon radiotherapy for head and neck 
cancer. Chapter 4 considers a multi-center cross-sectional study wherein the 
health related quality of life (HRQOL) is measured in head and neck cancer 
patients and the impact of treatment related toxicity on HRQOL is analysed. In 
Chapter 5, a model-based economic evaluation is presented to assess the 
cost-effectiveness in this first case study while acknowledging patient heteroge-
neity.  
In Chapter 6, aim 2b is considered by means of a model-based economic 
evaluation for non-small cell lung cancer wherein modified fractionation radio-
therapy schemes are compared with conventional fractionation radiotherapy 
while acknowledging patient heterogeneity. This economic evaluation is based 
on individual patient data from 10 randomized controlled trials.  
Finally, in Chapter 7 a general discussion is presented which ends with con-
cluding remarks and future perspectives.  
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Abstract 
Objective: To review and analyse recommendations from national pharmaco-
economic guidelines with regard to acknowledging patient heterogeneity in 
economic evaluations. 
Methods: National pharmacoeconomic guidelines were obtained through the 
ISPOR website. Guidance was extracted using a developed data extraction 
sheet. Extracted data were divided into subcategories based on consensus 
meetings. 
Results: Of the 26 included guidelines, 20 (77%) advised to identify patient 
heterogeneity. Most guidelines (77%) provided general methodological advice 
to acknowledge patient heterogeneity; including justifications for distinguishing 
subgroups (65%), prespecification of subgroups (42%) or methodology to 
acknowledge patient heterogeneity (77%). Stratified analysis of cost-
effectiveness was most commonly advised (20 guidelines; 77%), however, 
guidance on the specific application of methods was scarce (nine guidelines; 
34%) and generally limited if provided. Guidance to present patient heterogenei-
ty was provided by 15 guidelines (58%), most prominently to describe the 
definition (31%) and justification (31%) of subgroups. 
Conclusions: The majority of national pharmacoeconomic guidelines provide 
guidance on acknowledging patient heterogeneity in economic evaluations. 
However, since guidance is mostly not specific, its usefulness is limited. This 
may reflect that the importance of acknowledging patient heterogeneity is 
usually recognized while there is a lack of consensus on specific methods to 
acknowledge patient heterogeneity. We advise the further development of 
national pharmacoeconomic guidelines to provide specific guidance on the 
identification of patient heterogeneity, methods to acknowledge it and present-
ing the results. We present a checklist which can assist in formulating these 
recommendations. This could facilitate the systematic and transparent handling 
of patient heterogeneity in economic evaluations worldwide. 
 
Keywords: Patient heterogeneity; National pharmacoeconomic guideline; 
Economic evaluation; Systematic review 
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Introduction 
Considering the rapidly increasing healthcare costs and the finite amount of 
available resources, the criteria to grant reimbursement to new treatments have 
become more restricted. These reimbursement decisions are often made for 
groups of patients. However, a more individualized approach for the allocation 
of available resources, i.e. providing treatment reimbursement for subgroups of 
patients, has the potential to increase population health gains.1-4 Acknowledging 
patient heterogeneity in reimbursement decisions may lead to more efficient 
healthcare if these reimbursement decisions are based on cost-effectiveness.5 
As economic evaluations are frequently used to estimate cost-effectiveness and 
support reimbursement decision-making,6 it is essential that patient heterogene-
ity is incorporated in economic evaluations. Although there is consensus on its 
importance,7 patient heterogeneity is frequently neglected in economic evalua-
tions.8 
Patient heterogeneity might be neglected since subgroup policy sometimes is 
controversial due to ethical concerns. This may lead to equity constraints, 
where the use of certain characteristics is considered unacceptable to deter-
mine which subgroups have access to a technology. The acknowledgement of 
patient heterogeneity in economic evaluations seems also hampered by a lack 
of clarity on when and how this should be done.2,9 In this respect, there is an 
important role for national pharmacoeconomic guidelines. National pharmaco-
economic guidelines provide essential guidance how economic evaluations, 
with the purpose to support reimbursements decision-making, should be per-
formed within a jurisdiction. The objective of this study was therefore to review 
and analyse recommendations from national pharmacoeconomic guidelines 
with regard to acknowledging patient heterogeneity in economic evaluations.  
Methods 
Definition of patient heterogeneity 
Patient heterogeneity was defined as the part of the natural variation between 
patients (variability) that can be attributed to characteristics of those 
patients6,9,10. This was differentiated from treatment variability (differences in the 
nature of the treatment), differences between geographical regions that may 
impact cost-effectiveness and statistical heterogeneity. These concepts relate 
more to the generalizability of cost-effectiveness results9,11 and variation in 
outcomes between studies (e.g. included in a meta-analysis) and are beyond 
the scope of this review.  
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Characteristics that potentially explain patient heterogeneity include de-
mographics (e.g. age, gender, income), preferences (e.g. attitude, beliefs, risk 
tolerance) and/or clinical characteristics (e.g. disease severity, disease history, 
genetic profile).9 These sources of patient heterogeneity may impact on different 
input parameters used in an economic evaluation: baseline risks, relative treat-
ment effects, health state utility and resource utilization.9 Differences in unit 
costs are more likely a result of differences between geographical regions and 
are thus not considered in this review.9,12 
Search strategy and data extraction 
Consistent with previous reviews of national pharmacoeconomic guidelines,12,13 
national pharmacoeconomic guidelines were obtained through the link provided 
on the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) website (accessed February 22th, 2013)14 and retrieved from the 
website of the guideline agencies. This was done to ensure that the most recent 
versions were retrieved. The ISPOR website was considered a reliable and 
valid source as the overview of national pharmacoeconomic guidelines is based 
on contacts with experts from approximately 60 countries from around the 
world.12 Guidelines were included if they were available in English. To systemat-
ically extract relevant guidance, we used a data extraction sheet (Appendix 2.1) 
containing the following categories:  
1. Acknowledgement of patient heterogeneity: 
whether guidelines advised to identify patient heterogeneity and whether a 
distinction is made between different inputs of an economic evaluation: 1) 
baseline risk, 2) relative treatment effect, 3) health state utility and 4) re-
source utilization. 
2. Methodology to acknowledge patient heterogeneity: 
whether guidelines advised methodology to acknowledge patient heteroge-
neity. This contains guidance whether to justify for acknowledging patient 
heterogeneity (including equity constraints), guidance whether to prespecify 
potential sources of patient heterogeneity, general methods and the specific 
application of methods to acknowledge patient heterogeneity.  
3. Presentation of patient heterogeneity: 
whether guidelines advised what should be presented when acknowledging 
patient heterogeneity. 
Data were extracted and categorized (into the abovementioned categories) by 
one author (BR). Extracted data from all guidelines were divided into subcate-
gories. If the classification of guidance was ambiguous, it was independently 
judged by the other authors (JG and MJ). Possible discrepancies were dis-
cussed to reach consensus.  
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Results 
In total 33 guidelines were retrieved. Seven guidelines were excluded since 
they were not available in English.15-21 This accumulated to 26 included guide-
lines, published between 1997 and 2012.22-47 
Acknowledgement of patient heterogeneity 
Most guidelines (20; 77%) advise to identify patient heterogeneity in general.22-
41 Thirteen guidelines (50%) explicitly consider it relevant to identify the impact 
of patient heterogeneity on effects in general (irrespective of whether it has an 
impact on the baseline risk and/or treatment effect).22-34 Seven guidelines (27%) 
specify this into differences in baseline risk and treatment effect and consider 
them both as relevant.22-28 Additionally, four guidelines consider it relevant to 
reflect the impact of patient heterogeneity on health state utility.24,26,29,31 Nine 
guidelines (35%) consider differences in resource utilization as relevant input to 
acknowledge patient heterogeneity.23-26,28,30,31,33,34 None of the guidelines advise 
not to identify patient heterogeneity in any of these four key inputs of an eco-
nomic evaluation. 
Methodology to acknowledge patient heterogeneity in economic 
evaluations 
Methodological guidance on acknowledging patient heterogeneity is provided by 
20 guidelines (77%).22-41 
Arguments to justify acknowledging patient heterogeneity in economic 
evaluations 
Arguments to justify acknowledging patient heterogeneity are required by 17 
guidelines (65%).22-32,34-39 Only the England and Wales guideline25 lists equity 
constraints (Table 2.1). Instead of neglecting subgroups based on a particular 
equity point of view, the Canadian guideline24 proposes to calculate the oppor-
tunity costs of equity concerns using the framework proposed by Coyle et al.1 
These opportunity costs can be interpreted as the costs of neglecting sub-
groups based on grounds of equity. Hence, this framework aims to inform the 
tradeoff between equity and efficiency.1 Additionally, the German guideline 
states that only subgroups should be addressed for which an additional benefit 
or lesser harm was established.40 
Specification of potential sources of patient heterogeneity 
Eight guidelines (31%),22,24-27,30,32,37 advise to prespecify potential sources of 
patient heterogeneity (Table 2.1). The French guideline considers posthoc 
multivariate analysis acceptable to explore patient heterogeneity.29 Posthoc 
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analysis is allowed under certain conditions by eight guidelines (31%): only for 
differences in costs,23 with (strong) justification24,28 and/or if interpreted as 
explorative,23 with caution22,26,27 or hypothesis generating.24,32 
 
Table 2.1: Overview of advice on methodology from guidelines to acknowledge patient 
heterogeneity 
 Guidelines Countries 
Total 
20 (77%)   
AU, BC, BE, CA, EW,
FI, FR, DE, HU, IE, IT,
NZ, NO, PL, PT, SL,
ZA, ES, SE, US 
A Guidelines that advised to justify for acknowledging 
patient heterogeneity  17 (65%)  
AU, BC, BE, CA, EW,
FI, FR, HU, IE, NZ, NO,
PL, PT, SL, ZA, SE, US 
 Specific guidance:     
 • If plausible based on (pre)clinical evi-
dence/pharmacokinetics 
  11 (42%) 
AU, BC, BE, EW, FR,
HU, IE, NZ, PT, ZA, US 
 • If plausible based on a priori expectations of cost-
effectiveness 
  7 (27%) 
BC, BE, EW, HU, IE,
SE, US 
 • If biologically plausible   5 (19%) AU, EW, IE, NZ, SL 
 • If statistically plausible   4 (15%) AU, FR, NZ, ZA 
 • If patients for whom it is most (cost-)effective can be 
targeted/if relevant for decision 
  4 (15%) NZ, NO, ZA, US 
 • If relevant for distributive aspects/if patient groups likely 
to be disadvantaged can be targeted 
  2 (8%) CA, FR 
 • If informative for value based pricing   1 (4%) FI 
 • If subgroups are within the approved indication   1 (4%) ZA 
 • If not solely based on: 1) individual utilities for health 
states and patient preferences, or 2) differential 
treatment costs for individuals according to their social 
characteristics  
  1 (4%) EW 
B Guidelines that advised to prespecify potential sources 
of patient heterogeneity 
 11 (42%)  
AU, BE, CA, EW, FR,
HU, IE, NZ, PT, SL, ZA 
 Specific guidance:     
 • Prespecify subgroups   8 (31%) 
AU, CA, EW, HU, IE,
NZ, PT, ZA 
 • Interpret posthoc analysis as explorative/as hypothesis 
generating/ with caution 
  6 (23%) AU, BE, CA, IE, NZ, PT 
 • Adhoc data mining should be avoided   3 (12%) BE, EW, SL 
 • Posthoc analysis are only allowed with (strong) 
justification 
  2 (8%) CA, SL 
 • Posthoc analysis only for differences in costs   1 (4%) BE 
 • Posthoc multivariate analysis is acceptable to explore 
patient heterogeneity 
  1 (4%) FR 
Country codes according to the ISO 3166-1 Alpha-2 if applicable: Australia22 = AU, Baltics (Latvia, 
Estonia and Lithuania)34 = BC*, Belgium23 = BE, Canada24 = CA, England and Wales25 = EW*, 
Finland35 = FI, France29 = FR, Germany40 = DE, Hungary30 = HU, Ireland26 = IE, Israel41 = IL, New 
Zealand27 = NZ, Norway36 = NO, Poland31 = PL, Portugal32 = PT, Scotland28 = SL*, South Africa37 = 
ZA, Spain33 = ES, Sweden38 = SE, United States39 = US 
*Unofficial codes 
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Table 2.1 (continued): Overview of advice on methodology from guidelines to acknowledge 
patient heterogeneity 
 Guidelines Countries 
C Guidelines that advised how to acknowledge patient 
heterogeneity in economic evaluations  20 (77%)  
AU, BC, BE, CA, EW,
FI, FR, DE, HU, IE, IT,
NZ, NO, PL, PT, SL,
ZA, ES, SE, US 
 Suggested methods:     
 • Stratified analysis 
  20 (77%) 
AU, BC, BE, CA, EW,
FI, FR, DE, HU, IE, IT,
NZ, NO, PL, PT, SL,
ZA, ES, SE, US 
 • Decision analytic modelling   3 (12%) FR, DE, SL 
 • Sensitivity analysis/scenario analysis   3 (12%) AU, CA, EW 
 Specific advice on the application of methods:     
 • Statistical precision of subgroups estimates should be 
reflected in the analysis of parameter uncertainty 
  3 (12%) CA, EW, SL 
 • Calculate the impact of variability in baseline risk by 
multiplying the expected baseline risk across patient 
subgroups by the overall relative treatment effect 
(established in the whole population) 
  3 (12%) AU, BE, NZ 
 • Meta-regression to determine whether a treatment 
effect varies across patient groups 
  2 (8%) AU, SL 
 • Calculate the impact of variability in absolute treatment 
effect by applying the estimated relative treatment 
effect for the subgroups to the expected baseline risk 
for the subgroups 
  1 (4%) AU 
 • Discrete event simulation    1 (4%) DE 
 • Sensitivity analysis for equity concerns and subgroup 
thresholds 
  1 (4%) AU 
 • Scenario analysis for treatment continuation rules   1 (4%) EW 
 • Multivariate analysis to evaluate treatment effective-
ness depending on patient characteristics 
  1 (4%) FR 
 • Separate models for separate subgroups   1 (4%) CA 
 • Equivalent data for stratified analysis as for the whole 
group 
  1 (4%) FI 
 • Examine whether the relative risk is constant over 
different baseline risk 
  1 (4%) SL 
 • Explore the possibility that differences between groups 
emerge by chance  
  1 (4%) EW 
Country codes according to the ISO 3166-1 Alpha-2 if applicable: Australia22 = AU, Baltics (Latvia, 
Estonia and Lithuania)34 = BC*, Belgium23 = BE, Canada24 = CA, England and Wales25 = EW*, 
Finland35 = FI, France29 = FR, Germany40 = DE, Hungary30 = HU, Ireland26 = IE, Israel41 = IL, New 
Zealand27 = NZ, Norway36 = NO, Poland31 = PL, Portugal32 = PT, Scotland28 = SL*, South Africa37 = 
ZA, Spain33 = ES, Sweden38 = SE, United States39 = US 
*Unofficial codes 
How to acknowledge patient heterogeneity 
Most guidelines (20; 77%) provide general advice how to acknowledge patient 
heterogeneity.22-41 Stratified analysis is the most commonly advised method.22-41 
The French, German and Scottish guidelines generally advise the use of deci-
sion analytic modelling.28,29,40 Further, sensitivity and/or scenario analyses are 
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advised by the guidelines from Australia, Canada and England and Wales.22,24,25 
However, most guidelines merely provide general guidance; details on the 
specific application of methods is provided by a minority (35%) of guidelines 
(Table 2.1).22-25,27-29,35,40 
The German guideline advises a specific form of modelling: discrete event 
simulation (DES). They argue that patient heterogeneity can be incorporated 
into DES as each patient can be modeled with its unique characteristics.40 The 
Canadian guideline advises stratified cost-effectiveness analysis according to 
the framework by Coyle et al.1 to calculate the potential efficiency gain of sub-
group policy. The Australian guideline argues that meta-regression is preferred 
above stratified analysis since it allows to examine multiple covariates simulta-
neously.22 The French guideline advises the use of multivariate analysis to 
evaluate treatment effectiveness depending on patient characteristics.29 Addi-
tionally, the Australian guideline advises that the absolute treatment effect can 
be calculated in case of differences in baseline risk and/or treatment effect by 
applying the estimated relative treatment effect for the subgroups to the ex-
pected baseline risk for the subgroups.22 The Belgian and New-Zealand guide-
lines advise to multiply the expected baseline risk across patient subgroups by 
the overall relative treatment effect (assuming a constant relative treatment 
effect for all subgroups).23,27 
The Australian guideline recommends performing sensitivity analysis for equity 
concerns that affect the cost-effectiveness and subgroup thresholds for contin-
uous variables such as age.22 Additionally, the England and Wales guideline 
advises scenario analysis for treatment continuation rules.25 These rules can be 
used to adjust treatment plans based on patient heterogeneity that is revealed 
over time (e.g. differences in treatment response). The guideline provides 
guidance on the specification of treatment continuation rules focusing on the 
feasibility, robustness and equity of implementing these rules.25 Finally, the 
England and Wales guideline advises to explore the possibility that differences 
between subgroups emerge by chance, especially in case numerous subgroups 
are reported.25 
Presenting patient heterogeneity 
Guidance on presenting patient heterogeneity is provided by 15 guidelines 
(58%) (Table 2.2).22-29,31,33,34,37-40 For the methods section, the most common 
advice was to describe the definition22-25,27,28,37,40 and justification of 
subgroups.22,23,25-28,31,34 Cost-effectiveness estimates should be presented 
separately for each subgroup in the results section according to seven guide-
lines (27%).24-26,29,33,39,40 Presenting the implications of subgroup policy on 
distributional aspects is recommended by six guidelines (23%).22,24,26,29,39,40 This 
includes highlighting unmet needs of certain disadvantaged groups. The United 
States guideline advises to weigh subgroup outcomes against moral values.39 
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Detailed tables to present the assessment of treatment effects across sub-
groups are provided by the Australian guideline.22 For the discussion section, it 
was recommended to highlight biomarkers/diagnostic tests necessary to identify 
relevant subgroups,22,39 whether subgroup results lead to different conclusions 
than the overall trial results,22 the credibility of the claim to use subgroups22,39 
and the appropriate use of the intervention.24 
 
Table 2.2: Overview of advice on the presentation of patient heterogeneity from guidelines 
 Guidelines (%) Countries 
Total 
15 (58%)   
AU, BC, BE, CA, EW,
FR, DE, IE, NZ, PL, SL,
ZA, ES, SE, US 
A Present in the objective/methods section: 
 12 (46%)  
AU, BC, BE, CA, EW,
DE, IE, NZ, PL, SL, ZA,
SE 
 • Definition of subgroups   8 (31%) 
AU, BE, CA, EW, DE,
NZ, SL, ZA 
 • Justification for subgroups (prespecification or 
biological/clinical/statistical reasoning) 
  8 (31%) 
AU, BC, BE, EW, IE, NZ,
PL, SL 
 • Epidemiological data/number of persons for the 
subgroups 
  2 (8%) BE, SE 
 • How stratified analysis were undertaken, including the 
choice of scale on which any effect modification is 
defined 
 2 (8%) EW, SL 
 • Adjustments for multiple comparisons if subgroups 
were non-presepcified 
  1 (4%) AU 
 • Details of the statistical tests used   1 (4%) SL 
 • Expected differences between subgroups in methods   1 (4%) BE 
 • Used methods to identify the baseline data for stratified 
analysis 
  1 (4%) EW 
B Present in the results section:  9 (35%)  
AU, CA, EW, FR, DE, IE,
PL, ES, US 
 • Cost-effectiveness information separately for each 
subgroup 
  7 (27%) 
CA, EW, FR, DE, IE, ES,
US 
 • Implications for distributive aspects/equity    6 (23%) AU, CA, FR, DE, IE, US 
 • The impact of using the intervention for subgroups 
/how much the intervention is more cost-effective in the 
subgroups 
 2 (8%) DE, PL 
 • Subgroup results in a tornado diagram   2 (8%) CA, IE 
 • Cost-effectiveness acceptability curves/efficiency 
frontiers separately for each subgroup 
  1 (4%) IE 
 • The number of prespecified and non-prespecified 
stratified analysis 
  1 (4%) AU 
 • The subgroups "n (event) / N" per trial, overall trial 
results, treatment effect for subgroups, analysis as 
relative risk and risk difference both per trial and pooled
 1 (4%) AU 
Country codes according to the ISO 3166-1 Alpha-2 if applicable: Australia22 = AU, Baltics (Latvia, 
Estonia and Lithuania)34 = BC*, Belgium23 = BE, Canada24 = CA, England and Wales25 = EW*, 
France29 = FR, Germany40 = DE, Ireland26 = IE, New Zealand27 = NZ, Poland31 = PL, Scotland28 = 
SL*, South Africa37 = ZA, Spain33 = ES, Sweden38 = SE, United States39 = US 
*Unofficial codes 
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Table 2.2 (continued): Overview of advice on the presentation of patient heterogeneity from 
guidelines 
 Guidelines (%) Countries 
C Present in the discussion section:  3 (12%)  AU, CA, US 
 • Discuss the claim to justify the use of subgroups (e.g. 
evidence or pharmacological, biological and clinical 
plausibility for the variation in (cost-)effectiveness). 
 2 (8%) AU, US 
 • Discuss the biomarkers or other diagnostics (e.g. 
validity, reliability and feasibility for clinical practice) 
necessary to identify patient subgroups 
 2 (8%) AU, US 
 • Discuss whether subgroup results lead to different 
conclusions than the primary overall trial results. 
  1 (4%) AU 
 • Discuss the appropriate use of the intervention.   1 (4%) CA 
Country codes according to the ISO 3166-1 Alpha-2 if applicable: Australia22 = AU, Baltics (Latvia, 
Estonia and Lithuania)34 = BC*, Belgium23 = BE, Canada24 = CA, England and Wales25 = EW*, 
France29 = FR, Germany40 = DE, Ireland26 = IE, New Zealand27 = NZ, Poland31 = PL, Scotland28 = 
SL*, South Africa37 = ZA, Spain33 = ES, Sweden38 = SE, United States39 = US 
*Unofficial codes 
Discussion 
We reviewed guidance from national pharmacoeconomic guidelines with regard 
to acknowledging patient heterogeneity in economic evaluations. Although the 
majority of guidelines considered it relevant to acknowledge patient heterogene-
ity, only few specified specifically which inputs of an economic evaluation are 
relevant for this purpose. Consistently, most guidelines provide general guid-
ance on how to acknowledge patient heterogeneity (mostly stratified analysis). 
However, specific and in depth guidance on applying for instance stratified 
analysis or other methods was scarce and generally limited if provided. Also, 
guidance was “heterogeneous” between guidelines. This might reflect differ-
ences between healthcare systems or jurisdictions. For example, if cost-
effectiveness is important for reimbursement decisions, guidelines might be 
more specific and directive. This can be illustrated by England and Wales, 
where reimbursement decisions are based on cost-effectiveness outcomes, and 
which accordingly provides one of the most specific guidelines. Overall, our 
review revealed that the importance of acknowledging patient heterogeneity is 
usually recognized, while there is a lack of consensus and specific guidance on 
acknowledging and presenting patient heterogeneity. 
One study limitation was that we excluded seven guidelines which were not 
written in English. Translations of guidelines from South America and Asia 
would be helpful to obtain a complete overview. Nevertheless, with 26 included 
guidelines, this review provides a comprehensive and probably representative 
overview of guidance on handling patient heterogeneity in economic evaluation. 
Also, the review was restricted to guidelines available on the ISPOR website. 
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As a result, some guidelines may have been missed in the review. However, 
when considering that a large part of the national pharmacoeconomic guidelines 
is published in the “grey literature”, a systematic search strategy in for instance 
PubMed would most likely not lead to a representative and complete overview 
of guidelines. Alternatively, using personal knowledge and contacts to identify 
national pharmacoeconomic guidelines would potentially lead to selection bias, 
i.e. pharmacoeconomic guidelines from well-known guideline authorities (e.g. 
NICE) would be more likely to be included. In contrast, consulting the ISPOR 
website to identify national pharmacoeconomic guidelines can be regarded as a 
reproducible and thus systematic method to identify these guidelines and pro-
vide a representative overview of guidance. To our opinion, there is no better 
alternative to identify national pharmacoeconomic guidelines and consulting the 
ISPOR website can thus be regarded as the best available method for this 
purpose. Furthermore, there will certainly be subjectivity in our assessment of 
for example what is considered guidance and what is not. Hence, some of our 
evaluations may be criticized. However, by developing a data extraction sheet 
and organizing consensus meetings, we have put all efforts to keep the as-
sessments as systematic and objective as possible. Moreover, despite some 
potentially subjective judgments, this study aimed to facilitate informed discus-
sions and advance current practice of economic evaluations. Finally, our review 
was restricted to pharmacoeconomic guidelines, whereas guidelines on the 
clinical effectiveness/benefit assessment might provide recommendations on 
handling patient heterogeneity for differences in relative treatment effective-
ness. This restriction is to our opinion appropriate since economic evaluations 
have a broader perspective; they consider consequences on an absolute scale 
and include additional input parameters as baseline risk, health state utility and 
resource utilization. Additionally, health economic researchers will probably 
consult and adhere to the national pharmacoeconomic guideline.  
In addition to the limitations in the presented review, current literature and 
guidelines might sometimes be confusing concerning the handling of patient 
heterogeneity. The German guideline40 uses patient heterogeneity as an argu-
ment for patient-level simulation (DES). This argument is to our opinion incor-
rect. Patient-level simulation is not necessarily required to acknowledge patient 
heterogeneity (see for example48,49). Subgroups can for instance be modeled in 
cohort models by letting them start in different health states.50 Patient-level 
simulation is a useful alternative if this becomes too complex.9 
Although it inevitably takes time before new concepts are incorporated in guide-
lines, it is obvious that more clear and specific guidance would be useful. Ideal-
ly, guidelines would clearly state situations in which patient heterogeneity is 
considered irrelevant for decision-making in their jurisdiction (e.g. using equity 
constraints as the guideline from England and Wales25). This enables research-
ers to focus on subgroups that are potentially useful for decision-making. The 
framework presented by Grutters et al. might be valuable to systematically 
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explore which sources and inputs of patient heterogeneity are deemed 
(ir)relevant.9 Additionally, individual preferences are a special source of patient 
heterogeneity. Preference subgroups can be acknowledged by using individual 
preferences.5,51 However, it has been debated whether individual preferences 
should be incorporated in population reimbursement decisions.52-55 Subgroups 
based on individual utilities may be inconsistent with the idea that societal 
welfare should be determined by aggregating the preferences of society.56,57 
However, as proposed by Sculpher and Gafni, it is possible to acknowledge 
diversity in the preferences of individuals while maintaining the use of utility 
values of the general public.58 Guidelines should clarify how to deal with differ-
ences in individual preferences. The guideline from England and Wales for 
instance argues against subgroups solely based on individual utilities. 
Most guidelines consider patient heterogeneity that is known at the start of 
treatment. Additionally, the England and Wales guideline provides guidance to 
construct treatment continuation rules based on patient heterogeneity revealed 
over time.25 Treatment continuation rules (e.g. based on treatment response) 
can be used to adjust treatment plans after treatment start. However, it might be 
complex to attain feasible treatment continuation rules and inform actual reim-
bursement decisions based on patient heterogeneity revealed over time. There-
fore, guidelines should clarify, as the England and Wales guideline,25 how 
patient heterogeneity revealed over time should be handled. 
It is recommended that guidelines are as specific as possible when stratified 
analysis should be undertaken (e.g. what justification is required and in which 
circumstances posthoc analyses are allowed). This potentially prevents that 
subgroups are only analysed if overall cost-effectiveness is hard to show. 
Additionally, the possibility of false positives due to random noise in data might 
caution researchers or policy makers to use subgroups in their analysis or 
decision-making.9 However, these fears exist mainly from an epidemiological 
perspective.3 From a health economic perspective, the statistical significance of 
subgroups is irrelevant;59 rather its value for reimbursement decisions is rele-
vant. Certainly, this does not mean that uncertainty is irrelevant59,60 and data 
dredging should always be avoided. However, the role of stratified analysis in 
economic evaluations should to our opinion be considered based on its value 
for policy purposes (i.e. the forgone health benefits if subgroups are neglected), 
rather than from an epidemiological perspective.61 
The finding that none of the guidelines provided specific guidance how to select 
influential subgroups and determine subgroup thresholds or the optimal number 
of subgroups for continuous variables (e.g. to determine age groups) might 
reflect that there is no consensus on this topic. Thus, the selection of patient 
subgroups, particularly in case multiple (continuous) variables are considered 
simultaneously, may require further methodological research, as currently 
performed by, among others, Saramago62 and Espinoza et al63. Nevertheless 
efforts have been made in this direction, Willan, Briggs and Hoch demonstrated 
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that regression techniques can be used within the net benefit framework to 
explore and select statistically significant patient characteristics to define sub-
groups.61,64 Furthermore, Basu and Meltzer proposed a framework to estimate 
the expected value of individualized care5. By selecting potentially influential 
variables based on the parameter specific value of individualized care, this 
framework could be an alternative to the regression technique described 
above.5,65 The selected variables can subsequently be used in stratified anal-
yses by estimating the benefits of providing different treatments to different 
subgroups and hence calculating the potential value of subgroup policy.1 This 
would give decision-makers the opportunity to judge when the costs of equity 
constraints are too high.66 In decision analytic modelling, stratified analyses can 
be performed by using different input values for different subgroups. This can 
be implemented by linking input parameters to patient characteristics or by 
adding health states and letting different subgroups start out in different health 
states.4,6,9,50 
Additionally, it might be useful to provide guidance what should be presented to 
support potential reimbursement decisions based on subgroup outcomes. This 
includes for instance to describe and justify subgroups, provide guidance on 
specific tables/figures and highlighting issues as the appropriate use of the 
intervention and the feasibility of subgroup policy. These recommendations 
require a high level of prescription in guidelines, while many are currently not 
this directive. It is open to debate whether decision-makers wish to have such 
prescriptive guidelines, or prefer to leave this to the integrity of researchers. In 
our opinion, decision-makers should clearly state which results are needed for 
their appraisal and how these results should be achieved in the assessment, in 
order to support uniformity. Taking into account the differences between juris-
dictions (e.g.in terms of legislation and normative judgments), it was deemed 
impossible to formulate guidance that would be appropriate for all national 
pharmacoeconomic guidelines worldwide. Therefore, we present a checklist in 
Table 2.3 to assist national guideline authorities to formulate comprehensive 
recommendations with regards to acknowledging patient heterogeneity in 
economic evaluations on the topics identified in this review. Obviously, re-
searchers are allowed to deviate from guideline recommendations if appropri-
ately justified. However, especially when considering a normative subject where 
subgroups are potentially included or excluded from treatment reimbursement, 
guidelines should in our opinion be specific and directive. 
In conclusion, the majority of national pharmacoeconomic guidelines provide 
guidance on acknowledging patient heterogeneity in economic evaluations. 
However, since specific guidance is often lacking, its usefulness is limited. This 
may reflect that the importance of acknowledging patient heterogeneity is 
usually recognized while there is a lack of consensus on specific requirements 
and methodology to acknowledge and present patient heterogeneity in econom-
ic evaluations. We advise the further development of national pharmacoeco-
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nomic guidelines to provide specific guidance in each of the categories: the 
identification of patient heterogeneity, methods to acknowledge patient hetero-
geneity, and presenting the results when acknowledging patient heterogeneity. 
This could facilitate the systematic and transparent handling of patient hetero-
geneity in economic evaluations worldwide. 
 
Table 2.3: Checklist to formulate guidance on acknowledging patient heterogeneity in 
economic evaluation 
Acknowledgement of patient heterogeneity 
1 In economic evaluations patient heterogeneity  
   Should not be reflected  
   Should be reflected 
2 When acknowledging patient heterogeneity, the following inputs of an economic evaluation should be considered* 
   Baseline risk 
   Relative treatment effect 
   Health state utility  
   Resource utilization 
3 The following sources of patient heterogeneity should be considered* 
   Demographics 
   Preferences 
   Clinical characteristics 
Methodology to acknowledge patient heterogeneity 
4 In order to analyse different sources of patient heterogeneity* 
   No justification is required 
   This should be justified based on biological plausibility 
   This should be justified based on (pre)clinical evidence/pharmacokinetics 
   This should be justified based on statistical plausibility 
   This should be justified based on … 
5 Subgroups that are a priori not considered relevant for decision-making are those based solely on the following 
sources of patient heterogeneity 
   No subgroups are a priori considered irrelevant. 
   Subgroups based on the following sources are a priori considered irrelevant: … 
6 Patient heterogeneity should be explored based on  
   Prespecified subgroups and posthoc analysis should be avoided 
   Prespecified subgroups and posthoc analysis should only be used to generate hypotheses or to … 
   Either posthoc analysis or prespecified subgroups. 
7 The following methods are suggested to analyse patient heterogeneity * 
   Stratified analysis 
   Decision analytic modelling 
   Sensitivity or scenario analysis 
   Expected value of individualized care 
   Regression analysis 
   … 
*Possible to select multiple options 
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Table 2.3 (continued): Checklist to formulate guidance on acknowledging patient heteroge-
neity in economic evaluation 
8 These methods should be applied in order to* 
   Incorporate and analyse sources of patient heterogeneity if … 
   Incorporate and analyse variability in baseline risk and/or treatment effect through … 
   Determine subgroup thresholds and the number of subgroups in case of continuous variables through … 
   Reflect the precision of subgroup estimates. 
   Handle patient heterogeneity revealed over time. 
   … 
Presenting patient heterogeneity 
9 To support subgroup policymaking the following information should be presented* 
   Clear definition and justification of subgroups 
   Details on data used to produce subgroup estimates 
   Details on statistical analyses 
   Stratified cost-effectiveness outcomes 
   Tornado diagram 
   Separate cost-effectiveness acceptability curves 
   Implications for distributive aspects/equity 
   Validity, reliability and feasibility of biomarkers of diagnostics necessary to identify subgroups 
   Appropriate use of the intervention 
   … 
*Possible to select multiple options 
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Appendix 2.1: Data extraction sheet 
 
General 
Country:   
Year:    
Source or web link:   
Developed by:    
Type of Guideline:  Pharmacoeconomic / Submission 
 
Category 1: Identification of patient 
heterogeneity: 
Mentioned  Guidance  Guidance (Page 
number +Quote) 
  Effects Costs Not further specified  
Mentioned to identify patient heterogeneity? 
 
     
Specifically       
Heterogeneity in relative treatment effect       
Heterogeneity in baseline risk      
Factors revealed over time      
Category 2: Method to acknowledge 
patient heterogeneity: 
Recommendation (Page number +Quote) 
Do’s   
Don’ts  
Category 3: Presentation of patient 
heterogeneity 
Recommendation (Page number +Quote) 
Do’s  
Don’ts  
Category 4: Equity constraints Effects / 
Costs 
Base-line effect / 
Treatment effect 
Guidance (Page number +Quote) 
    
    
    
    
    
    
    
    
Ns = Not specified 
 
Other remarks: 
 
 
 
  
 
 
  
  
 
 
  
PART II 
Acknowledging heterogeneity in health 
technology assessment in radiotherapy 
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Abstract 
Objective: To synthesize and compare available evidence considering the 
effectiveness of carbon-ion, proton and photon radiotherapy for head and neck 
cancer.  
Methods: A systematic review and meta-analyses were performed to retrieve 
evidence on tumor control, survival and late treatment toxicity for carbon-ion, 
proton and the best available photon radiotherapy.  
Results: In total 86 observational studies (74 photon, 5 carbon-ion and 7 pro-
ton) and 8 comparative in-silico studies were included. For mucosal malignant 
melanomas, 5-year survival was significantly higher after carbon-ion therapy 
compared to conventional photon therapy (44% vs. 25%; P-value 0.007). Also, 
5-year local control after proton therapy was significantly higher for paranasal 
and sinonasal cancer compared to intensity-modulated photon therapy (88% vs. 
66%; P-value 0.035). No other statistically significant differences were ob-
served. Although poorly reported, toxicity tended to be less frequent in carbon-
ion and proton studies compared to photons. 
In-silico studies showed a lower dose to the organs at risk, independently of the 
tumor site. 
Conclusions: For carbon-ion therapy, the increased survival in mucosal malig-
nant melanomas might suggest an advantage in treating relatively radio-
resistant tumors. Except for paranasal and sinonasal cancer, survival and tumor 
control for proton therapy were generally similar to the best available photon 
radiotherapy. In agreement with included in-silico studies, limited available 
clinical data indicates that toxicity tends to be lower for proton compared to 
photon radiotherapy. 
Since the overall quantity and quality of data regarding carbon-ion and proton 
therapy is poor, we recommend the construction of an international particle 
therapy register to facilitate definitive comparisons. 
 
Keywords: Radiotherapy; Photon; IMRT; Particle; Carbon-ion; Proton; Head 
and neck cancer; Meta-analysis; Systematic review 
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Introduction 
Head and neck cancer (HNC) covers a heterogeneous group of cancers, which 
includes paranasal and sinonasal cancer and cancer of the salivary gland, lip, 
oral cavity, pharynx and larynx. When considering cancer of the oral cavity, 
pharynx and larynx in Europe, the annual incidence is approximately 147,500. 
This represents 4.6% of all cancer cases, accounting for 63,400 deaths.1 
Treatment options for HNC consist of radiotherapy, surgery, chemotherapy or a 
combination of these modalities. There is a growing body of evidence suggest-
ing that more aggressive treatment regimes, such as altered fractionation 
schedules for radiotherapy or (concomitant) chemo-radiation improve tumor 
control and survival.2-4 Recent meta-analyses showed absolute improvements 
in 5-year survival of 3% for altered fractionation versus conventional fractiona-
tion and of 5% for chemotherapy versus no chemotherapy.3,4 However, mainly 
due to the close proximity of critical organs and the often large irradiation fields, 
the improved outcomes in these aggressive treatment regimens come at the 
cost of increased treatment toxicity. Late toxicities (including xerostomia and 
dysphagia) affect a substantial proportion of HNC patients and negatively 
impacts patients’ functional outcomes and quality of life.5-9 
Particle therapy using carbon-ions or protons is currently gaining importance 
worldwide.10 Compared with photons, the in-depth dose distribution of particles 
allows a more accurate dose administration, resulting in an increased therapeu-
tic ratio. Based on these physical characteristics, it is supposed that less normal 
tissue will be irradiated compared with photon radiation, presumably resulting in 
less treatment related toxicity.11,12 On the other hand, the increased therapeutic 
ratio possibly permits dose escalation to the tumor, resulting in a higher tumor 
control probability. Next to these physical advantages, carbon-ion radiotherapy 
comprises an increased radiobiological efficacy, especially in the Bragg peak. 
Hence, to decrease treatment related toxicity and potentially further improve 
outcome, particle therapy could be a valuable technology in the treatment of 
HNC. Nevertheless, several reviews indicated that based on clinical evidence it 
remains unclear, mainly because of the absence of randomized trials, whether 
particle therapy is superior over radiotherapy with photons in HNC.13-20 This 
makes it difficult to decide whether particle therapy should be implemented as a 
(routine) treatment in clinical practice.21 However, decisions need to be made. 
In addition to the available clinical evidence, comparative in-silico studies, which 
analyse computer-predicted dose parameters in radiotherapy treatment plan-
ning for different radiation techniques, offer an alternative approach to estimate 
the potential gain of particle therapy.15,22 Our aim was therefore to synthesize all 
available evidence, from clinical studies as well as comparative in-silico studies. 
This resulted in the following objectives 1) to review and synthesize available 
clinical evidence considering the effectiveness (i.e. tumor control, survival and 
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late treatment toxicity) of carbon-ion and proton radiotherapy compared with the 
best available photon radiation in patients receiving radiotherapy treatment for 
HNC and, 2) to review available comparative in-silico studies comparing car-
bon-ion and proton radiotherapy with photon therapy in HNC. 
Methods 
Search Strategy and Selection Criteria 
Systematic literature searches were conducted to identify available clinical 
particle and photon studies. A first search query was constructed to identify 
studies using carbon-ions or protons in HNC. Included photon studies were 
identified using a second (intensity modulated radiotherapy) and third (conven-
tional radiotherapy) search query. The PICO (patient, intervention, comparison 
and outcome) framework23 was used to structure all three search queries in 
PubMed. MeSH terms as well as free text words were used. The keywords 
were ‘head and neck cancer’ AND (‘proton radiotherapy’ OR ‘carbon-ion radio-
therapy’ OR ‘intensity modulated radiotherapy’ OR ‘radiotherapy’) AND (‘surviv-
al’ OR ‘adverse effects’). The full search strategy is reported in Appendix 3.1. 
All search queries were updated until February 2010. In addition, manual 
searches of reference lists were performed to complement all three search 
queries. For particle therapy, supplementary manual searches of conference 
proceedings were performed. 
Clinical studies were included if they were published after 1990, written in 
English, examined carbon-ions, protons or photons, examined treatment of 
primary tumors, examined radical treatment (defined as a treatment with the 
intent to obtain loco-regional disease control) and had a patient sample ≥ 10. 
For photon therapy, if available, only studies using intensity modulated radio-
therapy (IMRT) were included. If no IMRT studies were available, studies ad-
ministering conventional photon therapy were included. Further, photon studies 
were only included if tumor control or survival data was reported. In order to 
collect all available evidence on particle therapy, particle studies were also 
included if they report toxicity data only. Occasionally data were reported in 
multiple publications. In case of overlap in data and if both studies reported the 
required data, only the study with the largest sample size was included. 
To identify in-silico studies comparing particle therapy and photon therapy in 
HNC, a fourth search strategy was constructed. This search query was struc-
tured as described above for clinical studies. The search query was equal to the 
first search query, except for the keyword ‘radiotherapy planning’ instead of 
(‘survival’ OR ‘adverse effects’) (Appendix 3.1).  
In-silico studies were included if they were published after 1990, written in 
English, performed a direct comparison of particle therapy (carbon-ions or 
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protons) with photon therapy, examined treatment of primary tumors, reported 
dose to the organs at risk and had a patient sample ≥ 5. 
Data Extraction  
General characteristics were extracted from clinical studies: first author, year of 
publication, treatment type, sample size, dose per fraction, number of fractions, 
total treatment dose, study population (age, tumor stage, location and histology, 
percentage of operated patients, percentage patients of receiving chemothera-
py), late treatment toxicity, local control, disease free survival and overall sur-
vival outcomes at 2- to 5-year. Since HNC represents a heterogeneous patient 
group with different treatment modalities and prognosis, the comparisons of 
clinical studies were categorized according to location or histology. The sub-
groups were nasopharyngeal cancer, oropharyngeal cancer, paranasal and 
sinonasal cancer, mucosal malignant melanomas and adenoid cystic carcino-
mas. Because radiotherapy toxicity is location specific, different types of toxici-
ties were examined for different subgroups. Xerostomia and dysphagia were 
considered in nasopharyngeal and oropharyngeal cancer, visual toxicity in 
paranasal and sinonasal cancer, visual, skin and mucosal toxicity in mucosal 
malignant melanomas and all reported toxicity in adenoid cystic carcinomas. 
Toxicity data were extracted per type and grade independently of the classifica-
tion system.  
The following characteristics were extracted for included in-silico studies: first 
author, year of publication, treatment types, sample size, tumor location and/or 
histology, dose parameters of target volume (coverage, conformity index24 and 
inhomogeneity) and dose to organs at risk (dose to the optic nerves for parana-
sal sinus carcinomas and for all other sites dose to the parotid glands and 
pharyngeal constrictors). These organs at risk were selected since they are 
associated with visual impairment,25 xerostomia26 and dysphagia.27,28 
All data were independently extracted by two reviewers (BR and MPJ), if nec-
essary data were extracted from figures. Discrepancies were solved in consen-
sus meetings with all authors. 
Statistical Analysis 
If tumor control or survival outcomes were available per subgroup for at least 2 
comparators, data from clinical studies were pooled for the longest available 
follow-up period. Pooling was performed by means of a random effect meta-
regression analysis. If corresponding standard errors (se) were not reported in 
included studies, we calculated them using the standard method for 
proportions.29 If patients were censored, we used the Peto method.30,31 In case 
the number of censored patients was not reported, we assumed the maximum 
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percentage of censored patients reported in the included studies in the sub-
group concerned. 
Through relating the outcomes (e.g. survival) to potentially confounding varia-
bles (e.g. differences between the included studies in the percentage of patients 
receiving chemotherapy) in the meta-regression analyses, we explored the 
effect of these covariates on the outcome.32 We did this by firstly calculating the 
overall mean for these covariates among all included studies in the subgroup 
concerned. Secondly, we calculated for each study separately how much the 
covariate deviated from the overall mean. Finally, this deviation from the overall 
mean was included in the meta-regression model as an independent covariate. 
This was done separately for each subgroup for the following covariates: the 
proportion of patients having T4 tumors, N3 tumors, stage IV tumors, the pro-
portion of patients receiving chemotherapy, the proportion of operated patients 
and publication year. Only covariates which significantly influenced the out-
comes were included in the final meta-regression models.  
For comparative in-silico studies, results were reviewed only and no statistical 
analyses were performed. 
All analyses were performed in STATA 9.1 and a P-value ≤ 0.05 was consid-
ered statistically significant. Further, this meta-analysis was performed accord-
ing to proposed guidelines.33 
Results 
The three search strategies considering clinical studies identified 86 eligible 
observational studies: 5 studies using carbon-ion therapy, 7 studies using 
proton therapy and 74 studies using photon therapy. The fourth search strategy 
identified 8 eligible comparative in-silico studies (Appendix 3.2). Included and 
excluded particle studies and in-silico studies were reported in Appendix 3.3. 
The characteristics of the clinical studies pooled in the meta-analyses were 
reported in Appendix 3.4. Further, results of the meta-analyses are presented in 
Figure 3.1 and Table 3.1. The 8 in-silico studies were reviewed separately from 
the clinical studies. 
Head and neck cancer 
Three studies on particle therapy (two carbon-ion and one proton)34-36 and eight 
studies on IMRT37-44 reported on a mixed group (multiple sub-sites) of HNC 
patients. Local control (LC) rates at 2- and 5 year were 80-85% and 60-70% for 
carbon-ion therapy, 87% and 74% for proton therapy and 2-year LC ranged 
between 76-100% for IMRT. Disease free survival (DFS) estimates at 2- and 5-
year were 56% and 29% for proton therapy and 81-90% at 2-year for IMRT. 
Overall survival (OS) at 2- and 5-year were respectively 74% and 33-48% for 
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carbon-ion therapy; 69% and 44% for proton therapy and 83-90% at 2-year for 
IMRT. Due to heterogeneity within and between these studies, these results 
deemed largely not comparable and outcomes were therefore not pooled in a 
meta-analysis. 
Nasopharyngeal carcinoma 
One proton study45 and 14 IMRT studies46-59 reported results for nasopharynge-
al carcinomas. Estimates of 3-year LC were 92% for proton therapy and 95% 
for IMRT. Pooled 3-year OS estimates were 74% for proton therapy and 90% 
for IMRT. Both LC and OS were not statistically significantly different (P-values 
0.780 and 0.298). 
The percentage of T4 patients in the proton study was approximately twice as 
high as in most IMRT studies (Appendix 3.4). Nevertheless, this covariate had 
no statistically significant influence on the outcome. The year of publication had 
a statistically significant (P-value 0.040) influence on the 3-year LC favoring 
older studies. The corrected estimates were similar to the uncorrected estimate 
for 3-year LC for both IMRT (both estimates were 95%) and proton therapy 
(decreased from 92% to 90%). As a result, differences in 3-year LC between 
IMRT and protons remained not statistically significant. The remaining covari-
ates considering disease stage, the proportion of patients receiving chemother-
apy or surgery were not statistically significant. 
For proton therapy no late xerostomia or dysphagia data were reported, hence it 
was not possible to perform comparisons considering late treatment related 
toxicity. 
Oropharyngeal carcinoma 
One proton study60 and 10 IMRT studies61-71 reported results for oropharyngeal 
carcinomas. Estimates of 2- and 5-year LC were 96% and 88% for proton 
therapy and for IMRT pooled 2-year LC was 95%. For DFS, 2- and 5-year rates 
were 81% and 65% for proton therapy, pooled 2-year DFS for IMRT was 87%. 
Both 2-year LC and DFS were not statistically significantly different (P-values 
0.782 and 0.570).  
No statistically significant covariates were observed. 
For proton therapy no late xerostomia or dysphagia data were reported, hence it 
was not possible to perform comparisons considering late treatment related 
toxicity. 
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Nasopharynx 
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Figure 3.1: Forest plots of random effect meta-regression 
Abbreviations: po = post-operative, bo = biopsy only, ps = partial surgery, cs = complete surgery, ct 
= chemotherapy 
□ = se retrieved from study, ■ = se calculated (proportion method),  = se calculated (Peto method), 
 = se calculated (Peto method assuming maximum % censoring reported in the particular sub-
analysis) 
* Consisted of only 1 study and therefore no pooled estimate is reported 
† Based on a study population consisting of 85% operated patients 
‡ Because of lacking data, it was not possible to correct for surgery for Carbon-ions 
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Mucosal malignant melanoma 
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Adenoid cystic Carcinoma 
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Figure 3.1 (continued): Forest plots of random effect meta-regression 
Abbreviations: po = post-operative, bo = biopsy only, ps = partial surgery, cs = complete surgery, ct 
= chemotherapy 
□ = se retrieved from study, ■ = se calculated (proportion method),  = se calculated (Peto method), 
 = se calculated (Peto method assuming maximum % censoring reported in the particular sub-
analysis) 
* Consisted of only 1 study and therefore no pooled estimate is reported 
† Based on a study population consisting of 85% operated patients 
‡ Because of lacking data, it was not possible to correct for surgery for Carbon-ions 
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Paranasal and sinonasal carcinoma 
One carbon-ion study35 two proton studies72,73 and two IMRT studies74,75 report-
ed results for paranasal or sinonasal carcinoma. The pooled estimates of 5-year 
LC were 49% for carbon-ion therapy, 88% for proton therapy and 66% for 
IMRT. Differences in 5-year LC between proton therapy and IMRT were statisti-
cally significant (P-value 0.035). Five-year DFS was 61% for protons and 54% 
for IMRT, while 5-year OS was 71% and 52% respectively. Both DFS and OS 
were not statistically significantly different (P-values 0.682 and 0.323). 
It was not possible to include the percentage of patient with T4, N3 or Stage IV 
tumors as covariates in the meta-analyses since none of the included studies 
reported the number of Stage IV tumors and the number of T4 tumors or N3 
tumors were only reported in the two photon studies (Appendix 3.4). None of 
the other covariates (including the percentage of operated patients) had a 
statistically significant influence on the outcome. 
One proton study reported that no late visual toxicity of RTOG grade 3 or higher 
was observed.72 However, another study considering visual outcomes after 
combined photon/proton therapy reported LENT/CTC v2.0 visual toxicity of 
grade 1, 2 and 3 of respectively 14%, 17% and 6%.76 For IMRT, one study 
reported CTC v2.0 grade 3 visual toxicity in 9% of the patients, of which 4 
patients (6%) had pre-treatment visual impairment.75 
Mucosal malignant melanoma 
For the treatment of mucosal malignant melanomas, 5-year OS was reported in 
two carbon-ion studies34,77 and 18 studies administering conventional radiother-
apy.78-95 Analyses showed a 5-year OS of 44% for carbon-ion radiotherapy, this 
was statistically significantly higher than the pooled estimate of 25% for conven-
tional photon radiotherapy (P-value 0.007). 
The percentage of operated patients as well as the percentage of patients with 
disease stage III could not be incorporated as potentially confounding variables 
since none of the studies on carbon-ion therapy reported these data (Appendix 
3.4). None of the other covariates were statistically significant. 
For carbon-ion therapy one study observed late RTOG grade 2 skin toxicity in 
3%, another 3% had grade 2 mucosal toxicity and the remaining patients had 
grade 0-1 toxicity.96 No photon studies reported skin or mucosal toxicity with 
accompanying grades. One study reported grade 3-4 visual toxicity in two (8%) 
patients (one dry eye syndrome and one optic nerve toxicity resulting in de-
creased visual acuity) after photon radiotherapy.84 For carbon-ion therapy no 
visual toxicity data were reported, hence it was not possible to perform compar-
isons considering late treatment related visual toxicity. 
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Table 3.1: Results of meta-analyses 
Treatment Outcome (95% CI) Comparison Difference (95% CI) I2 (%) P* 
Nasopharyngeal Carcinoma 
  3Y LC         
IMRT 0.947  
(0.923 to 0.970) 
        
Protons† 0.920  
(0.743 to 1.000) 
Protons - IMRT -0.027  
(-0.232 to 0.178) 
19.0 0.780 
  3Y OS         
IMRT 0.897  
(0.862 to 0.933) 
        
Protons† 0.740  
(0.471 to 1.000) 
Protons - IMRT -0.157  
(-0.473 to 0.158) 
67.5  0.298 
  3Y LC corrected for the year of publication  
IMRT 0.946  
(0.927 to 0.966) 
        
Protons† 0.898  
(0.695 to 1.000) 
Protons - IMRT -0.048  
(-0.252 to 0.156) 
0.0 0.609 
Oropharyngeal Carcinoma 
  2Y LC         
IMRT 0.947  
(0.898 to 0.995) 
        
Protons† 0.960  
(0.878 to 1.000) 
Protons - IMRT 0.013  
(-0.105 to 0.132) 
0.0  0.782 
  2Y DFS         
IMRT 0.865  
(0.812 to 0.918) 
        
Protons† 0.810  
(0.662 to 0.958) 
Protons - IMRT -0.055  
(-0.159 to 0.269) 
49.9 0.570 
Paranasal and Sinonasal Carcinoma 
  5Y LC         
IMRT 0.662  
(0.516 to 0.809) 
Carbon-ions - IMRT -0.172  
(-0.600 to 0.256) 
  0.327 
Protons 0.878  
(0.755 to 1.000) 
Protons - IMRT 0.216‡  
(0.025 to 0.407) 
  0.035 
Carbon-ions† 0.490  
(0.210 to 0.770) 
Protons - Carbon-ions   0.388  
(-0.033 to 0.809) 
0.0 0.063 
  5Y DFS         
IMRT 0.535  
(0.162 to 0.907) 
        
Protons 0.609  
(0.326 to 0.891) 
Protons - IMRT 0.074  
(-0.393 to 0.542) 
78.2  0.682 
  5Y OS         
IMRT 0.516  
(0.154 to 0.878) 
        
Protons 0.705  
(0.414 to 0.995) 
Protons - IMRT 0.188  
(-0.276 to 0.653) 
73.2  0.323 
* P-value for the difference between the treatments 
† Consisted of only one study and the study estimated instead of the pooled estimate is therefore 
reported 
‡ Statistically significant difference 
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Table 3.1 (continued): Results of meta-analyses 
Treatment Outcome (95% CI) Comparison Difference (95% CI) I2 (%) P* 
Mucosal Malignant Melanoma 
  5Y OS        
Photons 0.252  
(0.212 to 0.291) 
       
Carbon-ions 0.437  
(0.316 to 0.558) 
Carbon-ions - Photons 0.185‡  
(0.058 to 0.313) 
51.7  0.007 
Adenoid Cystic Carcinoma 
  5Y LC        
Photons 0.753  
(0.635 to 0.870) 
Carbon-ions - Photons 0.061  
(-0.249 to 0.371) 
 0.675 
Protons† 0.930  
(0.797 to 1.000) 
Protons - Photons 0.177  
(-0.252 to 0.607) 
 0.386 
Carbon-ions 0.691  
(0.405 to 0.978) 
Protons - Carbon-ions 0.239  
(-0.264 to 0.741) 
93.7 0.322 
  5Y OS        
Photons 0.731  
(0.674 to 0.789) 
Carbon-ions - Photons -0.027  
(-0.203 to 0.149) 
 0.752 
Protons† 0.770  
(0.639 to 0.901) 
Protons - Photons 0.039  
(-0.233 to 0.310) 
 0.769 
Carbon-ions 0.704  
(0.538 to 0.871) 
Protons - Carbon-ions 0.066  
(-0.248 to 0.379) 
77.8  0.666 
  5Y OS corrected for the percentage of operated patient  
Photons 0.728  
(0.672 to 0.784) 
        
Protons 0.893  
(0.611 to 1.000) 
Protons - Photons 0.165  
(-0.124 to 0.455) 
73.6  0.245 
* P-value for the difference between the treatments 
† Consisted of only one study and the study estimated instead of the pooled estimate is therefore 
reported 
‡ Statistically significant difference 
Adenoid cystic carcinoma  
For adenoid cystic carcinomas (ACC), one non-randomized comparative study 
which compared carbon-ion therapy (n=29) with photon radiation (n=34) 
showed no statistically significant differences.97 Further, two carbon-ion studies 
(including updated data of the comparative study),34,98 one proton study99 and 
22 conventional photon studies100-121 reported results for adenoid cystic carci-
nomas. 
Meta-analyses resulted in a pooled 5-year LC of 69% for carbon-ion therapy, 
93% for proton therapy and 75% for conventional photon therapy. Pooled 5-
year estimates for OS were 70% for carbon-ion therapy, 77% for proton therapy 
and 73% for photon therapy. No statistically significant differences were ob-
served between carbon-ion therapy, proton therapy and conventional photon 
therapy for 5-year LC and OS (see table 3.1 for P-values). 
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The percentage of operated patients had a statistically significant influence on 
OS (P-value 0.043) favoring studies with higher proportions of operated pa-
tients. Therefore 5-year OS estimates were corrected for this covariate. Due to 
lacking data, this was not possible for carbon-ion therapy (Appendix 3.4). The 
corrected estimate was similar to the uncorrected estimate for 5-year OS for 
photon therapy (both 73%), but for proton therapy the corrected estimate in-
creased from 77% to 89%. After correcting 5-year OS, the differences between 
IMRT and protons remained not statistically significant. The covariates consid-
ering disease stage and T4 tumors were not reported in the particle studies and 
were therefore not included in the analyses. The remaining covariates had no 
statistically significant influence on the outcome. 
For carbon-ion radiotherapy, late CTC v3.0 grade 1-2 toxicity was observed in 
63% of the patients and no toxicity of grade 3 or higher was reported.98 Report-
ed RTOG late grade 1-2 toxicity in photon studies was 64% and 84%105,118 and 
ranged between 4% and 11% for grade 3 and higher toxicity.105,110,115,118 
Comparative in-silico studies 
Eight comparative in-silico studies were included, one122 comparing carbon-ion 
therapy and photon therapy and seven123-129 comparing proton therapy and 
photon therapy.  
One in-silico study suggested that for paranasal sinus tumors, carbon-ion 
therapy has the ability to statistically significantly decrease the dose to the 
contralateral optic nerve.122 However, due to unknown differences in relative 
biological effectiveness for carbon-ion therapy, it is yet unclear how these 
differences in dose will translate into clinically relevant outcomes. Also, for 
proton therapy one in-silico study reported a lower dose to the optic nerves 
compared with IMRT (Table 3.2).125 No information was provided on to what 
extent this reduced dose would reduce the probability of visual impairment. 
For nasopharyngeal, oropharyngeal, hypopharyngeal and squamous cell carci-
nomas, six comparative in-silico studies consistently showed a lower dose to 
the parotid glands for proton therapy as opposed to IMRT (Table 3.2). The 
decrease in mean dose to the parotid glands between IMRT and proton therapy 
ranged from 2 GyE to 10 GyE. Based on normal tissue complication probability 
(NTCP) models, three studies124,128,129 predicted probability of complications of 
the parotid glands (defined as a decrease of the salivary flow to 25% of the 
pretreatment salivary flow). The absolute decrease (percentage points) of the 
complication probability of the parotid glands for proton therapy compared with 
IMRT ranged from 6% to 28% (Table 3.2).  
None of the included in-silico studies reported dose to the pharyngeal constric-
tors. 
C H A P T E R  3  
 
58 
 
 Ta
b
le
 3
.2
: 
D
o
s
e
 t
o
 o
rg
a
n
s
 a
t 
ri
s
k
 a
n
d
 c
o
m
p
li
c
a
ti
o
n
 p
ro
b
a
b
il
it
y
 r
e
p
o
rt
e
d
 i
n
 c
o
m
p
a
ra
ti
v
e
 i
n
-s
il
ic
o
 s
tu
d
ie
s
 
O
u
tc
o
m
e 
F
ir
st
 a
u
th
o
r 
N
 
T
u
m
o
r 
 
h
is
to
lo
g
y/
si
te
 
O
A
R
 
si
te
 
M
ea
n
 d
o
se
 in
 G
ra
y 
E
q
u
iv
al
en
t*
 
C
o
m
p
lic
at
io
n
 p
ro
b
ab
ili
ty
* 
P
h
o
to
n
s 
P
ro
to
n
s 
 
C
ar
b
o
n
-
io
n
s 
 
S
ig
.†
 
P
h
o
to
n
s 
P
ro
to
n
s 
 
C
ar
b
o
n
-
io
n
s 
 
S
ig
.†
 
N
T
C
P
 
M
o
d
el
‡  
3D
-C
R
T
 
IM
R
T
 
S
ca
n
n
ed
 
3D
-C
R
T
 
IM
R
T
 
S
ca
n
n
ed
 
Pa
ro
tid
 
gl
an
d 
 
Ta
he
ri-
Ka
dk
ho
da
12
7  
8 
Na
so
ph
ar
yn
x 
 
- 
40
 
36
 
- 
ye
s 
- 
- 
- 
- 
- 
 
W
id
es
ot
t12
9  
6 
Na
so
ph
ar
yn
x 
CL
 
- 
29
 
23
 
- 
ye
s 
- 
22
%
 
5%
 
- 
ye
s 
Ei
sb
ru
ch
13
2  
- 
20
%
 
14
%
 
- 
ye
s 
Ro
es
in
k1
33
 
IL
 
- 
31
 
25
 
- 
ye
s 
- 
42
%
 
14
%
 
- 
ye
s 
Ei
sb
ru
ch
13
2  
- 
25
%
 
18
%
 
- 
ye
s 
Ro
es
in
k1
33
 
Va
n 
de
 W
at
er
12
8  1
0 
O
ro
ph
ar
yn
x 
 
- 
28
 
18
 
- 
ye
s 
- 
41
%
 
21
%
 
- 
ye
s 
Se
m
en
en
ko
13
1  
Jo
ha
ns
so
n1
24
 
5 
Hy
po
ph
ar
yn
x 
Le
ft 
48
 
42
 
33
 
- 
nr
 
94
%
 
65
%
 
40
%
 
- 
nr
 
Sc
hi
lst
ra
13
0 
 
Ri
gh
t 
47
 
35
 
33
 
- 
nr
 
93
%
 
51
%
 
43
%
 
- 
nr
 
Co
zz
i12
3  
5 
SC
C 
 
Le
ft 
49
 
46
 
40
 
- 
nr
 
- 
- 
- 
- 
- 
- 
Ri
gh
t 
48
 
44
 
36
 
- 
nr
 
- 
- 
- 
- 
- 
- 
St
en
ek
er
12
6  
5 
SC
C 
 
- 
≈ 
55
%
§  
≈
 3
5%
§  
- 
nr
 
- 
- 
- 
- 
- 
- 
O
pt
ic 
ne
rv
e 
M
oc
k1
25
 
5 
Pa
ra
na
sa
l s
in
us
 
CL
 
66
%
§  
62
%
§  
51
%
§║
 
- 
nr
 
- 
- 
- 
- 
- 
- 
IL
 
95
%
§  
91
%
§  
90
%
§║
 
- 
nr
 
- 
- 
- 
- 
- 
- 
Am
iru
l I
sla
m
12
2  
7 
Pa
ra
na
sa
l s
in
us
 
CL
 
42
 
44
 
- 
24
 
ye
s 
- 
- 
- 
- 
- 
- 
IL
 
58
 
58
 
- 
54
 
no
 
- 
- 
- 
- 
- 
- 
A
bb
re
vi
at
io
ns
: 
C
L 
= 
co
nt
ra
la
te
ra
l, 
IL
 =
 ip
si
la
te
ra
l, 
O
A
R
 =
 o
rg
an
 a
t 
ris
k,
 S
ig
 =
 s
ta
tis
tic
al
ly
 s
ig
ni
fic
an
ce
, 
N
T
C
P
 =
 n
or
m
al
 t
is
su
e 
co
m
pl
ic
at
io
n 
pr
ob
ab
ili
ty
, 
nr
 =
 n
ot
 
re
po
rt
ed
, S
C
C
 =
 S
qu
am
ou
s 
ce
ll 
ca
rc
in
om
as
 
* 
T
he
 o
pt
im
al
 o
ut
co
m
e 
pe
r s
tu
dy
 is
 p
rin
te
d 
in
 b
ol
d 
 
† 
S
ta
tis
tic
al
ly
 s
ig
ni
fic
an
ce
 o
f t
he
 c
om
pa
ris
on
 IM
R
T
 v
er
su
s 
pr
ot
on
/c
ar
bo
n-
io
n 
th
er
ap
y 
(P
-v
al
ue
 ≤
 0
.0
5 
is
 c
on
si
de
re
d 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t) 
‡ 
E
nd
po
in
ts
 f
or
 t
he
 c
om
pl
ic
at
io
n 
pr
ob
ab
ili
ty
 o
f t
he
 p
ar
ot
id
 g
la
nd
: 
de
cr
ea
se
 o
f t
he
 s
al
iv
ar
y 
flo
w
 t
o 
25
%
 o
f 
pr
et
re
at
m
en
t f
lo
w
 a
t 
13
 w
ee
ks
 (
S
ch
ils
tr
a1
30
),
 6
 m
on
th
s 
(S
em
en
en
ko
13
1 )
 o
r 
1 
ye
ar
 (
E
is
br
uc
h1
32
 a
nd
 R
oe
si
nk
13
3 )
 a
fte
r 
ra
di
ot
he
ra
py
 
§ 
D
os
e 
to
 o
rg
an
 a
t r
is
k 
pr
es
en
te
d 
as
 %
 o
f t
he
 p
re
sc
rib
ed
 d
os
e 
║
 P
ro
to
ns
 s
ca
tte
re
d 
P A R T I C L E  A N D  P H O T O N  R A D I O T H E R A P Y  I N  H E A D  A N D  N E C K  C A N C E R  
 
59 
The reduced dose to organs at risk for carbon-ion and proton therapy was 
accomplished with a similar conformity index, dose homogeneity and coverage 
of the target volume for particle therapy. Hence, the decreased dose to the 
organs at risk will not result in a reduced tumor control probability.  
Discussion  
To the best of our knowledge, this review and meta-analysis was the first that 
reviewed all evidence (clinical and in-silico studies) and pooled the effective-
ness of photon, carbon-ion and proton radiotherapy in HNC. Based on currently 
available evidence, we found that carbon-ion radiotherapy resulted in a statisti-
cally significantly increased 5-year OS compared to conventional photon thera-
py for mucosal malignant melanomas. Melanomas are considered as relatively 
radio-resistant tumors.134,135 Therefore, our results might indicate that carbon-
ion therapy is advantageous in the treatment of relatively radio-resistant tumors 
in the head and neck region, which profit from the increased relative biological 
effectiveness. Because of lacking data, no comparisons were performed con-
sidering toxicity in mucosal malignant melanomas. Toxicity data for adenoid 
cystic toxicity was based on different classification systems (RTOG and CTC), 
which complicated the comparison. However, the incidence of toxicity for car-
bon-ion therapy in adenoid cystic carcinomas seemed lower than reported in 
conventional photon studies. 
Outcomes for proton therapy were generally comparable with the best available 
photon therapy in nasopharyngeal, oropharyngeal and adenoid cystic carcino-
mas. For paranasal and sinonasal cancer, DFS and OS were comparable for 
photon and proton therapy. Nevertheless, LC was statistically significantly 
increased for proton therapy. Besides a higher total treatment dose, this in-
crease may also be influenced by the proportion of patients that received sur-
gery (Appendix 3.4).73 For the remainder, the similar outcomes can be ex-
plained since the radiobiological differences between protons and photons are 
small and the total treatment doses among studies were generally comparable. 
Considering treatment toxicity in oropharyngeal cancer and nasopharyngeal 
cancer, no appropriate data concerning xerostomia or dysphagia were available 
to perform comparisons based on clinical data. Although based on different 
classification systems, in paranasal and sinonasal cancer the incidence of 
grade 3 visual toxicity seemed lower for proton therapy as compared to photon 
therapy.  
In paranasal carcinomas, one comparative in-silico studies showed a reduced 
dose to the optic nerves for carbon-ion therapy compared to photon therapy.122 
Nonetheless, it is not yet clear how this decrease in dose translates into clinical 
outcomes. For proton therapy compared to photon therapy, we found a de-
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creased dose to the optical nerves125 and to the parotid glands.123-129 Based on 
NTCP models, this latter dose reduction resulted in a lower complication proba-
bility for the parotid glands.124,128,129 However, the reported complication proba-
bilities varied largely among the in-silico studies, which is partly due to differ-
ences in the applied NTCP models. The decreased dose to the organs at risk 
was accomplished without compromising on the conformity index, dose homo-
geneity and coverage of the target volume.123-129 This indicates that the main 
advantage of proton therapy in HNC may currently be the ability to spare organs 
at risk without decreasing tumor control rates. However, clinical evidence to 
support this is not yet available.  
To explore potential confounding factors and subsequently correct for hetero-
geneity between studies we included covariates in our analyses. In two anal-
yses, statistically significantly influencing covariates were observed. Firstly, the 
year of publication was statistically significant in the analyses concerning 3-year 
LC in nasopharyngeal carcinomas, which might reflect changes over time such 
as the inclusion of more patients with nodal extension in more recent studies 
(Appendix 3.4). However, this covariate did not substantially affect the estimat-
ed 3-year LC. Secondly, in the analyses considering adenoid cystic carcinomas, 
the proportion of operated patients had a statistically significant influence on 5-
year OS. The estimate for conventional photon therapy remained unchanged 
whereas the 5-year OS for proton therapy increased substantially (Figure 3.1 
and Table 3.1). The remaining analyses did not reveal other covariates which 
statistically significantly influenced the outcomes.  
Radiotherapy was often combined with chemotherapy and/or surgery in the 
included studies. Since our analyses were restricted to group-level data and 
study outcomes were not stratified for chemotherapy and surgery, we were not 
able to clarify the individual impact of chemotherapy or the positioning of sur-
gery. It would be an interesting topic for future research to examine whether and 
when proton or carbon-ion radiotherapy could best be combined with chemo-
therapy and/or surgery. 
Further, the potential gain of particle therapy in terms of tumor control may rely 
on higher doses to the tumor while remaining an equal dose to the organs at 
risk. Correcting for differences in treatment dose would therefore remove the 
potential gain of particle therapy. For that reason, our analyses were not cor-
rected for differences in radiotherapy dosage schemes. 
The present study has some limitations. Most importantly, the evidence on the 
effectiveness of particle therapy consists of a limited number of (mainly small) 
observational studies. Also, influencing variables were not always reported 
adequately. As a consequence correcting for confounding variables was only 
possible to a limited extent. These data issues may bias the comparisons as a 
result of differences in setting or treatment properties. This is considered a main 
drawback of meta-analysis of observational studies.33,136 However, in the ab-
sence of randomized trials, meta-analysis of observational studies is one of the 
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few methods to synthesize effectiveness and present uncertainty33 and follows 
the recommendation that all relevant studies should be taken into account.137 
Another data concern was the scarcely reported toxicity data among studies, 
and as a result it was not possible to adequately compare late treatment toxicity 
based on clinical data.  
Implications for practice 
It has been subject of debate whether the high initial and treatment costs of 
particle therapy are justified given the currently available evidence surrounding 
its effectiveness.21 Based on the available evidence, particle therapy seems as 
least as effective as photon therapy in tumor control, and may have advantages 
in sparing organs at risk. However, with regard to the paucity of available proton 
and carbon-ion studies and the potential bias of comparisons between (small) 
observational studies, the superiority of particle therapy in terms of tumor con-
trol and survival as well as the question whether the benefits outweigh the costs 
remains uncertain. 
Implications for research 
Particles are used in the treatment of cancer since 1954.138 However, the num-
ber of published studies which administer particle therapy in HNC is limited and 
much of the currently available data have been gathered in less than optimal 
physic-based settings. Therefore, it is difficult to establish the potential effec-
tiveness of particle therapy in more optimal clinical settings. Studies evaluating 
the effectiveness of particle therapy in HNC stratified by location and/or histolo-
gy are therefore needed.  
Curative radiation therapy for HNC is often accompanied with a trade-off be-
tween radiation toxicity and survival. The length of survival alone is therefore 
insufficient to determine the success of a treatment, and the quality of survival 
needs to be considered simultaneously.139 However, complete (late) treatment 
toxicity data is infrequently and inconsistently reported. Hence, there is a need 
for studies to systematically examine both minor and severe radiation toxicity 
per type and grade. This is especially important if decreasing treatment toxicity 
is regarded as the potential benefit of particle therapy in HNC. 
As recommended previously,18 to facilitate comparisons on both survival and 
treatment toxicity between particle therapy and photon radiation; the construc-
tion of an international particle therapy register, which contains anonymous data 
from patients who have been treated with particle therapy, would be a straight-
forward and effective solution. Such registries become particularly evident if 
randomized trials comparing photon therapy and particle therapy are not to be 
expected.140 
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For now, in the absence of comprehensive toxicity data, comparative in-silico 
studies combined with dose-response models offer a complementary way of 
estimating the potential added value of particle therapy in HNC in relation to its 
costs.15,22 
Conclusions 
Currently available clinical evidence for HNC indicates that survival for carbon-
ion radiotherapy in mucosal malignant melanomas is statistically significantly 
increased as opposed to photon radiation. This suggests that carbon-ion radio-
therapy, with its increased biological efficacy, might be advantageous in the 
treatment of relatively radio-resistant tumors. Besides local control in paranasal 
and sinonasal cancer, survival and tumor control outcomes for proton therapy 
were to a large extent similar to the best available photon radiation. Based on 
limited data, this review indicates that a clinically relevant benefit of proton 
therapy probably lies in reducing treatment toxicity in HNC. This finding is in 
accordance with available comparative in-silico studies.  
Since the overall quantity and quality of data regarding carbon-ion and proton 
therapy is poor and considering the risk of bias in comparisons between (small) 
observational studies, the reported results do not allow for definite conclusions. 
Therefore, we recommend the construction of an international particle therapy 
register to facilitate definitive comparisons on both survival and treatment toxici-
ty between particle and photon radiotherapy. 
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Appendix 3.1: Detailed overview of the search queries 
Search query 1: Particle therapy studies 
Patient 
#1 "Salivary gland" OR "Oropharyngeal" OR "Oropharynx" OR "nasopharynx" OR "Nasopharyngeal" OR 
"Paranasal Sinus" OR "paranasal" OR "hypopharynx" OR "pharynx" OR "oral cavity" 
#2 (Neoplasm*) OR "cancer" OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*) OR (Head 
and Neck Neoplasms [mesh]) 
#3 #1 AND #2 
#4 (Carcinoma, Adenoid Cystic/*radiotherapy [mesh]) OR (Neoplasms, Squamous Cell [mesh]) OR (melanoma 
[mesh]) OR "Adenoid Cystic" OR "Squamous Cell" OR "melanoma" OR "cancer" OR (neoplasm*) OR "tumor" OR 
"tumour" OR (malignan*) OR (oncol*) 
#5 (("cancer" OR (neoplasm*) OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*)) AND 
Head Neck) OR (Head and Neck Neoplasms [mesh]) 
#6 #4 AND #5 
#7 ((Head and Neck Neoplasms [mesh]) OR (Salivary Gland Neoplasms [mesh]) OR (Oropharyngeal Neoplasms 
[mesh]) OR (Nasopharyngeal Neoplasms [mesh]) OR (Pharyngeal Neoplasms [mesh]) OR (Paranasal Sinus Neoplasms 
[mesh])) 
#8 #3 OR #6 OR #7 
 
Intervention and Comparison 
#9 (proton therap*) OR "proton" 
#10 "particle" OR (heavy ion*) OR (light ion*) OR "hadron" OR "carbon" 
#11 "beam irradiation" OR "radiation" OR "irradiation" OR "beam radiation" OR (radiotherap*) OR (beam therap*) 
#12 #11 OR (ion therap*) 
#13 #9 AND #11 
#14 #10 AND #12 
#15 (Protons/*therapeutic use [mesh]) OR (Carbon Radioisotopes/*therapeutic use [mesh]) 
#16 #13 OR #14 OR #15 
 
Outcome 
#17 "Mortality" OR (adverse effect*) OR (adverse event*) OR (side effect*) OR (toxicit*) OR (xerostomi*) OR 
"Disease free survival" OR "overall survival" OR "local control" OR "tumor control" OR "tumour control" 
#18 (Mortality [mesh]) OR (Head and Neck Neoplasms/*mortality [mesh]) OR (Treatment Outcome [mesh]) OR 
("Outcome Assessment (Health Care)" [mesh]) OR (adverse effects [subheading]) OR (radiotherapy/adverse effects 
[mesh]) OR (Sickness Impact Profile [mesh]) OR (Survival Rate [mesh]) OR ("Xerostomia" [mesh]) OR (Disease free 
survival [mesh]) 
#19 #17 OR #18 
 
PICO = #8 AND #16 AND #19 
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Search query 2: Intensity modulated radiotherapy studies 
Patient 
#1 "Salivary gland" OR "Oropharyngeal" OR "Oropharynx" OR "nasopharynx" OR "Nasopharyngeal" OR 
"Paranasal Sinus" OR "paranasal" OR "hypopharynx" OR "pharynx" OR "oral cavity" 
#2 (Neoplasm*) OR "cancer" OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*) OR (Head 
and Neck Neoplasms [mesh]) 
#3 #1 AND #2 
#4 (Carcinoma, Adenoid Cystic/*radiotherapy [mesh]) OR (Neoplasms, Squamous Cell [mesh]) OR (melanoma 
[mesh]) OR "Adenoid Cystic" OR "Squamous Cell" OR "melanoma" OR "cancer" OR (neoplasm*) OR "tumor" OR 
"tumour" OR (malignan*) OR (oncol*) 
#5 (("cancer" OR (neoplasm*) OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*)) AND 
Head Neck) OR (Head and Neck Neoplasms [mesh]) 
#6 #4 AND #5 
#7 ((Head and Neck Neoplasms [mesh]) OR (Salivary Gland Neoplasms [mesh]) OR (Oropharyngeal Neoplasms 
[mesh]) OR (Nasopharyngeal Neoplasms [mesh]) OR (Pharyngeal Neoplasms[mesh]) OR (Paranasal Sinus Neoplasms 
[mesh])) 
#8 #3 OR #6 OR #7 
 
Intervention and Comparison 
#9 ((intensity modulated) AND ((radiotherap*) OR (radiotherapy [subheading]) OR (radiotherapy [mesh]))) OR 
"IMRT" OR (radiotherapy, intensity-modulated [mesh]) 
 
Outcome 
#10 "Mortality" OR (adverse effect*) OR (adverse event*) OR (side effect*) OR (toxicit*) OR (xerostomi*) OR 
"Disease free survival" OR "overall survival" OR "local control" OR "tumor control" OR "tumour control" 
#11 (Mortality [mesh]) OR (Head and Neck Neoplasms/*mortality [mesh]) OR (Treatment Outcome [mesh]) OR 
("Outcome Assessment (Health Care)"[Mesh]) OR (adverse effects [subheading]) OR (radiotherapy/adverse effects 
[mesh]) OR (Sickness Impact Profile [mesh]) OR (Survival Rate [mesh]) OR ("Xerostomia"[mesh]) OR (Disease free 
survival [mesh]) 
#12 #10 OR #11 
 
PICO = #8 AND #9 AND #12 
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Search query 3: Conventional radiotherapy studies for Mucosal Malignant Melanoma and Adenoid Cystic Carcinomas* 
Patient 
#1 "Salivary gland" OR "Oropharyngeal" OR "Oropharynx" OR "nasopharynx" OR "Nasopharyngeal" OR 
"Paranasal Sinus" OR "paranasal" OR "hypopharynx" OR "pharynx" OR "oral cavity" 
#2 (Neoplasm*) OR "cancer" OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*) OR (Head 
and Neck Neoplasms [mesh]) 
#3 #1 AND #2 
#4 (melanoma [mesh]) OR "melanoma" OR (Carcinoma, Adenoid Cystic/*radiotherapy [mesh]) OR "Adenoid 
Cystic" 
#5 (("cancer" OR (neoplasm*) OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*)) AND 
Head Neck) OR (Head and Neck Neoplasms [mesh]) 
#6 #4 AND #5 
#7 ((Head and Neck Neoplasms [mesh]) OR (Salivary Gland Neoplasms [mesh]) OR (Oropharyngeal Neoplasms 
[mesh]) OR (Nasopharyngeal Neoplasms [mesh]) OR (Pharyngeal Neoplasms [mesh]) OR (Paranasal Sinus Neoplasms 
[mesh])) 
#8 (#3 OR #7) AND (#6) 
 
Intervention and Comparison 
#9 (radiotherap*) OR (radiotherapy [subheading]) OR (radiotherapy [mesh]) 
 
Outcome 
#10 "Mortality" OR (adverse effect*) OR (adverse event*) OR (side effect*) OR (toxicit*) OR (xerostomi*) OR 
"Disease free survival" OR "overall survival" OR "local control" OR "tumor control" OR "tumour control" 
#11 (Mortality [mesh]) OR (Head and Neck Neoplasms/*mortality [mesh]) OR (Treatment Outcome [mesh]) OR 
("Outcome Assessment (Health Care)"[Mesh]) OR (adverse effects [subheading]) OR (radiotherapy/adverse effects 
[mesh]) OR (Sickness Impact Profile [mesh]) OR (Survival Rate [mesh]) OR ("Xerostomia"[mesh]) OR (Disease free 
survival [mesh]) 
#12 #10 OR #11 
 
PICO = #8 AND #9 AND #12 
*For Mucosal Malignant Melanoma and Adenoid Cystic Carcinomas, no studies using intensity 
modulated radiotherapy were available  
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Search query 4: Comparative in-silico studies 
Patient 
#1 "Salivary gland" OR "Oropharyngeal" OR "Oropharynx" OR "nasopharynx" OR "Nasopharyngeal" OR 
"Paranasal Sinus" OR "paranasal" OR "hypopharynx" OR "pharynx" OR "oral cavity" 
#2 (Neoplasm*) OR "cancer" OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*) OR (Head 
and Neck Neoplasms [mesh]) 
#3 #1 AND #2 
#4 (Carcinoma, Adenoid Cystic/*radiotherapy [mesh]) OR (Neoplasms, Squamous Cell [mesh]) OR (melanoma 
[mesh]) OR "Adenoid Cystic" OR "Squamous Cell" OR "melanoma" OR "cancer" OR (neoplasm*) OR "tumor" OR 
"tumour" OR (malignan*) OR (oncol*) 
#5 (("cancer" OR (neoplasm*) OR "tumor" OR "tumour" OR (malignan*) OR (oncol*) OR (carcinoma*)) AND 
Head Neck) OR (Head and Neck Neoplasms [mesh]) 
#6 #4 AND #5 
#7 ((Head and Neck Neoplasms [mesh]) OR (Salivary Gland Neoplasms [mesh]) OR (Oropharyngeal Neoplasms 
[mesh]) OR (Nasopharyngeal Neoplasms [mesh]) OR (Pharyngeal Neoplasms[mesh]) OR (Paranasal Sinus Neoplasms 
[mesh])) 
#8 #3 OR #6 OR #7 
 
Intervention and Comparison 
#9 (proton therap*) OR "proton" 
#10 "particle" OR (heavy ion*) OR (light ion*) OR "hadron" OR "carbon" 
#11 "beam irradiation" OR "radiation" OR "irradiation" OR "beam radiation" OR (radiotherap*) OR (beam therap*) 
#12 #11 OR (ion therap*) 
#13 #9 AND #11 
#14 #10 AND #12 
#15 (Protons/*therapeutic use [mesh]) OR (Carbon Radioisotopes/*therapeutic use [mesh]) 
#16 #13 OR #14 OR #15 
 
Outcome 
#17 Planning AND (radiotherapy OR (radiotherapy [mesh])) 
#18 Radiotherapy Planning, Computer-Assisted/methods [mesh] 
#19 #17 OR #18 
 
PICO = #8 AND #16 AND #19 
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Appendix 3.2: Flow chart of the inclusion and exclusion process for the 
search strategies  
Query Pubmed 
Particle studies 
Until February 2010 
323 
 
- Clearly irrelevant 
25 
- 307 
Exclusion criteria: 
- Reports on (partly) the same patient data (n=9) 
- Published before 1990 (n=3) 
- Re-treatment (n=1) 
Hand search: 
- References 
- Journals 
- Conference proceedings 
 
+9 
12 
Proton 
7 
C-ion* 
5 
- 13 
Nasopharynx 
Pr: 1 
Oropharynx 
Pr: 1 
Paranasal 
Pr: 3 Ci: 1 
ACC 
Pr: 1 Ci: 2 
MM 
Ci: 3 
 
Abbreviations: Pr = Proton therapy, Ci/C-ions = carbon-ion therapy, MM = mucosal malignant 
melanomas, ACC = adenoid cystic carcinomas 
* Data/sub-analysis extracted from two carbon-ion studies were used in multiple subgroups 
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Query Pubmed 
IMRT Photon studies 
Until February 2010 
 
1238 
- Duplicates (n=19) 
- Clearly irrelevant (n=1103) 
127 
- 1122 
Exclusion criteria: 
- Reports on (partly) the same patient data (n=10) 
- No appropriate outcome data (n=17) 
- No (separate) IMRT data (n=3) 
- Not the correct patient population (n=18) 
- Review (no original clinical data) (n=5) 
 
Hand search: 
- References 
- Journals 
+11 
74 
- 53 
Nasopharynx 
14 
Oropharynx 
10 
Paranasal 
2 
ACC 
22 
MM 
18 
General 
8 
Query Pubmed 
Conventional Photon studies* 
Until February 2010 
 
680 558 
 
Abbreviations: IMRT = intensity modulated radiotherapy, MM = mucosal malignant melanomas, 
ACC = adenoid cystic carcinomas 
* Search query specified for mucosal malignant melanomas and adenoid cystic carcinomas (for 
these subgroups no IMRT studies were available). 
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Query Pubmed 
In-silico studies 
Until February 2010 
 
178 
 
- Clearly irrelevant 
 
19 
- 165 
Exclusion criteria: 
- Reports on (partly) the same patient data  
- Published before 1990 
- Patient sample < 5 (n=10) 
- Dose to the organs at risk was not reported (n=1) 
-  
Hand search: 
- References 
- Journals 
- Conference proceedings 
+6 
8 
Proton 
7 
C-ion 
1 
- 11 
Nasopharynx 
Pr: 2 
Oropharynx 
Pr: 1 
Paranasal 
Pr: 1 
Hypopharynx 
Pr: 1 
 
General 
Pr: 2 Ci:1 
 
Abbreviations: Pr = Proton therapy, Ci/C-ion = carbon-ion therapy, ACC = adenoid cystic carcino-
mas 
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Appendix 3.3: Included and excluded particle studies and in-silico studies  
Included clinical studies 
First Author Year Comparison(s) (outcomes) 
Resto 2009 Paranasal and Sinonasal Carcinoma (LC, DFS and OS) 
Nishimura 2009 Paranasal and Sinonasal Carcinoma (LC, DFS, OS, and toxicity) 
Mizoe 2009 Mucosal Malignant Melanoma (OS) 
Mizoe 2009 
Head and neck cancer (LC and OS), Mucosal Malignant Melanoma (OS), Adenoid Cystic 
Carcinoma (LC and OS) 
Munter 2009 Adenoid Cystic Carcinoma (LC, OS and toxicity) 
Yanagi 2009 Mucosal Malignant Melanoma (toxicity) 
Pommier 2006 Adenoid Cystic Carcinoma (LC and OS) 
Weber 2006 Paranasal and Sinonasal Carcinoma (toxicity) 
Slater 2005 Oropharyngeal Carcinoma (LC and DFS) 
Chan 2004 Nasopharyngeal Carcinoma (LC and OS) 
Mizoe 2004 Head and neck cancer (LC and OS), Paranasal and Sinonasal Carcinoma (LC) 
Tokuuye 2004 Head and neck cancer (LC,DFS and OS) 
 
Excluded clinical studies 
First Author Year Reason(s) for exclusion 
Truong 2009 Overlap in patient sample (with Resto et al, 2008) 
Takagi 2007 Overlap in patient sample (with Mizoe et al, 2009) 
Chan 2004 Overlap in patient sample (with Resto et al, 2008) 
Schulz-Ertner 2005 Overlap in patient sample (with Munter et al, 2009) 
Schulz-Ertner 2004 Overlap in patient sample (with Munter et al, 2009) 
Schulz-Ertner 2003 Overlap in patient sample (with Munter et al, 2009) 
Fitzek 2002 Overlap in patient sample (with Resto et al, 2008) 
Lin 1999 Re-treatment 
Thornton 1998 Overlap in patient sample (with Resto et al, 2008) 
Tsujii 1992 Overlap in patient sample (with Tokuuye et al, 2004) 
Castro 1988 Published before 1990 and other particles than protons and carbon-ions only (including He, C, 
Ne and Si) 
Munzenrider 1985 Published before 1990 
Castro 1982 Published before 1990 
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Appendix 3.3 (continued): Included and excluded particle studies and in-
silico studies  
Included comparative in-silico studies 
First Author Year Tumor site/histology 
Amirul Islam 2008 In close proximity of the optic pathways 
Taheri-Kadkhoda 2008 Nasopharynx 
Van de Water 2008 Oropharynx 
Widesott 2008 Nasopharynx 
Steneker 2006 Squamous cell carcinoma 
Johansson 2004 Hypopharynx  
Mock 2004 Paranasal sinus 
Cozzi 2001 Squamous cell carcinoma 
Amirul Islam 2008 In close proximity of the optic pathways 
   
Excluded comparative in-silico studies 
First Author Year Reason(s) for exclusion 
Chera 2009 Patients sample < 5 
Thorwarth 2008 Patients sample < 5 
Muzik 2008 Patients sample < 5 
Flynn 2008 Patients sample < 5 
Lomax 2003 Patients sample < 5 
Schulz-Ertner 2003 Dose to the organs at risk was not reported  
Lomax 1999 Patients sample < 5 and no comparison of particle therapy and photons 
Lomax 1999 Patients sample < 5 
Slater 1992 Patients sample < 5 
Mirabell 1992 Patients sample < 5 
Brown 1989 Patients sample < 5 and published before 1990 
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Appendix 3.4A: Characteristics of nasopharyngeal and oropharyngeal 
studies* 
 N Modality Number of  
fractions† 
Total  
Treatment 
dose (GyE) † 
Age† % 
Ct 
% 
Operated 
patients 
% 
T3/T4 
% 
T4 
% 
N+ 
% 
N3 
% 
Stage IV 
Nasopharynx             
Chan (2004)45  17 P-rt + X-rt 46 73.6 41 59% 0% 100% 100% 53% 6% 100% 
Zheng (2010)59 59 X-rt 33 70.7 48 100% nr 50% 28% 85% 20% 43% 
Kim (2009)49 25 X-rt 30 67.5 44 100% 0% 44% 24% 96% 24% 48% 
Lee (2009)52 68 X-rt 33 70.0 49 84% 0% 34% 19% 74% 12% 28% 
Lin (2009)54 323 X-rt 30/31 66.0/69.8 nr 91% 0% 61% 24% 91% 6% 29% 
Nishimura (2009)55 35 X-rt 28-35 68.0 56 89% nr 46% 26% 66% 11% 34% 
Tham (2009)56 195 X-rt 35 70.0 52 56% 0% nr 26% nr nr 30% 
Wong (2009)58 175 X-rt 33 70.0 48 73% 0% 35% 15% 72% 9% 24% 
Fang (2008)47 110 X-rt 36-42 64.8-75.6 nr 57% 0% 25% 11% 68% 1% 12% 
Koom (2008)50 24 X-rt 27 64.8 46 100% 0% 29% 13% 96% 25% 33% 
Wolden (2006)57 74 X-rt 30 70.2 45 93% 0% 51% 31% 78% 24% 47% 
Chong (2004)46 104 X-rt 25-30 64.0-70.0 43 nr nr nr nr nr nr 16% 
Kam (2004)48 63 X-rt 33 66.0 48 30% 0% 51% 19% 70% 5% 22% 
Kwong (2004)51 33 X-rt 34 68.0-70.0 43 0% 0% 3% 0% 18% 0% 0% 
Lee (2002)53 67 X-rt nr 65.0-70.0 49 75% 0% 43% 21% 78% 12% 37% 
Oropharynx             
Slater (2005)60 29 P-rt + X-rt 45 75.9 nr 0% 0% 55% 21% 83% 10% 62% 
Daly (2010)62 107 X-rt 30 60.0/66.0 nr 80% 21% 47% 29% 91% 11% 86% 
Eisbruch (2009)63 67 X-rt 30 66.0 56 0% 0% 0% 0% 43% 0% 0% 
Lawson (2008)66 34 X-rt 33 70.3 61 100% 0% 41% 29% 91% 9% 85% 
Rusthoven (2008)68 32 X-rt 33 69.3 nr 100% 0% 41% 19% 97% 3% 84% 
Schoenfeld (2008)69 64 X-rt 42 67.5/72.0 nr 54%‡ 0% 42%‡ 20%‡ 70%‡ 5%‡ 63%‡ 
Garden (2007)64 51 X-rt 30 63.0-66.0 54 10% 0% 0% 0% 67% 4% 53% 
Lee (2006)67 41 X-rt 40/42 70.0-72.0 55 100% 0% 39% nr 90% 5% 85% 
Yao (2006)70 66 X-rt nr 60.0-74.0 53 70% 6% 41% 29% 88% 14% 88% 
Chao (2004)71 74 X-rt 35 66.0/70.0 55 23% 58% 45% nr 84% nr 70% 
Huang (2003)65 41 X-rt 33 70.0 55 73% 7% 17% 7% 76% 5% 68% 
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Appendix 3.4B: Characteristics of paranasal and sinonasal and mucosal 
malignant melanoma studies* 
 
N Modality Total 
treatment  
dose (GyE)† 
Age† % 
Ct 
%  
Operated 
patients 
%  
T4 
%  
N3 
%  
Stage III§ 
Paranasal and Sinonasal  
Resto Cs (2008)73 20 P-rt + X-rt 67.6 50‡ 33%‡ 100% nr nr na 
Resto Ps (2008)73 50 P-rt + X-rt 75.6 50‡ 33%‡ 100% nr nr na 
Resto Bo (2008)73 32 P-rt + X-rt 75.4 50‡ 33%‡ 0% nr nr na 
Nishimura (2007)72 14 P-rt 65.0 56 29% 50% nr nr na 
Mizoe (2004)35 10 C-rt 48.6-64.8 60‡ 6%‡ 33%‡ nr nr na 
Madani (2009)75 73 X-rt 70.0 63 0% 89%‡ 39%‡ 0% na 
Daly (2007)74 36 X-rt 70.0 57 22% 89% 69% 0% na 
Mucosal Malignant Melanoma 
Mizoe (2009)34 100 C-rt 57.6 57‡ 0% nr na na nr 
Mizoe +Ct (2009)77 57 C-rt 57.6 60 100% nr na na nr 
Meleti (2008)88 42 X-rt 30.0 64 2% 90% na na 3%‡ 
Nakashima (2008)89 20 X-rt 54.0 62 6% 100% na na 0% 
Wagner (2008)94 17 X-rt 66.9 64 0% 76% na na 0% 
Huang (2007)82 15 X-rt nr 69 20% 93% na na 0% 
Krengli (2006)84 74 X-rt 55.1 66 5% 80% na na 8% 
Bridger (2005)79 27 X-rt nr 66 0% 100% na na nr 
Temam (2005)93 69 X-rt 64.9 58 0% 100% na na 0% 
Owens (2003)90 44 X-rt nr 56 0% 100% na na nr 
Yii (2003)95 89 X-rt nr 64 10% 97% na na 7% 
Patel (2002)91 59 X-rt nr 63 0% 100% na na 7% 
Loree (1999)85 28 X-rt nr nr 18% 61% na na 4% 
Lund (1999)86 58 X-rt nr 64 16% 100% na na 0% 
Manolidis (1997)87 14 X-rt nr 71 0% 86% na na nr 
Kingdom (1995)83 10 X-rt nr nr 0% 100% na na nr 
Guzzo (1993)81 48 X-rt nr 58 29% 90% na na 8% 
Shibuya (1993)92 28 X-rt nr nr 0% 0% na na 0% 
Andersen (1992)78 26 X-rt 54.0 65 0% 77% na na 4% 
Gilligan (1991)80 28 X-rt 45.0-55.0 65 0% 0% na na nr 
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Appendix 3.4C: Characteristics of adenoid cystic carcinoma studies* 
  
N Modality Total  
treatment 
dose (GyE)† 
Age† % 
Ct 
%  
Operated  
patients 
%  
T4 
%  
N3 
%  
Stage IV 
Adenoid Cystic Carcinoma 
Pommier (2006)99 23 P-rt + X-rt 73.3/76.4 46 4% 52% nr 0% nr 
Mizoe (2009)34 107 C-rt 57.6 57‡ nr nr nr nr nr 
Munter (2009)98 59 C-rt + X-rt 72.0 52 nr nr nr nr nr 
Iseli (2009)111 171 X-rt 60.0-70.0 53 0% 82% nr nr 37% 
Agarwal (2008)100 76 X-rt 56.0 nr 0% 97% 54% nr 59% 
Gomez (2008)105 59 X-rt 63.0 52 10% 92% 34% nr nr 
Leonetti (2008)114 16 X-rt 51.0-60.0 47 0% 100% nr nr nr 
Da Cruz Perez (2006)103 18 X-rt 53.6 39 17% 61% nr nr nr 
Rhee (2006)117 35 X-rt nr 47 9% 77% 49% nr nr 
Bhattacharyya (2005)102 18 X-rt nr 59‡ nr nr nr nr nr 
Gurney (2005)106 33 X-rt 60.0 49 0% 100% nr nr 31% 
Rapidis (2005)116 23 X-rt nr 60 26% 96% nr nr nr 
Kokemeuller (2004)113 74 X-rt 60.0 58 0% 100% 42% 0% 45% 
Mendenhall (2004)115 101 X-rt 10.5-79.2 58 2% 58% 44% 0% 45% 
Silverman (2004)118 75 X-rt nr 52 0% 100% 31% 0% 31% 
Hsu (2003)109 25 X-rt nr 50 0% 100% nr nr 12% 
Harbo (2002)107 26 X-rt nr 64‡ 0% 49%‡ 7%‡ 2%‡ 36%‡ 
Huber (2001)110 25 X-rt 64.0 55‡ 0% 68% nr nr nr 
Khan (2001)112 68 X-rt nr 52 3% 87% 22% nr 31% 
Takagi (2001)120 20 X-rt 40.0-65.0 59 35% 85% nr nr nr 
Avery (2000)101 15 X-rt nr 53 7% 100% nr nr 33% 
Therkildsen (1998)121 87 X-rt 60.0-66.0 60‡ 0% 91%‡ nr nr 17%‡ 
Garden (1995)104 198 X-rt 60.0 50 0% 100% nr nr nr 
Hosokawa (1992)108 41 X-rt 40.0-70.0 58 0% 79% nr nr nr 
Spiro (1992)119 184 X-rt nr 57 0% 95% nr nr 12%‡ 
Abbreviations: X-rt = photon radiotherapy, P-rt = proton radiotherapy, C-rt = carbon-ion radiothera-
py, Cs = complete surgery, Ps = partial surgery, Bo = biopsy only, Ct = chemotherapy, nr = not 
reported, na = not applicable 
* Only characteristics of studies included in meta-analyses were reported  
† Median/mean value  
‡ Figures are for the whole study sample not only for this subgroup  
§ According to Ballantyne’s staging system  
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Abstract 
Objective: To examine the impact of late treatment-related xerostomia and 
dysphagia on health-related quality of life (HRQOL) in head and neck cancer 
(HNC) patients after radiotherapy. 
Methods: A multi-center cross-sectional survey was performed. Patients with a 
follow-up of at least 6 months after curative radiotherapy, without evidence of 
recurrent disease were eligible for inclusion. The Euroqol-5D questionnaire 
(EQ-5D) was filled out and toxicity was scored and converted to the RTOG 
scale. The EQ-5D measures generic HRQOL in terms of utility and Visual 
Analogue Scale (VAS) scores. Missing data on the EQ-5D were imputed using 
multiple imputation. 
HRQOL was compared between subgroups of patients with and without toxicity. 
Subsequently, the impact of xerostomia and dysphagia on HRQOL was ana-
lysed using multivariate regression analyses. Both analyses were performed 
separately for utility scores and VAS scores. 
Results: The study population was composed of 396 HNC patients. The aver-
age utility and VAS scores were 0.85 (scale 0-1) and 75 (scale 0-100). Sub-
groups of patients with xerostomia and/or dysphagia showed statistically signifi-
cantly lower utility and VAS scores (P=0.000-0.022). The multivariate regression 
model showed that xerostomia and dysphagia were negative predictors of both 
utility and VAS scores. Other factors which influenced HRQOL in at least one of 
the two regression models were: sex, tumor location and the addition of surgery 
to radiotherapy.  
Conclusion: Xerostomia and dysphagia diminish generic HRQOL. Moreover 
dysphagia affects patients’ HRQOL stronger than xerostomia. 
 
Keywords: Quality of life; Head and neck cancer; Xerostomia, Dysphagia; 
Radiotherapy 
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Introduction 
An increasing number of options become available for the treatment of head 
and neck cancer (HNC). Traditionally, treatment decisions were primarily based 
on local tumor control and the length of survival. However, treating HNC often 
involves a trade-off between (disease-free) survival and treatment-related 
toxicity. After radiotherapy, in particular xerostomia and dysphagia negatively 
affect health-related quality of life (HRQOL).1,2 Therefore, the length of survival 
after treatment has to be weighed against the quality of survival. As a result, 
HRQOL and factors influencing HRQOL (such as treatment-related toxicity) are 
increasingly recognized as important treatment outcomes in HNC.1,3-5 
To take into account HRQOL, disease-specific measures are often used. Alt-
hough these questionnaires are relevant for patients and physicians, the main 
disadvantage of disease-specific measures is their inability to compare HRQOL 
in different disease areas. In contrast, generic HRQOL can be compared in 
different disease areas. Measures of generic HRQOL assess the preferences of 
individuals for a certain health status; the more preferable the outcome, the 
higher the score.6 This can be measured by inquiring how patients value their 
own health status (patients’ perspective) or based on the preferences of the 
society (general public perspective). Preferences for health states can be com-
bined with life expectancy, resulting in Quality Adjusted Life Years (QALYs). 
The main advantage of QALYs is that they capture life expectancy and quality 
of life in a single measure.6 This is useful to inform the aforementioned trade-off 
between length of survival and treatment-related toxicity (quality of survival). 
Previous studies have assessed health state preferences in HNC.7-11 However, 
to our knowledge, no study provided health state preferences based on sub-
groups distinguished by treatment-related toxicity for primary treated HNC 
patients. Hence, knowledge on the impact of toxicity on generic HRQOL is 
lacking. Therefore, we aimed to examine the impact of late treatment-related 
xerostomia and dysphagia on HRQOL (patient and general public perspective) 
in disease free HNC patients treated with radiotherapy.  
The aim of this study was twofold: (1) to compare HRQOL across subgroups 
subdivided by xerostomia and dysphagia and, (2) to examine the influence of 
late treatment-related toxicity on HRQOL.  
Methods 
Conceptual model 
To examine the influence of late treatment-related toxicity on HRQOL, we 
constructed a conceptual model (Figure 4.1). In order to minimize multicollinear-
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ity in our analyses, we only included factors that are directly related to HRQOL, 
excluding indirect factors (i.e. variables that influence HRQOL through other 
variables).  
HRQOL is negatively affected by radiotherapy induced xerostomia and dyspha-
gia.1,2,12 Since dysphagia may be the consequence of xerostomia, these out-
come measures might correlate or even interact. Next to these main variables 
of interest, other potentially predictive factors were subdivided into patient 
related factors, disease related factors and treatment-related factors. Patient 
related factors include sex and age; HRQOL scores are likely to decrease with 
increasing age and tend to be lower for females.13-15 Disease related factors 
include tumor location and disease stage. Tumor location has a varying impact 
on HRQOL.1,2,16,17 In contrast, disease stage is unlikely to directly affect 
HRQOL.1,2,16,17 In case of a lower HRQOL for patients with advanced disease 
stage, the decreased HRQOL is suggested to be related to cancer treatment, 
treatment toxicity and/or disease progression rather than to cancer stage direct-
ly 2,16,18 Hence, disease stage can be considered as an indirect predictor of 
HRQOL and is for this reason not included in our conceptual model. Finally, 
with regard to treatment-related factors, the combination of radiotherapy with 
surgery or chemotherapy is suggested to have a negative influence on 
HRQOL.1,16 The interval after radiotherapy (follow-up period) has a varying 
impact on HRQOL.1,19 
Data collection 
From June 2009 to March 2010, a multi-center cross-sectional survey was 
performed during planned follow-up visits in two Dutch hospitals.20 The study 
population consisted of HNC patients, who were treated with curative intend by 
radiotherapy alone or combined with surgery and/or chemotherapy. Patients 
with a follow-up period of 6 months or longer after the start of radiotherapy and 
without evidence of recurrent disease were eligible for inclusion.  
The EuroQol-5D questionnaire21 (EQ-5D) was filled out in the hospital before 
the patients visited their physician. During the follow-up visit, severity of xero-
stomia and dysphagia was scored by a trained researcher (radiation technolo-
gist) or the treating physician and converted to the RTOG scale22 (Appendix 
4.1). The following data were retrieved from patients’ medical records: date and 
type of initial treatment, primary tumor location and initial tumor stage. This 
study was approved by the Institutional Review Board. 
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Figure 4.1: Conceptual model 
EuroQol-5D 
The EQ-5D is the most frequently used multi-attribute health status classifica-
tion system and is recommended by the National Institute for Health and Clini-
cal Excellence.6,21,23-25 The EQ-5D consists of questions considering five dimen-
sions of generic HRQOL (mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression).21 The answers to these questions can be combined to 
calculate health state preferences (so-called utility scores) from a general public 
perspective using a scoring function. This scoring function was based on the 
preferences of 2.997 UK respondents, who valued 42 different health states 
from the EQ-5D using the time trade-off method (TTO).26 Utility scores calculat-
ed by this scoring function range from -0.59 (health state worse than death, 
severe problems in all five dimensions), through 0 (death) to 1 (full health, no 
problems in all dimensions). Next to the five questions, a Visual Analogue Scale 
(VAS) is included in the EQ-5D that ranges from 0 (worst imaginable health 
state) to 100 (best imaginable health state).21 The VAS measures the patients’ 
self-rated HRQOL (patients’ perspective).27  
Data analyses 
Missing data 
Patients with missing data for late toxicity scores were excluded from the anal-
yses. As recommended for handling missing HRQOL data,28 missing data on 
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the EQ-5D were replaced using multiple imputation. To impute the missing 
values on the five questions and the VAS score of the EQ-5D, five datasets 
were created (m=5). The imputation model included the variables described in 
the conceptual model (Figure 4.1), plus the questions and VAS of the EQ-5D. 
Categorical variables were imputed as scale variables and variables containing 
more than two categories were converted into dummy variables.29,30 After 
multiple imputation, values for the separate questions of the EQ-5D were con-
verted back to categorical variables.29 
To obtain pooled estimates of the mean, variance and parametric tests the 
method as described by Rubin31 and more recently by Carlin et al32 was used. 
There is no generally accepted method for pooling the (adjusted) R2, medians, 
quartiles and non-parametric tests. The (adjusted) R2 was pooled by averaging 
the separate values for the (adjusted) R2 from all 5 regression analyses. Medi-
ans and quartiles were pooled by obtaining the median of all 5 imputed datasets 
combined. Non-parametric tests were pooled by averaging the test statistic for 
the separate tests for all 5 imputed datasets, which was subsequently used to 
calculate p-values. 
Analyses 
First, descriptive statistics were computed for the population characteristics. 
Second, we examined differences in utility and VAS scores between subgroups 
with toxicity and without toxicity. For this purpose, patients were subdivided 
according to grade 0, 1, 2 and ≥3 for both xerostomia and dysphagia. Only 
subgroups with ≥10 patients were included in the analyses. Subsequently, 
skewness and kurtosis of the HRQOL distribution within these subgroups were 
examined. If the skewness and kurtosis fell between -2.0 and 2.0, the differ-
ences between subgroups were compared using one way analysis of variance 
(ANOVA) and if significant multiple paired Student’s t-tests were performed. 
Kruskal-Wallis tests and if statistically significant pairwise comparison Mann-
Whitney U tests were performed if the skewness or kurtosis exceeded this 
range. 
Third, to test the conceptual model presented in Figure 4.1, utility and VAS 
scores were separately included as dependent variables in multivariate regres-
sion analyses. The variables which were considered to influence HRQOL were 
included in the regression model as independent variables. Grade of xerostomia 
and dysphagia, as well as sex, tumor location, surgery of the primary tumor and 
chemotherapy were included as categorical variables. Xerostomia and dyspha-
gia were subdivided into dummy variables for grade 0 (reference category), 1, 2 
and ≥3. For tumor location dummy variables were created for oral cavity and lip, 
pharynx, larynx and other sites (reference category). Larynx and pharynx were 
separate categories since laryngeal carcinomas are typically early stage tumors 
and subsequently treated with limited radiation fields as opposed to pharynx 
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carcinomas which are mostly locally advanced and treated with large radiation 
fields. Further, age and follow-up period after radiotherapy were included as 
scale variables. Since there is a possible interaction between xerostomia and 
dysphagia, effect modification (by means of an interaction term) was considered 
between these two variables.  
Independently of the significance, none of the potentially influencing variables 
were excluded from the regression model. Only the interaction term between 
xerostomia and dysphagia was excluded if not statistically significant. The final 
regression models were checked for assumptions of linear regression.  
All analyses were performed using SPSS 17.0. P-values <0.05 were considered 
statistically significant.  
Results 
Population characteristics 
Altogether, 92% of all approached patients agreed to participate. In total 426 
patients filled out the questionnaire, 30 of these patients were excluded since 
toxicity data were missing. This resulted in a study population of 396 patients of 
which 55 patients (14%) had missing values on the EQ-5D which were imputed. 
Population characteristics are presented in Table 4.1. The average utility and 
VAS scores among all 396 patients were 0.85 (sd: 0.18) and 75 (sd: 15) respec-
tively. 
HRQOL among patients subdivided by xerostomia and dysphagia 
Subgroups were categorized by grades of xerostomia and/or dysphagia (based 
on the RTOG scale). In total, 84 patients (21%) had no xerostomia or dyspha-
gia. Xerostomia was more prevalent than dysphagia (Figure 4.2).  
For the utility scores, a ceiling effect (the scores are clustered around the upper 
end of the scale) was observed for the subgroup without toxicity. This resulted 
in a distribution with a high skewness (-2.4) and kurtosis (7.2). For VAS scores, 
the skewness and kurtosis were within the proposed range. Therefore, sub-
group analyses were performed using non-parametric tests for utility scores and 
using parametric tests for VAS scores. 
Utility scores were significantly different between subgroups (Kruskal-Wallis 
test, P < 0.001). Pairwise comparisons showed significantly higher utility scores 
for patients without toxicity compared to patients with ≥ grade 1 dysphagia 
independently of the grade of xerostomia. For patients with dysphagia grade 0, 
average utility scores ranged between 0.91 (xerostomia grade 0) and 0.85 
(xerostomia grade 2). For dysphagia grade 1 this ranged between 0.84 and 
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0.82 and between 0.80 and 0.76 for ≥ grade 2 dysphagia (Table 4.2 and Figure 
4.2). 
Also VAS scores were significantly different among subgroups (ANOVA, P < 
0.001). Pairwise comparisons showed significantly lower VAS scores if patients 
had ≥ grade 1 for both xerostomia and dysphagia, except for the subgroup with 
grade 1 xerostomia and grade 2 dysphagia. For patients with dysphagia grade 
0, average VAS scores ranged between 80 (xerostomia grade 0) and 76 (xero-
stomia grade 2). For dysphagia grade 1 this ranged between 74 and 70 and 
between 74 and 65 for ≥ grade 2 dysphagia (Table 4.2 and Figure 4.2). 
 
Table 4.1: Characteristics of the study population* 
Patient characteristics    Disease characteristics (continued)   
    Male  276 70%  Node classification   
    Female 120 30%      N0 194 49% 
Age (years)        N1 57 14% 
    Mean (Sd) 63.2 (11.8)      N2 121 31% 
    Minimum, maximum 20 99      N3 9 2% 
Follow-up period (months)        Unknown 15 4% 
    Median (IR) 20 (23.0)  Stage (UICC)   
    Minimum, maximum 6 152      0 7 2% 
        I 55 14% 
Disease characteristics        II 59 15% 
Tumor location        III 78 20% 
    Oral cavity and Lip 51 13%      IV 139 35% 
    Pharynx 115 29%      Unknown 58 15% 
    Larynx 125 32%     
    Nasal cavity and sinuses 20 5%  Treatment characteristics   
    Salivary gland 23 6%  Surgery of the primary tumor   
    Other† 49 12%      No 258 65% 
    Unknown 13 3%      Yes 138 35% 
Tumor classification    Chemotherapy   
    Tis 8 2%      No 339 86% 
    T0 17 4%      Yes 57 14% 
    T1 92 23%     
    T2 115 29%     
    T3 55 14%     
    T4 82 21%     
    Unknown 27 7%     
Abbreviations: Sd = standard deviation, RT = radiotherapy, IR = interquartile range  
* Values are numbers (percentages) unless stated otherwise. 
† Including skin and unknown primary tumors 
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Figure 4.2: HRQOL categorized by grade of xerostomia and dysphagia 
Only subgroups with more than 10 patients are presented, error bars indicate the 95% confidence 
interval of the mean and values in the bars represent the N per subgroup. 
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Table 4.3: Multivariate regression model* 
 
Dependent variable:  
utility score 
Dependent variable:  
VAS score 
 
R2 = 42%†,  
Adjusted R2 = 17%‡ 
R2 = 39%†,  
Adjusted R2 = 16%‡ 
Independent variables Beta Se P-value Beta Se P-value 
  Constant 0.836 0.057 0.000 79.4 4.9 0.000 
Treatment toxicity           
  Xerostomia||           
    Grade 1 -0.013 0.021 0.540 -1.6 1.9 0.412 
    Grade 2 -0.059 0.028 0.040 -7.7 2.6 0.003 
    Grade 3+ -0.336 0.123 0.006 8.2 11.1 0.460 
  Dysphagia||          
    Grade 1 -0.059 0.021 0.005 -5.6 1.8 0.002 
    Grade 2 -0.126 0.029 0.000 -7.2 3.0 0.026 
    Grade 3+ -0.074 0.040 0.060 -10.8 3.4 0.002 
Patient characteristics           
  Sex          
    Male 0.052 0.019 0.006 1.4 1.7 0.397 
  Age 0.000 0.001 0.747 -0.1 0.1 0.310 
Disease characteristics           
  Tumor location||          
    Oral cavity and lip 0.081 0.030 0.006 5.9 2.7 0.031 
    Pharynx 0.063 0.027 0.018 4.7 2.3 0.040 
    Larynx  0.032 0.026 0.226 1.9 2.2 0.398 
Treatment characteristics          
  Surgery of the primary tumor          
    Yes 0.062 0.022 0.006 4.0 2.0 0.043 
  Chemotherapy          
  Yes 0.040 0.027 0.148 4.4 2.4 0.068 
  Follow-up period 0.000 0.000 0.499 0.0 0.0 0.757 
Interaction          
  Xerostomia and Dysphagia - - ns - - ns 
Abbreviations: VAS = Visual Analogue Scale, Se = standard error, ns = not statistically significant 
* For the complete case analyses see Appendix 4.2 
† R2 = the fraction of the total squared error that is explained by the regression model.33 
‡ Adjusted R2 = measure indicating how much variance in the outcome would be accounted for if 
the model had been derived from the population from which the sample was taken.33 
|| Reference category for dummy variables was Grade 0 toxicity and other tumor locations. 
Factors influencing HRQOL 
Utility scores were significantly negatively affected by grade 2 and ≥3 xerosto-
mia in the multivariate regression analyses (Table 4.3). This was also true for 
dysphagia grade 1 and grade 2. Grade 1 xerostomia and ≥ grade 3 dysphagia 
had no significant impact on utility scores. Other variables that have a signifi-
cant influence on utility scores were sex, tumor location and whether surgery of 
the primary tumor was performed. The interaction term for xerostomia and 
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dysphagia was not significant and therefore excluded from the regression 
model.  
VAS scores were significantly negatively influenced by grade 2 xerostomia in 
the multivariate regression analyses (Table 4.3). Also, all grades of dysphagia 
(grade 1, 2 and ≥3) had a significantly negative impact on VAS scores. Xero-
stomia grade 1 and ≥3 had no significant impact on VAS scores. Other statisti-
cally significant variables in the regression model were: tumor location, whether 
surgery of the primary tumor was performed and whether patients received 
chemotherapy. The interaction term for xerostomia and dysphagia was not 
statistically significant and therefore excluded from the regression model.  
The regression models were checked for the assumptions of linear regression 
and no severe deficiencies were observed.  
Discussion 
To the best of our knowledge, this study was the first to analyse the impact of 
late treatment-related toxicity on patient-rated utility and VAS scores in HNC. 
Our analyses demonstrated that dysphagia and xerostomia both have a nega-
tive impact on HRQOL. Moreover, dysphagia had the largest impact on 
HRQOL. Except for age, follow-up period and whether patients received chemo-
therapy, all independent variables reported in the conceptual model (Figure 4.1) 
were significant predictors of HRQOL in at least one of the two regression 
analyses. The relations were as expected, except for surgery. The complete 
case analyses resulted in comparable regression models (Appendix 4.2). 
Potential limitations of this study included the low number of patients with grade 
≥3 toxicity (Table 4.2). This might explain the fact that grade ≥3 dysphagia was 
not a significant predictor of utility scores. The same may apply to grade ≥3 
xerostomia for VAS scores. Also, the cross-sectional design and hence the 
inability to correct for baseline HRQOL may be considered as a limitation. 
However, we corrected for potentially confounding variables and to our 
knowledge there was no rationale to assume that the HRQOL before treatment 
was on average different between the subgroups subdivided by treatment 
toxicity. Therefore, the impact of late treatment-related toxicity on HRQOL in our 
study can probably not be attributed to the cross-sectional design. Neverthe-
less, prospective studies measuring utility and VAS scores in HNC patients with 
different grades of toxicity are needed to confirm our results. Finally, we includ-
ed patients who had a follow-up period of at least six months from treatment 
start. This includes patients who have been studied 4-5 months following com-
pletion of radiotherapy. It is unclear whether xerostomia and dysphagia have 
stabilized after this period. However, additional analyses showed that if the 21 
patients (5%) with a shorter follow-up than six months from treatment comple-
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tion were excluded, the HRQOL estimates stratified by xerostomia and dyspha-
gia remained similar. 
The current study showed on average relatively higher utility than VAS scores. 
In contrast with our results, previous studies indicated that patients with a 
specific condition (patients’ perspective) are inclined to place higher scores for 
their own health state compared with non-patients (general public perspective), 
presumably due to adaptation.34-37 However, corresponding with our results, 
most studies indicated that due to differences in measurement methods, utility 
scores based on the TTO method (as in this study) are higher than VAS 
scores.6,34 Despite these abovementioned differences between utility and VAS 
scores, the decrements between the subgroups subdivided by xerostomia and 
dysphagia were comparable between the two methods. Therefore, the differ-
ences between utility and VAS scores probably represent an overall shift in 
HRQOL for all subgroups and do not alter the estimated impact of xerostomia 
and dysphagia on HRQOL. 
Previously, utility scores in HNC have been estimated using various methods.7-
11 Based on the EQ-5D filled out by 50 oncology nurses, Brown et al reported 
an average utility score of 0.86 for post-treatment HNC patients with loco-
regional disease control.7 This corresponds with the overall average utility score 
of 0.85 in our study. Ringash et al applied the TTO method in 112 disease free 
laryngeal cancer patients resulting in a higher utility score of 0.91.10 Due to 
difference in patient populations or subgroups it was not possible to compare 
utility scores from the other studies with our results.8,9,11 
Marra et al,38 defined 0.03 as a minimally important difference in utility scores 
(measured by the EQ-5D). Accordingly, the main clinical implications of our 
results are that treatment strategies aimed at reducing dysphagia and/or xero-
stomia have the potential to result in a meaningful improvement of generic 
HRQOL. This emphasizes that next to the expected length of survival also 
treatment toxicity should be considered when treatment choices are made. Our 
results can be used to inform this trade-off. In consideration of this trade-off, 
xerostomia is more prevalent than dysphagia, whereas dysphagia has a higher 
impact on HRQOL than xerostomia. Therefore, preventing xerostomia could 
benefit more patients, whereas preventing dysphagia might result in a larger 
benefit per patient. 
To reduce treatment toxicity, it may be useful to focus on patients who have the 
highest risk of experiencing xerostomia and/or dysphagia. In our study popula-
tion, 84 patients (21%) had no toxicity. Compared with the 312 patients (79%) 
with any grade of toxicity, the patient group without toxicity consisted of less 
patients with advanced disease stage (III/IV: 27% versus 62%), had relatively 
less pharyngeal cancer patients (29% versus 43%) and more laryngeal cancer 
patients (36% versus 5%). Hence, patients with advanced disease stage and/or 
pharyngeal cancer may have a higher chance of experiencing xerostomia 
and/or dysphagia. However, this needs to be confirmed in prospective studies. 
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In conclusion, our results can be used to support clinical decision-making. They 
underscore the importance that, next to survival data, clinical studies examine 
toxicity and its impact on generic HRQOL. This assists the trade-off between 
length and quality of survival. Our study suggests that xerostomia and dyspha-
gia have a negative impact on HRQOL; moreover it was found that dysphagia 
affects patients’ HRQOL stronger than xerostomia.  
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Appendix 4.1: RTOG scale for Xerostomia (Salivary glands) and 
Dysphagia (Esophagus) 
 Organ tissue  
 Salivary Glands Esophagus 
Grade 0 None None 
Grade 1 Slight dryness of mouth 
Good response on stimulation 
Mild fibrosis 
Slight difficulty in swallowing solids 
No pain on swallowing 
Grade 2 Moderate dryness of mouth 
Poor response on stimulation 
Unable to take solid food normally 
Swallowing semi-solid food 
Dilatation may be indicated 
Grade 3 Complete dryness of mouth 
No response on stimulation 
Severe fibrosis 
Able to swallow only liquids 
May have pain on swallowing 
Dilation required 
Grade 4 Fibrosis Necrosis/ Perforation 
Fistula 
Grade 5 Death directly related to late radiation effects Death directly related to late radiation effects 
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Appendix 4.2: Complete case analyses of the multivariate regression 
model 
 
Dependent variable:  
utility score 
Dependent variable:  
VAS score 
 
R2 = 43%†,  
Adjusted R2 = 18%‡ 
R2 = 38%†,  
Adjusted R2 = 14%‡ 
Independent variables Beta Se P-value Beta Se P-value 
  Constant 0.836 0.059 0.000 80.6 5.1 0.000 
Treatment toxicity           
  Xerostomia||           
    Grade 1 -0.014 0.022 0.529 -1.9 1.9 0.308 
    Grade 2 -0.069 0.030 0.020 -7.6 2.5 0.003 
    Grade 3+ -0.346 0.125 0.006 -6.0 14.8 0.684 
  Dysphagia||          
    Grade 1 -0.057 0.022 0.009 -5.6 1.9 0.003 
    Grade 2 -0.128 0.031 0.000 -7.2 2.7 0.007 
    Grade 3+ -0.071 0.041 0.083 -9.7 3.7 0.008 
Patient characteristics           
  Sex          
    Male 0.051 0.020 0.009 1.1 1.7 0.528 
  Age 0.000 0.001 0.807 -0.1 0.1 0.215 
Disease characteristics           
  Tumor location||          
    Oral cavity and lip 0.079 0.031 0.010 5.0 2.7 0.064 
    Pharynx 0.065 0.027 0.019 4.5 2.4 0.062 
    Larynx  0.031 0.027 0.249 1.9 2.4 0.430 
Treatment characteristics          
  Surgery of the primary tumor          
    Yes 0.066 0.023 0.005 4.1 2.0 0.043 
  Chemotherapy          
  Yes 0.043 0.028 0.125 4.0 2.5 0.103 
  Follow-up period 0.000 0.000 0.451 0.0 0.0 0.436 
Interaction          
  Xerostomia and Dysphagia - - ns - - ns 
* Interaction between xerostomia and dysphagia was not statistically significant 
† R2 = the fraction of the total squared error that is explained by the regression model. 
‡ Adjusted R2 = measure indicating how much variance in the outcome would be accounted for if 
the model had been derived from the population from which the sample was taken. 
|| Reference category for dummy variables was Grade 0 toxicity and other tumor locations. 
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Abstract 
Objective: To explore the (cost-)effectiveness of swallowing sparing intensity-
modulated proton radiotherapy (IMPT) compared with swallowing sparing 
intensity-modulated radiotherapy with photons (IMRT) in head and neck cancer 
(HNC).  
Methods: A Markov model was constructed to examine and compare the costs 
and quality-adjusted life years (QALYs) of the following strategies: 1) IMPT for 
all patients; 2) IMRT for all patients and; 3) IMPT if efficient. The assumption of 
equal survival for IMPT and IMRT in the base case analysis was relaxed in a 
sensitivity analysis. 
Results: IMPT and IMRT for all patients yielded 6.620 and 6.520 QALYs and 
costed €50,989 and €41,038, respectively. IMPT if efficient yielded 6.563 QAL-
Ys and costed €43,650. The incremental cost-effectiveness ratio of IMPT if 
efficient versus IMRT for all patients was €60,278 per QALY gained.  
In the sensitivity analysis, IMRT was more effective (0.967 QALYs) and less 
expensive (€8,218) and thus dominated IMPT for all patients. 
Conclusions: Cost-effectiveness analysis based on NTCP models and plan-
ning studies proved feasible and informative and enables the analysis of indi-
vidualized strategies. The increased effectiveness of IMPT does not seem to 
outweigh the higher costs for all HNC patients. However, when assuming equal 
survival among both modalities, there seems value in identifying those patients 
for whom IMPT is cost-effective.  
 
Keywords: Cost-effectiveness; Proton radiotherapy; Intensity-modulated radio-
therapy; Head and neck cancer; Quality-adjusted life years; Markov model  
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Introduction 
The costs of cancer care are expected to accelerate due to the ageing popula-
tion and costly new treatments such as proton radiotherapy.1,2 Since resources 
are scarce, it is important to consider the (cost-)effectiveness of new technolo-
gies.2 Economic evaluations are often performed using decision-analytic model-
ing to examine the cost-effectiveness ratio and guide evidence-based decision-
making under uncertainty.3 Economic evaluations frequently rely on compara-
tive effectiveness research to estimate the effectiveness, patient reported 
outcomes and resource use. However, comparative effectiveness research is 
sparsely available for proton radiotherapy.4 Normal tissue complication probabil-
ity (NTCP) models combined with comparative planning studies might be in-
formative to bridge this gap of evidence. NTCP models estimate the probability 
of toxicity based on the expected radiation dose to healthy tissues. Comparative 
planning studies compare the dose-distributions in patients for different radio-
therapy techniques. Hence, NTCP models and comparative planning studies 
can be used in economic evaluations to estimate the expected benefit of inno-
vative radiotherapy techniques. To explore this methodology, we examine the 
cost-effectiveness of intensity modulated proton radiotherapy (IMPT) opposed 
to the current standard: intensity-modulated radiotherapy with photons (IMRT) 
in head and neck cancer (HNC). 
After radiotherapy for HNC, treatment-related toxicities like xerostomia and 
dysphagia substantially affect patients’ health-related quality of life.5 Planning 
studies suggest that proton radiotherapy, with its favorable in-depth dose distri-
bution, has the ability to reduce the radiation dose to healthy tissues and hence 
the occurrence of toxicity compared with photons.6 However, there is no clinical 
evidence which supports these theoretical benefits of protons.4,6 Therefore, we 
aimed to combine NTCP models and comparative planning data in a model-
based economic evaluation to explore the (cost-)effectiveness of swallowing 
sparing IMPT (scanned) compared with swallowing sparing IMRT for HNC 
patients. Swallowing sparing techniques have the ability to reduce the dose to 
swallowing structures with similar dose to the parotid and submandibular glands 
compared with standard techniques. Consequently, swallowing sparing tech-
niques may reduce the occurrence of dysphagia and hence limit the impact of 
treatment on quality of life.5,7 These swallowing sparing techniques can be 
considered the best available IMRT and IMPT treatments. It is expected that not 
all HNC patients have an equal expected benefit from IMPT. Therefore, we will 
also examine an individualized strategy wherein IMPT is only administered to 
patients for whom IMPT is expected to be cost-effective.  
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Methods 
Markov model description 
The study population consisted of locally advanced (stage III-IV) HNC patients 
(oral cavity, laryngeal and pharyngeal cancer), aged on average 61 years at 
start radiotherapy and pre-treatment RTOG <grade 2 dysphagia and xerosto-
mia. A decision-analytic Markov cohort model was constructed to estimate the 
expected costs and effects of three treatment strategies:  
1. IMPT for all patients; 
2. IMRT for all patients; 
3. IMPT if efficient: patients for whom IMPT is expected to be cost-effective 
receive IMPT, the remaining patients receive IMRT. 
Our analysis focuses on the question what type of radiotherapy should be 
provided if radiotherapy is the therapy of choice. Since surgery is complemen-
tary to radiotherapy, it is not considered as comparator. 
Through transiting a hypothetical cohort of patients between mutually exclusive 
health states, a Markov model aims to reflect the course of a disease to com-
pare outcomes for competing interventions.3 The Markov model consisted of 
seven health states (Figure 5.1): 
(a) Disease free without toxicity 
(b) Disease free with xerostomia RTOG ≥grade 2 
(c) Disease free with xerostomia and dysphagia RTOG ≥grade 2  
(d) Disease free with dysphagia RTOG ≥grade 2 
(e) Loco-regional recurrence 
(f) Distant metastasis 
(g) Death 
 
To incorporate the reversibility of acute toxicity during the first six months after 
radiotherapy, a cycle time of six months was used in the first year; afterwards 
the cycle time was one year. A lifetime time horizon was used. 
Markov model assumptions 
The main assumption was that disease progression (including radiation-induced 
cancer) and thus survival were equal for the comparators. This was assumed 
since the tumor dose in the planning studies used to estimate toxicity was 
similar for both modalities and available clinical evidence does not show statisti-
cally significant differences in survival.6 Secondly, toxicity occurring in the first 6 
months was (partly) acute toxicity and thus (partly) reversible. Patients can for 
instance transit from disease free with xerostomia to disease free without toxici-
ty after the first six months. Thereafter, toxicity was assumed to be irreversible. 
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(e) Loco-regional
Recurrence†
(f) Distant 
metastasis
(b) Disease free 
xerostomia 
grade ≥2*
(c) Disease free 
dysphagia & xerostomia 
grade ≥2*
(d) Disease free 
dysphagia
grade ≥2*
(a) Disease free 
no toxicity
(g) Death (all causes mortality)
Figure 5.1: Diagrammatical representation of the model structure 
Toxicity that occurred in the first 6 months was (partly) reversible. Therefore, patients are allowed to 
move between health state a, b, c and d six months after radiotherapy. Thereafter, toxicity was 
assumed to be irreversible.  
* Toxicity was defined according to the presence of RTOG grade 2 or higher  
† There was no transition from loco-regional recurrence to death via distant metastasis. This was 
done firstly because patients who develop distant metastasis are expected to die within one year 
(Appendix 5.3). If we would add the transition from loco-regional recurrence to death via distant 
metastasis, it will last one year or more before patients die due to distant metastasis. Secondly, the 
intermediate step to distant metastasis was already included in the probabilities used to calculate 
death after loco-regional recurrence (Appendix 5.3). 
Markov model input 
Transition probabilities 
The occurrence of xerostomia and/or dysphagia was estimated based on two 
available NTCP models.8,9 Mean radiation dose to the parotis ipsilateral and 
parotis contralateral were used to predict xerostomia RTOG ≥grade 2 at 6 and 
12 months after radiotherapy.8 Mean dose to the pharyngeal constrictor muscle 
superior and the supraglottic area predicted dysphagia RTOG ≥grade 2 at 6 and 
12 months after radiotherapy (Appendix 5.1).9 The required dose parameters 
were retrieved from a planning study (N=25) comparing swallowing sparing 
IMRT and swallowing sparing IMPT.7 Subsequently, the individual dose param-
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eters and NTCP models were used to calculate individual IMPT/IMRT toxicity 
probabilities. These individual probabilities were averaged to obtain the average 
probabilities. The toxicity probabilities for IMPT if efficient were obtained by 
firstly determining which treatment (IMPT/IMRT) was expected to be cost-
effective for each individual patient. This was done by using the individual dose 
parameters and toxicity probabilities to calculate individual cost-effectiveness. 
Secondly, in patients for whom IMPT was expected to be cost-effective, the 
IMPT probabilities were used, while the IMRT probabilities were used in the 
remaining patients. Thirdly, the obtained individual probabilities were averaged 
(calculation is illustrated in Table 5.1). 
The proportion of patients who had both xerostomia and dysphagia was calcu-
lated using conditional toxicity probabilities from a cross-sectional survey (Ap-
pendices 5.1 and 5.2)5 
 
Table 5.1: Method to calculate toxicity for the IMPT if efficient strategy: illustrated for xero-
stomia 6 months after radiotherapy 
 Probability of xerostomia  ICER  Preferred 
IMPT/IMRT 
Probability of 
xerostomia  
Patient IMPT  IMRT    IMPT if efficient* 
      
1 25.5% 41.3% € 93,302  IMRT 41.3% 
2 18.9% 36.6% € 169,448  IMRT 36.6% 
3 23.6% 55.2% € 44,358  IMPT 23.6% 
4 26.7% 37.2% € 150,041  IMRT 37.2% 
 
 
 
 
 
 
     
25 25.8% 45.1% € 89,593  IMRT 45.1% 
Mean probability of xerostomia for the IMPT if efficient strategy 37.1% 
Abbreviations: ICER = Incremental cost-effectiveness ratio, vs = versus 
*Patients will only receive IMPT in this scenario if IMPT is expected to be cost-effective compared 
with IMRT (grey fields), thus if the ICER is below the threshold of €80,000 per QALY gained. 
 
Disease progression for all comparators was based on a meta-analysis which 
compared radiotherapy with and without chemotherapy in curatively treated 
non-metastatic HNC.10 These probabilities were extracted from the concomitant 
chemotherapy arm (current standard treatment for advanced HNC). Age de-
pendent background mortality was used for disease free patients. An increased 
mortality probability was used for patients who had loco-regional recurrence or 
distant metastases (Appendix 5.3).  
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Effects and costs 
Quality of life in terms of utility scores was used as outcome measure. Utility 
scores provide a single index value for health status ranging from 0 (death) to 1 
(full health). Utility scores were derived from a cross-sectional study (N=396) 
using the Euroqol-5D questionnaire in Dutch HNC patients (Appendix 5.3).5 
Utility scores were combined with life expectancy to calculate quality adjusted 
life years (QALYs).  
The health care perspective was used to calculate costs using activity based 
costing. Unit prices and resource use were based on guidelines, a cross-
sectional survey5 or if necessary expert opinion (Appendices 5.4 and 5.5).  
The primary treatment costs for IMPT were calculated by multiplying treatment 
costs for IMRT with a cost ratio of 2.1.1,11 For IMPT if efficient, both IMPT and 
IMRT treatment plans were made to compare individual dose distributions and 
decide upon the most efficient treatment per patient. Therefore, costs of an 
extra treatment plan (€88) were added for this strategy.  
A half-cycle correction was applied for QALYs and costs.12 Future QALYs and 
costs were discounted by rates of 1.5% and 4.0% respectively.13 All costs were 
converted to the 2010 price level.  
Markov model analyses 
Expected mean costs, occurrence of toxicity, disease and toxicity free life years 
(DTFLYs) and QALYs were estimated for all comparators. Subsequently, the 
incremental cost-effectiveness ratio (ICER) was calculated by dividing the 
incremental costs by the incremental QALYs. The ICER represents the costs of 
an additional QALY gained when comparing two strategies. Whether a treat-
ment strategy is considered cost-effective depends on how much society is 
willing to pay per gained QALY, which is referred to as the ceiling ratio. We 
adopted a ceiling ratio of €80,000, since this is the informal ceiling ratio for a 
high burden of disease in the Netherlands.  
Sensitivity analyses 
The assumption of equal disease progression for IMPT and IMRT was relaxed 
in a sensitivity analysis. The probabilities used in this analysis were based on a 
synthesis6 of available clinical studies for oropharyngeal carcinomas (Appendix 
5.3).  
Probabilistic sensitivity analyses were performed to reflect the uncertainty in the 
input parameters and its impact on the estimated (cost-)effectiveness.3 This was 
done by assigning a distribution to the input parameters (Appendices 5.1-5.4) 
and subsequently drawing random values from these distributions using Monte 
Carlo simulation (20,000 iterations). The results of the probabilistic sensitivity 
analyses were presented using cost-effectiveness acceptability curves. For 
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different ceiling ratios this curve shows the probability that a treatment strategy 
is cost-effective.3 
Value of information analyses 
As the results are surrounded by uncertainty, chances are that the wrong deci-
sion is being made when implementing the most cost-effective strategy. The 
expected value of perfect information (EVPI) analysis assesses the expected 
costs of this decision uncertainty. Hence, the EVPI places a maximum that 
society should be willing to pay for further evidence to reduce this uncertainty.3 
The population EVPI was calculated by multiplying the EVPI per patient by the 
effective population in the next 10 years (expected life span of the technology) 
and discounted by a rate of 4%.13 The effective population was calculated 
based on a yearly incidence of 2265 HNC patients in the Netherlands (Dutch 
cancer registry 2008) of which 2063 were expected to receive radiotherapy, 
minus the estimated proportions of patients with early stage HNC (33%) and/or 
pre-treatment dysphagia and/or xerostomia ≥grade 2 (36%).  
To identify the most valuable research topics, the EVPI for (groups of) parame-
ters was calculated for the NTCP models, disease progression, utility scores 
and costs. All analyses were performed in Microsoft Office Excel. 
Results 
The estimated occurrence of xerostomia and dysphagia at 12 months was 
lowest for IMPT for all patients (22% and 18%), followed by IMPT if efficient 
(36% and 21%) and IMRT for all patients (44% and 23%) (Appendix 5.1). 
IMPT for all patients was the most effective (6.620 QALYs, 5.800 DTFLYs) and 
most expensive (€50,989) strategy (Table 5.2). IMRT for all patients was the 
least effective (6.520 QALYs, 4.197 DTFLYs) and least expensive (€41,038) 
strategy. The difference in costs between these two strategies was mainly due 
to higher primary treatment costs (€21,100 versus €10,048). For all 25 patients, 
IMPT resulted in more QALYs compared to IMRT. Restricting IMPT to the 7 
patients (28%) for whom IMPT is expected to be cost-effective (IMPT if efficient) 
would yield 6.563 QALYs and 4.875 DTFLYs at an estimated cost of €43,650.  
IMPT if efficient opposed to IMRT for all patients resulted in an ICER of €60,278 
per QALY gained. IMPT for all patients compared with IMPT if efficient resulted 
in an ICER of €127,946 per QALY gained. IMPT if efficient can thus be regard-
ed as the most cost-effective strategy (Table 5.2).  
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IMPT if efficient had the highest probability (62%) of being the most cost-
effective strategy (Figure 5.2). The value of further research was estimated to 
be €2,4 million for the total population. Further research focusing on utility 
scores after xerostomia (€0.7 million), NTCP models for dysphagia (€0.3 mil-
lion) and for xerostomia (€ 0.1 million) is most worthwhile.  
In the sensitivity analysis, IMRT for all patients yielded 1.493 more QALYs, was 
€8,093 less expensive and thus dominated IMPT for all patients (Table 5.3). 
This was the case for all individual patients. The individualized strategy was 
thus equal to IMRT for all patients plus the costs of an extra treatment plan and 
is therefore not considered in the sensitivity analysis. IMRT for all patients had 
the highest probability (75%) of being cost-effective (Figure 5.2). 
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Figure 5.2: Cost-effectiveness acceptability curves 
The vertical line represents the ceiling ratio which was adopted in our analyses (€80,000 per QALY 
gained).  
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Discussion 
The original aspect of this assessment was that despite the lack of comparative 
effectiveness research, we were able to explore the cost-effectiveness of IMPT 
versus IMRT. The present study showed that employing NTCP models com-
bined with comparative planning studies into model-based economic evalua-
tions is feasible and informative. Besides examining the (cost-)effectiveness, 
this methodology can potentially be used to identify patients for whom particular 
treatments are more or less (cost-)effective than for the whole group. If equal 
disease control is assumed, IMPT is more effective than IMRT for all HNC 
patients. Thus, based on effectiveness, IMPT would be the treatment of choice 
for all patients. However, the increased effectiveness of IMPT does not out-
weigh its additional costs for all patients. Administering IMPT only to selected 
patients for whom it is expected to be cost-effective (IMPT if efficient), seems 
the most cost-effective treatment strategy. IMRT is the dominant strategy if 
disease progression is based on clinical evidence. The quality and quantity of 
available studies is however poor.6 Accordingly, it is possible that differences in 
disease progression found in these studies and thus the dominance of IMRT 
are not a reflection of actual differences.  
Some limitations should also be discussed. Firstly, the presented methodology 
is not yet validated. As with any novel methodology, further research and appli-
cation of the methodology in practice are needed to demonstrate its validity. 
Secondly, disease progression was based on a meta-analysis which included 
trials conducted before 2000 As recent studies show more favorable results,10 
disease progression might have been overestimated. Thirdly, the health care 
perspective was used for cost calculation. The societal perspective, including 
productivity losses, might favor IMPT since less toxicity presumably reduces 
productivity losses. The preceding two limitations can be regarded as conserva-
tive towards IMPT. Fourthly, radiation-induced cancer was not incorporated, 
because evidence on the magnitude and direction of this effect is lacking.14 
Also, given that radiation-induced cancer generally occurs years after radiother-
apy, it is probably not an influential factor in this older population. Fifthly, utility 
scores for the different health states were retrieved from a cross-sectional 
study.5 Preferably, these utility scores are based on a prospective study to 
correct for possible baseline differences. However, the occurrence of xerosto-
mia and/or dysphagia is expectedly independent of baseline utility scores. 
Sixthly, two available prediction models8,9 were used to predict the occurrence 
of toxicity. As with all prediction models, these models can possibly be opti-
mized to achieve more accurate predictions. For the validity of the proposed 
methodology, it is of great importance to use valid prediction models. This 
uncertainty is incorporated in the probabilistic sensitivity analysis. 
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Seventhly, the analyses were based on swallowing sparing radiotherapy tech-
niques. Choice of these techniques most likely decreases the QALY gain for 
IMPT compared with IMRT due to a smaller reduction of dysphagia.7 Hence, 
using swallowing sparing techniques can be regarded as conservative towards 
IMPT. Those interested can use the interactive decision support tool 
(www.predictcancer.org) to examine the cost-effectiveness of IMPT versus 
IMRT for any other radiotherapy technique. Eighthly, incorporating additional 
time points to estimate toxicity, would lead to a more realistic representation of 
clinical practice. However, since this concerns both comparators, the impact on 
the difference in toxicity and consequently the difference in QALYs is probably 
small. Finally, to estimate the occurrence of toxicity, we used NTCP models 
validated with photons. It has been argued that using these NTCP models for 
protons possibly requires modification as photons and protons differ in low to 
intermediate dose distributions.15 At this moment, it is unknown to what degree 
NTCP models validated in photon studies can be used for protons.  
One previous study16 addressed the cost-effectiveness of proton radiotherapy in 
HNC and reported a substantially lower ICER of €3,811 per QALY for proton 
versus photon radiotherapy than the present study. This discrepancy can be 
explained by differences in assumptions. Our model assumed equal survival for 
both comparators, whereas Lundkvist et al. assumed a mortality risk reduction 
of 24% for proton radiotherapy.16  
To our knowledge, no other studies used NTCP models in economic evalua-
tions. However, Konski et al.17 used dose-response data to predict recurrences 
in an economic evaluation for proton radiotherapy in prostate cancer.  
The main research implication is that the applied study method, possibly com-
bined with dose-response data for disease progression,17 is feasible and in-
formative to explore the potential (cost-)effectiveness of innovative radiotherapy 
techniques if clinical evidence is lacking. Clinical data and especially compara-
tive evidence is obviously superior to the proposed methodology. However, the 
proposed methodology offers a solution if clinical data are lacking and it is not 
desirable to wait or postpone decisions until clinical data become available. For 
proton radiotherapy this methodology may provide new insights to the debate 
considering pros and cons of clinical trials comparing proton and photon radio-
therapy.4 It would be interesting for this debate to explore which radiotherapy 
technique is optimal and consider planning studies primarily focused on sparing 
other structures than the swallowing structures. Additionally, further research on 
utility scores after xerostomia and NTCP models seems most valuable to re-
duce decision uncertainty.  
Our results showed that, based on equal survival for IMPT and IMRT, IMPT is 
cost-effective for individually selected patients in the Netherlands. For clinical 
practice it is therefore recommended to make a trade-off between expected 
costs and benefits for each individual patient. The presented methodology can 
be used to make this individual trade-off. This is in line with recent policy rec-
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ommendations.18 In these recommendations it is mentioned that a clinical 
significant reduction of complications is required for patients to be eligible for 
IMPT. However, it is not specified what can be considered as a clinical signifi-
cant reduction. It is required to specify a threshold when patients are eligible for 
IMPT, either based on cost-effectiveness or solely on effectiveness. In our 
analyses, the reduction in complications was expressed in terms of QALYs. The 
adopted ceiling ratio of €80,000 per QALY gained enabled us to calculate which 
treatment is preferred based on cost-effectiveness.  
In deciding which patients receive IMPT, the proposed methodology, if validated 
by clinical data, could act as a clinical decision support tool. Our tool is pub-
lished online as example (www.predictcancer.org). Treatment allocation could 
then be based on individual patient data to ensure that IMPT is assigned to 
patients for whom it is expected to be worthwhile. 
Acknowledgement 
Hans-Paul van der Laan, Ivo Beetz, Miranda Christianen and Tara van de Water are gratefully 
acknowledged for providing additional data. 
This study was supported by an unrestricted research grant (No. 152002021) from the Dutch 
Organization of Health Research and Development (ZonMw). ZonMw had no influence on the study 
design, data analyses, data interpretation, manuscript writing or the decision to submit the manu-
script for publication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C H A P T E R  5  
 
114 
References 
1. Peeters A, Grutters JP, Pijls-Johannesma M, et al: How costly is particle therapy? Cost analy-
sis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol 
95:45-53, 2010 
2. Sullivan R, Peppercorn J, Sikora K, et al: Delivering affordable cancer care in high-income 
countries. Lancet Oncol 12:933-80, 2011 
3. Briggs A, Sculpher MJ, Claxton K: Decision Modelling for Health Economic Evaluation. Oxford, 
Oxford University Press, 2006  
4. De Ruysscher D, Mark Lodge M, Jones B, et al: Charged particles in radiotherapy: A 5-year 
update of a systematic review. Radiother Oncol 103:5-7, 2012 
5. Ramaekers BL, Joore MA, Grutters JP, et al: The impact of late treatment-toxicity on generic 
health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol 
47:768-74, 2011 
6. Ramaekers BL, Pijls-Johannesma M, Joore MA, et al: Systematic review and meta-analysis of 
radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. 
Cancer Treat Rev 37:185-201, 2011 
7. van der Laan HP, van de Water TA, van Herpt HE, et al: The potential of intensity-modulated 
proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck can-
cer: A planning comparative study. Acta Oncol 52:561-9, 2013 
8. Beetz I, Schilstra C, Burlage FR, et al: Dose distributions in the minor salivary glands and the 
development of radiation-induced patient-rated xerostomia. Radioth Oncol 96:S84-S85, 2010 
9. Christianen ME, Schilstra C, Beetz I, et al: Predictive modelling for swallowing dysfunction after 
primary (chemo)radiation: Results of a prospective observational study. Radiother Oncol 
105:107-14, 2012 
10. Pignon JP, le Maitre A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck 
cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 
92:4-14, 2009 
11. Goitein M, Jermann M: The relative costs of proton and X-ray radiation therapy. Clin Oncol (R 
Coll Radiol) 15:S37-50, 2003 
12. Hunink MG, Glasziou PP: Decision Making in Health and Medicine: Integrating Evidence and 
Values. Cambridge, Cambridge University Press, 2001 
13. Health Care Insurance Board: Guidelines for pharmaco-economic research [in Dutch]. Diemen, 
Health Care Insurance Board 2006 
14. Hall EJ: Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J 
Radiat Oncol Biol Phys 65:1-7, 2006 
15. Michalski JM, Gay H, Jackson A, et al: Radiation dose-volume effects in radiation-induced 
rectal injury. Int J Radiat Oncol Biol Phys 76:S123-9, 2010 
16. Lundkvist J, Ekman M, Ericsson SR, et al: Proton therapy of cancer: potential clinical advan-
tages and cost-effectiveness. Acta Oncol 44:850-61, 2005 
17. Konski A, Speier W, Hanlon A, et al: Is proton beam therapy cost effective in the treatment of 
adenocarcinoma of the prostate? J Clin Oncol 25:3603-8, 2007 
18. Health Care Insurance Board: Indications for proton therapy (part 2): model-based indications 
[In Dutch]. Diemen, Health Care Insurance Board, 2011 
B R I D G E  T H E  G A P  O F  E V I D E N C E  F O R  P R O T O N S  
 
115 
Appendix 5.1: NTCP models, planning studies and toxicity probabilities 
NTCP models 
Probability RTOG ≥grade 2 xerostomia  
6 months after radiotherapy (N=354) 
Coefficient Se Distribution Source 
Constant -2.852 0.313 Multivariate normal*1 
Mean dose to parotis ipsilateral 0.031 0.009 Multivariate normal*1 
Mean dose to parotis contralateral 0.036 0.010 Multivariate normal*1 
 
Probability RTOG ≥grade 2 xerostomia  
12 months after radiotherapy (N=251) 
Coefficient Se Distribution Source 
Constant -2.949 0.386 Multivariate normal*1 
Mean dose to parotis ipsilateral 0.025 0.011 Multivariate normal*1 
Mean dose to parotis contralateral 0.045 0.012 Multivariate normal*1 
  
Probability RTOG ≥grade 2 dysphagia  
6 months after radiotherapy (N=354) 
Coefficient Se Distribution Source 
Constant -6.094 0.925 Multivariate normal*2 
Mean dose to pharyngeal constrictor muscle superior 0.057 0.009 Multivariate normal*2 
Mean dose to supraglottic area 0.037 0.012 Multivariate normal*2 
 
Probability RTOG ≥grade 2 dysphagia  
12 months after radiotherapy (N=230) 
Coefficient Se Distribution Source 
Constant -6.343 1.186 Multivariate normal*2 
Mean dose to pharyngeal constrictor muscle superior 0.058 0.012 Multivariate normal*2 
Mean dose to supraglottic area 0.027 0.015 Multivariate normal*2 
 
Radiation dose to healthy tissues based on comparative planning study (GyE) 
 IMRT Range† IMPT Range† Source 
Mean dose to parotis ipsilateral 45.4 25.6 - 65.0 28.5 15.2 - 48.6 3 
Mean dose to parotis contralateral 35.0 24.3 - 48.3 21.2 6.5 - 30.7 3 
Mean dose to pharyngeal constrictor  
muscle superior 62.6 50.3 - 70.8 61.6 44.5 - 70.1 3 
Mean dose to supraglottic area 53.4 25.3 - 70.3 40.3 10.0 - 70.3 3 
 
Overlap between RTOG ≥grade 2 xerostomia and RTOG ≥grade 2 dysphagia 
  Distribution Source 
Probability of dysphagia conditional on having xerostomia  
P(dysphagia | xerostomia) 55.8%         Fixed 4 
Probability of xerostomia conditional on having dysphagia 
P(xerostomia | dysphagia) 65.9%         Fixed 4 
 
Calculated average probabilities of RTOG ≥grade 2 xerostomia and dysphagia without taking into account  
overlap (%)‡ 
 IMRT Range† IMPT Range† 
RTOG ≥grade 2 xerostomia (6 months) 45.8 23.6 - 65.7 23.8 10.6 - 38.5 
RTOG ≥grade 2 xerostomia (12 months) 44.5 23.1 - 64.8 22.5 9.4 - 36.6 
RTOG ≥grade 2 dysphagia (6 months) 37.6 17.7 - 62.0 29.9 4.3 - 61.9 
RTOG ≥grade 2 dysphagia (12 months) 23.0 11.1 - 40.7 18.4 3.2 - 40.3 
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Appendix 5.1 (continued): NTCP models, planning studies and toxicity 
probabilities 
Input parameters for Markov model 
Calculated probabilities of RTOG ≥grade 2 xerostomia and RTOG ≥grade 2 dysphagia taking into account  
overlap (%) 
6 months after radiotherapy IMRT IMPT 
RTOG ≥grade 2 xerostomia and  
RTOG ≥grade 2 dysphagia§                             Average 25.2    16.0   
95% CI|| 21.9 - 28.7  13.5 - 19.4 
RTOG ≥grade 2 xerostomia without  
RTOG ≥grade 2 dysphagia¶                             Average 20.6    7.8   
95% CI||  15.0 - 26.3  3.9 - 12.0 
RTOG ≥grade 2 dysphagia without  
RTOG ≥grade 2 xerostomia#                        Average  12.5    13.2   
95% CI|| 7.2 - 19.5  8.1 - 21.8 
12 months after radiotherapy         
RTOG ≥grade 2 xerostomia and 
RTOG ≥grade 2 dysphagia§                             Average 19.4    12.3   
95% CI|| 15.7 - 24.3  9.7 - 16.9 
RTOG ≥grade 2 xerostomia without  
RTOG ≥grade 2 dysphagia¶                             Average 25.1    10.2   
95% CI|| 17.5 - 32.4  4.9 - 15.6 
RTOG ≥grade 2 dysphagia without  
RTOG ≥grade 2 xerostomia#                            Average  3.6    6.1   
95% CI|| 0.0 - 11.2  1.9 - 16.3 
Abbreviations: Se = standard error, CI = confidence interval, NTCP = normal tissue complication 
probability, IMRT = intensity-modulated radiotherapy with photons, IMPT = intensity-modulated 
proton radiotherapy, RTOG = Radiation Therapy Oncology Group, GyE = gray equivalent 
* The multivariate normal distribution was constructed using Cholesky decompositions5 
† The range of point estimates across all 25 patients.  
‡ The average toxicity probability was calculated based on the individual toxicity probabilities per 
patient.  
§ The formula: √((P(xerostomia) * P(dysphagia | xerostomia))*(P(dysphagia) * P(xerostomia | 
dysphagia))) was used to calculate the probability that patients had both xerostomia and dysphagia.  
|| The 95% confidence interval represents the parameter uncertainty accompanying the point 
estimate, and was generated in the probabilistic sensitivity analysis. 
¶ The formula: P(xerostomia) - P(xerostomia and dysphagia) was used to calculate the probability 
that patients had xerostomia without dysphagia  
# The formula: P(dysphagia) - P(xerostomia and dysphagia) was used to calculate the probability 
that patients had dysphagia without xerostomia 
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Appendix 5.2: Toxicity probabilities for the all strategies  
Input parameters for Markov model 
Calculated probabilities of RTOG ≥grade 2 xerostomia and RTOG ≥grade 2 dysphagia taking into account  
overlap (%)† 
6 months after radiotherapy IMRT for all patients  IMPT for all patients  IMPT if efficient 
RTOG ≥grade 2 xerostomia and 
RTOG ≥grade 2 dysphagia Average 25.2 16.0 21.2 
 95% CI‡ 21.9 - 28.7 13.5 - 19.4 18.3 - 24.9 
RTOG ≥grade 2 xerostomia without 
RTOG ≥grade 2 dysphagia Average 20.6 7.8 15.9 
 95% CI‡ 15.0 - 26.3 3.9 - 12.0 11.0 - 20.8 
RTOG ≥grade 2 dysphagia without 
RTOG ≥grade 2 xerostomia Average 12.5 13.2 11.8 
 95% CI‡ 7.2 - 19.5 8.1 - 21.8 6.8 - 19.5 
12 months after radiotherapy  
RTOG ≥grade 2 xerostomia and 
RTOG ≥grade 2 dysphagia Average 19.4 12.3 16.4 
 95% CI‡ 15.7 - 24.3 9.7 - 16.9 13.2 - 21.5 
RTOG ≥grade 2 xerostomia without 
RTOG ≥grade 2 dysphagia Average 25.1 10.2 19.2 
 95% CI‡ 17.5 - 32.4 4.9 - 15.6 12.5 - 25.6 
RTOG ≥grade 2 dysphagia without 
RTOG ≥grade 2 xerostomia Average 3.6 6.1 4.2 
 95% CI‡ 0 .0  -  11 .2  1.9  -  16.3  0.3 - 13.3 
Abbreviations: CI = confidence interval, IMRT = intensity-modulated 
* The average toxicity probability was calculated based on the individual toxicity probabilities per 
patient instead of average dose parameters 
† See Appendix 5.1 for calculation steps 
‡ The confidence interval represents the parameter uncertainty accompanying the point estimate, 
and was generated in the probabilistic sensitivity analyses. 
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Appendix 5.3: Treatment independent transition probabilities and health 
state utility scores  
Parameter Estimated  
value 
Se Distribution Source 
Transition probabilities (%)     
From disease free with or without toxicity     
Loco-regional recurrence 0-2 year after radiotherapy* 0.256 0.003 Beta 6 
Loco-regional recurrence 2-5 year after radiotherapy 0.038 0.006 Beta 6 
Loco-regional recurrence more than 5 year after radiotherapy† 0.010 0.011 Beta 6 
     
Distant metastases 0-2 year after radiotherapy* 0.058 0.002 Beta 6 
Distant metastases 2-5 year after radiotherapy 0.021 0.003 Beta 6 
Distant metastases more than 5 year after radiotherapy† 0.003 0.004 Beta 6 
     
Cancer-related mortality from:     
Loco-regional recurrence* 0.480 0.051 Beta 7 
Distant metastases 1.000 Fixed - 8 and Eo 
     
Sensitivity analysis     
From disease free with or without toxicity     
IMRT     
Loco-regional recurrence 0-2 year after radiotherapy* 0.027 0.013 Beta 9 
Loco-regional recurrence 2-5 year after radiotherapy‡ 0.027 0.013 Beta 9 
Loco-regional recurrence more than 5 year after radiotherapy‡ 0.027 0.013 Beta 9 
     
Distant metastases§ 0-2 year after radiotherapy* 0.042 0.019 Beta 9 
Distant metastases§ 2-5 year after radiotherapy‡ 0.042 0.019 Beta 9 
Distant metastases§ more than 5 year after radiotherapy‡ 0.042 0.019 Beta 9 
     
IMPT     
Loco-regional recurrence 0-2 year after radiotherapy* 0.020 0.022 Beta 9 
Loco-regional recurrence 2-5 year after radiotherapy‡ 0.020 0.022 Beta 9 
Loco-regional recurrence more than 5 year after radiotherapy‡ 0.020 0.022 Beta 9 
     
Distant metastases§ 0-2 year after radiotherapy* 0.078 0.046 Beta 9 
Distant metastases§ 2-5 year after radiotherapy‡ 0.078 0.046 Beta 9 
Distant metastases§ more than 5 year after radiotherapy‡ 0.078 0.046 Beta 9 
     
Health state utility scores     
Disease free, no toxicity 0.880 0.010 Beta 4 
Disease free, xerostomia ≥grade 2 0.826 0.027 Beta 4 
Disease free, dysphagia ≥grade 2 0.803 0.036 Beta 4 
Disease free, xerostomia ≥grade 2 and dysphagia ≥grade 2 0.761 0.029 Beta 4 
Loco-regional disease and distant disease 0.720 0.070 Beta 4 
Abbreviations: Se = standard error, Eo = expert opinion 
* The 6 months probability was calculated from the yearly probability using the following formula5:
 P(6 months) = 1- e (ln (1- P(1 year)) * 0.5)    
† The yearly loco-regional and distant failure probabilities between 5- and 7-year were assumed to 
remain constant for life-time. 
‡ Assumed equal as the 0-2 year probability 
§ Calculated by subtracting the loco-regional control probabilities from the disease free survival 
probabilities9
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Appendix 5.4: Resource use and unit prices 
Parameter Estimated 
value 
Range / Se Distribution Source 
Number of speech therapist examinations 1.0 Fixed - Eo 
Number of speech therapist consults 8.0 6.0 - 10.0 Beta PERT Eo 
Radiation technician hours per treatment plan 3.0 1.0 - 6.0 Beta PERT Eo 
Number of follow-up consults per year  
(year 1 after primary treatment/re-treatment) 5.0 Fixed - 10 
Number of follow-up consults per year  
(year 2 after primary treatment/re-treatment) 4.0 Fixed - 10 
Number of follow-up consults per year  
(year 3 after primary treatment/re-treatment) 2.5 Fixed - 10 
Number of follow-up consults per year  
(year 4 after primary treatment/re-treatment) 2.0 Fixed - 10 
Number of follow-up consults per year  
(year 5 after primary treatment/re-treatment) 2.0 Fixed - 10 
Related to xerostomia grade 0-1       
Number of fillings 2.3 0.8 Gamma 4 
Number of crowns 7.5 5.5 Gamma 4 
Number of fixed partial dentures 1.5 0.5 Gamma 4 
Number of extra dentist consults per year 0.0 Fixed - 11 
Gram Natriumfluoride gel per year 0.0 Fixed - Eo 
% of patients who had fillings† 4.0% 1.2% Beta 4 
% of patients with crowns† 1.0% 0.6% Beta 4 
% of patients who had fixed partial dentures† 1.0% 0.6% Beta 4 
% of patients who had root canal treatment† 2.0% 0.8% Beta 4 
% of patients who had dental plates† 10.0% 1.8% Beta 4 
% of patients who had dental plates† 7.0% 1.5% Beta 4 
% of patients who had dental implants† 1.0% 0.7% Beta 4 
% of patients who had dental implants† 2.0% 0.8% Beta 4 
% of patients with extra dentist consults 0.0% Fixed - 11 
% of patients with Natriumfluoride gel 0.0% Fixed - 10 
Related to xerostomia ≥grade 2       
Number of fillings 3.0 0.6 Gamma 4 
Number of crowns 0.0 0.0 Gamma 4 
Number of fixed partial dentures 0.0 0.0 Gamma 4 
Number of extra dentist consults per year 2.0 Fixed - 11 
Gram Natriumfluoride gel per year 365.0 Fixed - Eo 
% of patients who had fillings† 7.0% 3.0% Beta 4 
% of patients with crowns† 0.0% 0.0% Beta 4 
% of patients who had fixed partial dentures† 0.0% 0.0% Beta 4 
% of patients who had root canal treatment† 0.0% 0.0% Beta 4 
% of patients who had dental plates† 11.0% 3.0% Beta 4 
% of patients who had dental plates† 8.0% 3.0% Beta 4 
% of patients who had dental implants† 1.0% 1.0% Beta 4 
% of patients who had dental implants† 3.0% 2.0% Beta 4 
% of patients with extra dentist consults 100.0% Fixed - 11 
% of patients with Natriumfluoride gel 100.0% Fixed - 10 
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Appendix 5.4 (continued): Resource use and unit prices 
Related to dysphagia grade 0-1       
Portions of liquid nutrition per day 2.7 0.3 Gamma 4 
Liter of tube feeding per year 0.0 0.0 Gamma 4 
% of patients with liquid nutrition  11.0% 2.0% Beta 4 
% for patients with tube feeding 0.0% 0.0% Beta 4 
Related to dysphagia ≥grade 2       
Portions of liquid nutrition per day 3.7 0.3 Gamma 4 
Liter of tube feeding per year 1237.5 151.9 Gamma 4 
% of patients with liquid nutrition  56.0% 5.0% Beta 4 
% for patients with tube feeding 15.0% 4.0% Beta 4 
     
Unit prices (€)‡     
Cost ratio for IMPT (primary treatment) 2.1 1.8 - 2.4 Beta PERT 12,13 
Cost of IMRT (primary treatment) 10,036.49  Fixed - 14 
Cost per speech therapist examination 44.49  Fixed - 15 
Cost per speech therapist consult 22.25  Fixed - 15 
Cost per radiotherapist consult 62.16  Fixed - 14 
Cost per dentist consult 19.47  Fixed - 15 
Cost of radiation technician (per hour) 29.49 Fixed  12 
Costs per 100 gram Natriumfluoride gel (1% LNA) 7.55  Fixed - MP 
Costs per portion of Liquid nutrition (125 mL) 3.70  Fixed - MP 
Costs per 125 mL of tube feeding 2.76  Fixed - MP 
Costs of placing and removing tube  210.91  Fixed - 14 
Costs per filling 76.87  Fixed - Appendix 5.5 
Costs per crown 586.21  Fixed - Appendix 5.5 
Costs per fixed partial denture 1,595.95  Fixed - Appendix 5.5 
Costs per root canal treatment 271.74  Fixed - Appendix 5.5 
Costs per dental plate (upper or lower teeth) 463.09  Fixed - Appendix 5.5 
Costs per dental implant (upper or lower teeth) 2,339.45  Fixed - Appendix 5.5 
Other costs (€)     
Cost of salvage therapy after loco-regional recurrence 11,210.14  Fixed - 16 
Costs of cancer death 23,295.28  Fixed - 17 
Costs of non-cancer death 16,603.30  Fixed - 17 
Abbreviations: Se = standard error, Eo = expert opinion, MP = market price retrieved from 
http://www.efarma.nl/ or http://www.sorgente.nl/ 
* These resources were once only 
† In the last 6 months 
‡ All unit prices were converted to the 2010 price level based on price indices18 
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Appendix 5.5: Unit prices dentist costs 
Item Code Procedure Costs (€) Source 
 A10 Anesthesia 12.81  15 
 V12 Restoration 33.31  15 
 V21 Cauterization and foundation 20.50  15 
 V50 Cofferdam  10.25  15 
Costs per filling   76.87   
 X10 Radiograph 14.35  15 
 A10 Anesthesia (2x) 25.62  15 
 R31 Plastic construction 30.74  15 
 V21 Cauterization and foundation 20.50  15 
 R25 Dentist tariff crown 225.00  15 
 R00 Dental technique costs 270.00  15 
Costs per crown   586.21   
 X10 Radiograph 14.35  15 
 A10 Anesthesia (2x) 25.62  15 
 V21 Cauterization and foundation (2x) 41.00  15 
 R31 Plastic construction (2x) 61.48  15 
 R25 Dentist tariff crown (2x) 450.00  15 
 R40 Dentist tariff between part 153.50  15 
 R00 Dental technique costs 850.00  15 
Costs per fixed partial denture   1,595.95   
 A10 Anesthesia (2x) 25.62  15 
 X10 Radiograph (4x) 57.40  15 
 V50 Cofferdam (2x) 20.50  15 
 E85 Electronic determination of length 12.81  15 
 E13 Single-canal element 92.23  15 
 E01 Dentist consult 19.47  15 
 E04 Surcharge instrumentation costs 43.71  15 
Costs per root canal treatment   271.74   
 P15 Partial plate prosthesis 5-13 elements 153.72  15 
 P16 Individual print 56.37  15 
 R00 Dental technique costs 253.00  15 
Costs per dental plate   463.09   
 X21 Orthopantomogram 61.49  15 
 J01 Initial examination implantodontics 66.61  15 
 J02 Extended examination implantodontics 102.48  15 
 J97 Overhead costs implants 188.50  15 
 J20 Placing first implant 199.84  15 
 J23 2nd phase operation 76.86  15 
 J44 Abutment for crown 25.62  15 
 R25 Dentist tariff crown 225.00  15 
 X10 Radiograph (3x) 43.05  15 
 J00 Material costs implantodontics 500.00  15 
 R00 Dental technique costs 450.00  15 
 - Bone reconstruction procedure 400.00  15 
Costs per dental implant   2,339.45   
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Abstract 
Objective: To examine and compare the cost-effectiveness of different modi-
fied radiotherapy schemes and CRT in the curative treatment of unresected 
NSCLC patients. 
Methods: A probabilistic Markov model was developed based on individual 
patient data from the Meta-Analysis of Radiotherapy in Lung Cancer (MAR-LC; 
N=2,000). Dutch healthcare costs, quality-adjusted life years (QALYs) and net 
monetary benefits (NMB) were compared between two accelerated schemes 
(very accelerated (VART) and moderately accelerated (MART)), two hyperfrac-
tionated schemes (using an identical (HRTI) or higher (HRTH) total treatment 
dose than CRT) and CRT.  
Results: All modified fractionations were more effective and costly than CRT 
(1.12 QALYs, €24,360). VART and MART were most effective (1.30 and 1.32 
QALYs) and cost €25,746 and €26,208 respectively. HRTI and HRTH yielded 
less QALYs than the accelerated schemes (1.27 and 1.14 QALYs), and cost 
€26,199 and €29,683 respectively. MART had the highest NMB (€79,322; 95% 
CI €35,478-€133,648) and was the most cost-effective treatment followed by 
VART (€78,347; 95% CI €64,635-€92,526). CRT had a NMB of €65,125 (95% 
CI €54,663-€75,537). MART had the highest probability of being cost-effective 
(43%), followed by VART (31%), HRTI (24%), HRTH (2%) and CRT (0%).  
Conclusions: Implementing accelerated radiotherapy is almost certainly more 
efficient than current practice (CRT) and should be recommended as standard 
radiotherapy for the curative treatment of unresected NSCLC not receiving 
concurrent chemo-radiotherapy. 
 
Keywords: Radiotherapy; Dose Fractionation; Non-Small-Cell Lung Cancer; 
Cost-Benefit Analysis; Markov Chain  
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Introduction 
Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancer which is 
the third most diagnosed form of cancer and causes the greatest number of 
cancer deaths.1,2 Radiotherapy with or without chemotherapy is increasingly 
being used in the curative treatment for unresected NSCLC.3 The therapeutic 
effect of radiation alone in lung cancer follows a clear dose-response relation-
ship (i.e. higher biological doses lead to better local tumor control).4-6 Hence, as 
recently shown by an individual patient meta-analysis,7 modified fractionation 
radiotherapy schemes, with increased biological dose, have the ability to im-
prove overall survival (OS) compared with conventional radiotherapy schedules 
(hazard ratio (HR): 0.88). Additionally, modified radiotherapy increased the risk 
of acute esophageal toxicity.7 
With regard to the scarcity of resources and accelerating costs of cancer care, it 
is increasingly important to consider the cost-benefit ratio of (new) treatments to 
guide decision-making.8,9 Economic evaluations are frequently performed using 
decision-analytic modelling to synthesize different sources of evidence (e.g. 
effectiveness, patient reported outcomes and costs), compare the cost-
effectiveness of competing interventions and support decision-making under 
uncertainty.9 As cost-effectiveness estimates are inevitably surrounded by 
uncertainty, it is essential to characterize uncertainty in economic evaluations.9 
Although parameter uncertainty (as exact estimates for parameters like effec-
tiveness are often unknown) is frequently acknowledged in decision-analytic 
modelling, patient heterogeneity is often ignored.10,11 The objective of the pre-
sent study is to perform a cost-effectiveness analysis comparing multiple modi-
fied fractionation radiotherapy schemes with conventional fractionation radio-
therapy in the curative treatment of unresected NSCLC while taking into ac-
count both parameter uncertainty and patient heterogeneity. 
Methods 
MAR-LC  
The Meta-Analysis of Radiotherapy in Lung Cancer (MAR-LC) database was 
used as primary data source. This database consists of individual patient data 
from twelve randomized clinical trials (RCTs) that compared. conventional and 
modified fractionated radiotherapy.7 The ten RCTs with a population of unre-
sected NSCLC patients were selected for the present study. These RCTs 
accrued a total of 2,000 patients between 1989 and 2006 (median follow-up: 6.9 
years). In four trials, the same chemotherapy was administered in both arms 
either concomitantly with radiotherapy (two trials) or as induction chemotherapy 
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(two trials). No chemotherapy was given in the other RTCs. Most patients were 
male (75%), aged 60-69 years (42%), had squamous cell carcinoma (SCC) 
(60%) and stage III disease (83%). Performance status was good (Eastern 
Cooperative Oncology Group (ECOG) performance status=0) for 43% of the 
patients.  
Markov model description 
A probabilistic decision-analytic Markov cohort model was developed. To com-
pare competing interventions, this model aims to reflect the course of a disease 
using a hypothetical cohort of patients who transit between mutually exclusive 
health states.9 These health states were based on whether patients were alive 
and presence of toxicity (Figure 6.1). Subsequently, the expected costs and 
effects were estimated for conventional fractionated radiotherapy and four types 
of modified fractionation radiotherapy. These modified fractionation schemes 
are based on two types of modified fractionation and their combination: 1) 
accelerated radiotherapy schemes which consist of a reduced overall treatment 
time (OTT) compared with conventional fractionation and 2) hyperfractionated 
radiotherapy schemes which consist of a higher number of fractions with a 
smaller dose per fraction compared with conventional radiotherapy. Five 
schemes were compared using the MAR-LC database (Appendix 6.1): 
1. Conventional fractionation radiotherapy (CRT; 10 trials, N=944): 5 weekly 
fractions of 1.8-2.0 Gray (Gy), accumulating to a total treatment dose (TTD) 
of 60-70 Gy. 
2. Very accelerated radiotherapy (VART; 6 trials, N=700): reduced OTT with 
≥50%, using an identical (±5%) or lower (5-10%) TTD compared with CRT 
(OS HR: 0.88 (95% confidence interval (95% CI) 0.78-0.98) versus CRT).7 
3. Moderately accelerated radiotherapy (MART; 1 trial, N=29): reduced OTT 
with 14-49%, using a TTD identical (±5%) to CRT (OS HR: 0.90 (95% CI 
0.52-1.54) versus CRT).7 
4. Hyperfractionated radiotherapy using identical TTD (HRT
I
; 2 trials, N=164): 
the average dose per fraction is decreased to ≤1.75 Gy using a TTD identi-
cal (±5%) to CRT (OS HR: 0.87 (95% CI 0.69-1.10) versus CRT).7 
5. Hyperfractionated radiotherapy using higher TTD (HRT
H
; 1 trial, N=163): the 
average dose per fraction is decreased to ≤1.75 Gy using a higher (5-15%) 
TTD than CRT (OS HR: 0.92 (95% CI 0.74-1.15) versus CRT).7 
A lifetime time horizon and a cycle time of one month were used. Additionally, a 
half-cycle correction was applied. Future costs and effects were discounted by 
rates of 4.0% and 1.5% respectively, according to the Dutch pharmacoeconom-
ic guideline. 
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Figure 6.1: Diagrammatical representation of the Markov model structure* 
* The numbers (1 and 2) next to the arrows correspond to the Weibull models in Appendix 6.2. 
† Acute toxicity included grade 3 or higher pulmonary toxicity, esophageal toxicity and hematologi-
cal toxicity (see Appendix 6.3 for the corresponding logistic regression models). 
‡ Late toxicity included grade 3 or higher pulmonary toxicity and esophageal toxicity (Table 6.1). 
§ Non-cancer mortality was defined as deaths resulting from causes other than cancer and not 
occurring after disease progression. 
 
Since a model is a simplified representation of reality, assumptions about reality 
are inherent to modelling. The main assumptions were:  
1. Based on an analysis of the Radiation Therapy Oncology Group database, 
acute toxicity was assumed to increase from start of radiotherapy to 3 
months and then reverse.12 Late toxicity was assumed to be irreversible, to 
begin 3 months after start of radiotherapy and to increase in frequency up to 
1.5 years with the assumption that it had plateaued.12 
2. There is no overlap between toxicities, i.e. a patient can only have one 
toxicity and not for example both pulmonary and esophageal toxicity con-
currently. However, one patient can have different acute and late toxicities. 
No overlap between toxicities was assumed since there was only limited 
overlap in the MAR-LC database (3.1% for acute and 0.1% for late toxicity). 
Incorporating overlapping toxicities would unnecessarily increase the com-
plexity and hence decrease the transparency of the model. 
3. As mentioned above, modified radiotherapy may reduce non-cancer mor-
tality (most likely due to differences in treatment-related death).7 Neverthe-
less, we conservatively assumed that there is no difference in non-cancer 
mortality between the radiotherapy schemes. This was assumed since non-
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cancer mortality, which included treatment-related deaths, was not reported 
for MART.  
Transition probabilities 
Time dependent survival probabilities were estimated by means of parametric 
survival models using a Weibull distribution (Appendix 6.2).13 Separate Weibull 
regression models were developed for non-cancer mortality and cancer mortali-
ty. Logistic regression models were developed to estimate acute toxicity (grade 
≥3) probabilities, separately for acute pulmonary, esophageal and hematologi-
cal toxicity (Appendix 6.3). All regression models were stratified by trial to 
preserve randomization and obtain unbiased estimates.14 Potential heterogenei-
ty in baseline risks was acknowledged through these regression models using 
the following covariates: treatment arm (CRT; VART; MART; HRTI; HRTH), sex 
(male; female), age (≤59; 60-69; ≥70), performance status (mild; good), histolo-
gy (SCC; non-SCC) and disease stage (I/II; IIIA; IIIB). All variables were includ-
ed in the initial model as categorical variables. Selection of covariates was 
performed as described by Hosmer et al,15 except for the treatment arm varia-
ble. The treatment arm variable was not included in the Weibull model to predict 
non-cancer mortality, and was always included in the Weibull regression model 
that predicts cancer mortality. Individual characteristics were needed to calcu-
late the acute toxicity probabilities using the logistic regression models. For this 
purpose, a hypothetical cohort of individual patients was replicated based on 
average characteristics and their correlations from the MAR-LC database 
(Appendix 6.3). 
To estimate late pulmonary and esophageal toxicity (grade ≥3), the proportions 
from the MAR-LC database were used. Consistent with the meta-analysis, late 
toxicity was assumed to be equal for all comparators (Table 6.1).7 
All parameters retrieved from the MAR-LC database were computed in the 
Department of Biostatistics and Epidemiology of IGR by BL and BR. 
Effects and costs 
Utility scores were used as effect measure. Utility is a single score measure for 
generic health-related quality of life and ranges from 0 (death) to 1 (full health). 
These utility scores were combined with life expectancy to calculate quality 
adjusted life years (QALYs). Utility scores were derived from a Dutch cross-
sectional study (N=260)16 which used the Euroqol-5D17 questionnaire. Patients 
with unresected NSCLC (N=85) were selected from this study (Table 6.1).  
Patients who died due to NSCLC in the Markov model were assigned a disutili-
ty. This was the average disutility for recurrent disease (0.152) multiplied by the 
average life expectancy after recurrent disease (6 months in the MAR-LC 
database).  
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Costs were calculated using the Dutch health care perspective and converted to 
the 2011 price level based on price indices from Statistics Netherlands (CBS). 
Resource use and unit prices are reported in Table 6.2.  
 
Table 6.1: Input parameters: probabilities and health state utility 
Parameter Estimated  
value 
Standard 
error 
Distribution Source 
Probabilities     
Probability of non-cancer mortality Dependent on time and patient characteristics (Appendix 6.2) 
Probability of cancer mortality  Dependent on time and patient characteristics (Appendix 6.2) 
     
Probability of acute pulmonary toxicity Dependent on patient characteristics (Appendix 6.3) 
Probability of acute esophageal toxicity Dependent on patient characteristics (Appendix 6.3) 
Probability of acute hematological toxicity Dependent on patient characteristics (Appendix 6.3) 
     
Probability of late pulmonary toxicity* 15.4% 14.0% Beta MAR-LC 
Probability of late esophageal toxicity* 3.3% 2.9% Beta MAR-LC 
     
Health state utility     
No recurrence No toxicity 0.800 0.029 Beta 16 
 Acute hematological toxicity† 0.710   16,18 
 Acute pulmonary toxicity‡ 0.493 0.075 Beta 16 
 Acute esophageal toxicity‡ 0.493 0.075 Beta 16 
 Late pulmonary toxicity‡ 0.493 0.075 Beta 16 
 Late esophageal toxicity‡ 0.493 0.075 Beta 16 
      
Recurrence No toxicity 0.794 0.038 Beta 16 
 Acute hematological toxicity† 0.704   16,18 
 Acute pulmonary toxicity‡ 0.129 0.061 Beta 16 
 Acute esophageal toxicity‡ 0.129 0.061 Beta 16 
 Late pulmonary toxicity‡ 0.129 0.061 Beta 16 
 Late esophageal toxicity‡ 0.129 0.061 Beta 16 
Abbreviations: NSCLC = non-small cell lung cancer 
* It was assumed that late toxicity increases from 3 months after start radiotherapy up to 18 months 
after start radiotherapy to the total probability. The monthly probability was then calculated from the 
total probability using the following formula:9 
P(1 month) = 1- e (ln (1- P(total)) * 1/15) 
† This health state utility was calculated based the utilities without toxicity from Grutters et al.,16 and 
a disutility from Nafees et al.,18 
‡ It was assumed that patients with acute or late esophageal or pulmonary toxicity had the same 
utility scores. 
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Table 6.2: Input parameters: resource use and costs  
Parameter Estimated  
value 
Se / Range Distribution Source 
Primary treatment costs       
          Time per fraction of radiotherapy (minutes) 10 8 - 18 Beta PERT EO 
          Costs per 10 minutes of radiotherapy  €233 €194 - €291 Beta PERT 19 
     
          Number of fractions for CRT 30 0.2 Gamma MAR-LC 
Costs of CRT  €6,940    
          Number of fractions for VART 36 0.2 Gamma MAR-LC 
Costs of VART €8,290    
          Number of fractions for MART* 38 0.2 Gamma MAR-LC 
Costs of MART €8,940    
          Number of fractions for HRTI* 38 0.2 Gamma MAR-LC 
Costs of HRTI €8,940    
          Number of fractions for HRTH 53 1.1 Gamma MAR-LC 
Costs of HRTH €12,237    
     
Acute pulmonary toxicity costs (≥ grade 3)     
          Probability of hospitalization (%) 2.5 0.3 Beta EO 
          Days of hospital admission 11 2.0 Gamma 20 
          Costs Hospital admission (per day) €463 Fixed  21 
          Medication costs  €22 Fixed  CvZ 
Acute pulmonary toxicity costs €147    
     
Acute esophageal toxicity costs (≥ grade 3)     
          Days of hospital admission  2 0.3 Gamma EO 
          Costs Hospital admission (per day) €463 Fixed  21 
          Days of tube feeding when hospitalized 21 2.0 Gamma EO 
          Costs of tube nutrition per day €18 Fixed  MP 
          Costs of placing and removing tube  €269 Fixed  NZa 
          Medication costs for acute esophageal 
          toxicity 
€31 Fixed  CvZ 
Acute esophageal toxicity costs €1,604    
Abbreviations: Se = standard error, EO = expert opinion, MP = market price, NZa = Nederlands 
Zorgautoriteit / Dutch Healthcare Authority, CvZ = College voor Zorgverzekeringen / Health Care 
Insurance Board 
* Due to a lack of data, the number of fractions was assumed to be 96% of the theoretical number of 
fractions (as observed on average for the other comparators) and the standard error from very 
accelerated radiotherapy was used 
† Standard error was based on expert opinion 
‡ The chemotherapy costs have to be multiplied by the proportion of patients who received chemo-
therapy (29.5%) to calculate the average chemotherapy costs 
 
M O D I F I E D  F R A C T I O N A T I O N  R A D I O T H E R A P Y  F O R  L U N G  C A N C E R  
 
131 
Table 6.2 (continued): Input parameters: resource use and costs 
Parameter Estimated  
value 
Se / Range Distribution Source 
Acute hematological toxicity costs (≥ grade 3)     
Costs of an episode of febrile neutropenia  €3,754 €1241 Gamma 
22 
     
Mortality costs (costs of last life-year before dying)     
Cancer mortality €22,793 €2000† Gamma 23 
Non-cancer mortality €16,246 €2000† Gamma 23 
     
Follow-up costs      
          Costs per follow-up visit €73 Fixed  21 
          Number of follow-up visits in first year 4 Fixed  NSCLC 
guideline  
Monthly costs of follow-up first year €24    
          Number of follow-up visits in second year 2 Fixed  NSCLC 
guideline 
Monthly costs of follow-up second year €12    
          Number of follow-up visits after second year 1 Fixed  NSCLC 
guideline 
Monthly costs of follow-up after second year €6    
     
Late Toxicity costs     
          Yearly costs of irreversible dyspnoea ≥ grade 3 €1099 €100†  20 
Monthly costs of irreversible dyspnoea ≥ grade 3 €92    
Abbreviations: Se = standard error, EO = expert opinion, MP = market price, NZa = Nederlandse 
Zorgautoriteit / Dutch Healthcare Authority, CvZ = College voor Zorgverzekeringen / Health Care 
Insurance Board 
* Due to a lack of data, the number of fractions was assumed to be 96% of the theoretical number of 
fractions (as observed on average for the other comparators) and the standard error from very 
accelerated radiotherapy was used 
† Standard error was based on expert opinion 
‡ The chemotherapy costs have to be multiplied by the proportion of patients who received chemo-
therapy (29.5%) to calculate the average chemotherapy costs 
Markov model analysis 
Expected life years (LYs), QALYs, costs and net monetary benefit (NMB) were 
estimated for all comparators. The NMB was calculated by multiplying the 
number of QALYs with the ceiling ratio and subtracting the total costs. The 
treatment strategy with the highest NMB is considered as most cost-effective.  
We adopted a ceiling ratio of €80,000, since this is the informal ceiling ratio for a 
high burden of disease in the Netherlands.18 The incremental cost-effectiveness 
ratio (ICER) was calculated by dividing the incremental costs by the incremental 
QALYs. The ICER represents the costs of an additional QALY gained and was 
used to estimate the cost-effectiveness of a treatment 1) opposed to CRT and 
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2) opposed to the next best alternative. A treatment is deemed cost-effective 
when its ICER is below the ceiling ratio. 
The Markov model was analysed in Microsoft Excel 2003 (computer software, 
Microsoft Corporation, Redmond, United States). The required analyses to 
retrieve the input parameters were performed in SAS version 9.2 (computer 
software, SAS Institute, Cary, United States), except the Weibull analysis which 
was performed in R version 2.13.1 (open source computer software, R Founda-
tion, Vienna, Austria) as SAS did not support stratifying by trial in this analysis. 
Parameter uncertainty 
To explore the impact of parameter uncertainty on the estimated (cost-
)effectiveness, probabilistic sensitivity analysis was performed using Monte 
Carlo simulation (15,000 iterations).9 For this purpose a distribution was as-
signed to the input parameters (Table 6.1 and 6.2). The Weibull and logistic 
regression models were included using Cholesky decompositions.9 Cost-
effectiveness acceptability curves were created to show for different ceiling 
ratios the probability that a treatment is most cost-effective.9 
Since the estimated cost-effectiveness is surrounded by uncertainty it is possi-
ble that based on current information, the ‘wrong’ decision is being made. The 
expected value of perfect information (EVPI) analysis quantifies the costs of this 
decision uncertainty. It estimates the value of further research to gain 
knowledge of the ‘true’ parameter values.9 Thus, the EVPI represents the upper 
limit that society should be willing to pay to reduce decision uncertainty and 
inform the decision in the future.9 The EVPI per patient was multiplied by the 
effective population in the next five years (expected lifespan of the technology) 
and discounted by a rate of 4% to calculate the population EVPI. The effective 
population was calculated based on a yearly incidence of 8,661 NSCLC pa-
tients in the Netherlands (Dutch Cancer Registration, 2010) minus the estimat-
ed proportion of resected NSCLC patients (20%) and the estimated proportion 
with metastatic disease among unresected patients (40%), this resulted in an 
annual population of 4,157 patients. To identify the most valuable research 
topics, the EVPI for (groups of) parameters (EVPPI) was calculated.  
Heterogeneity 
The expected value of individualized care (EVIC) was calculated to examine the 
impact of patient heterogeneity on cost-effectiveness.19,20 The EVIC estimates 
the value of providing the optimal treatment for each individual instead of the 
average best treatment for all patients. The same hypothetical cohort of individ-
ual patients as for the logistic regressions was used for this calculation (Appen-
dix 6.3). The EVIC per patient was estimated by calculating 1) the NMB of the 
optimal treatment per patient (NMBpatient_max); 2) the NMB of the average best 
treatment (NMBaverage_max); 3) EVICpatient = NMBpatient_max - NMBaverage_max for all 
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individual patients and 4) calculating the average EVICpatient and multiplying it by 
the effective population. 
Results 
Expected survival ranged from 20 months for CRT (1.63 LYs) and HRTH (1.66 
LYs), to 22 months for HRTI (1.83 LYs), up to 23 months for VART (1.88 LYs) 
and MART (1.90 LYs). MART was also the most effective treatment (1.32 
QALYs) in terms of QALYs, followed by VART (1.30 QALYs), HRTI (1.27 QAL-
Ys), HRTH (1.14 QALYs) and CRT (1.12 QALYs). HRTH was most costly 
(€29,683), followed by MART (€26,208), HRTI (€26,199), VART (€25,746) and 
CRT (€24,360). Costs differences were mainly due to differences in the number 
of fractions leading to differences in primary treatment costs. 
CRT was both the least effective and least expensive treatment. Compared with 
CRT, all comparators except HRTH (ICER: €228,852) were cost-effective with 
ICERs ranging between €7,592 (VART) and €12,379 (HRTI).  
HRTH was both more effective (0.02 QALYs) and expensive (€5,323) than CRT. 
This resulted in an ICER of €228,852. Given the ceiling ratio of €80,000 per 
QALY gained, HRTH was not cost-effective opposed to CRT. HRTI was also 
more effective (0.15 QALYs) and expensive (€1,839) than CRT leading to an 
ICER below the ceiling ratio (€12,379). HRTI was thus cost-effective opposed to 
CRT. VART was more effective (0.03 QALYs) and less expensive (€453) and 
thus dominated HRTI. MART was more effective (0.02 QALYs) and more ex-
pensive (€462) than VART. The calculated ICER (€25,716) was below the 
ceiling ratio. Thus, MART is the most cost-effective radiotherapy scheme (Table 
6.3). 
Figure 6.2 and Appendix 6.4 show the uncertainty surrounding the results. 
Taking into account this uncertainty, MART had the highest probability of being 
cost-effective (43%), followed by VART (31%), HRTI (24%), HRTH (2%) and 
CRT (0%) (Figure 6.2). Additionally, the estimated EVPI was €228 million 
(Figure 6.3). More specifically, the EVPPI indicated that further research would 
be most valuable for the primary treatment costs of MART (€8.2 million) and 
cancer mortality after VART (€6.7 million) and MART (€5.4 million). The EVIC 
showed a value of individualizing care of €0.1 million (Figure 6.3). 
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Figure 6.2: Cost-effectiveness acceptability curves* 
* The vertical line represents the ceiling ratio which was adopted in our analyses (€80,000 per 
QALY gained). 
 
€ 0 
€ 250 
€ 500 
€ 750 
€ 1,000 
€ 1,250 
€ 1,500 
€ 1,750 
€ 2,000 
€ 2,250 
€ 2,500 
€ 2,750 
€ 3,000 
€ 0
€ 25
€ 50
€ 75
€ 100
€ 125
€ 150
€ 175
€ 200
€ 225
€ 250
€ 275
€ 300
€ 0 € 10,000 € 20,000 € 30,000 € 40,000 € 50,000 € 60,000 € 70,000 € 80,000 € 90,000 € 100,000 
E
xp
ec
te
d
 V
al
ue
 o
f I
nd
iv
id
ua
liz
ed
 C
ar
e 
(i
n 
th
o
us
a
nd
s)
E
xp
e
ct
e
d 
V
al
ue
 o
f P
e
rf
ec
t 
In
fo
rm
a
tio
n 
(i
n 
m
ill
io
n
s)
   
  
Ceiling ratio (€ / QALY)
Expected Value of Perfect Information
Expected Value of Individualized Care
 
Figure 6.3: Expected value of individualized care and expected value of perfect information* 
* The vertical line represents the ceiling ratio which was adopted in our analyses (€80,000 per 
QALY gained). 
Discussion 
All modified radiotherapy schemes were more effective and more costly than 
CRT. While MART was the most cost-effective treatment strategy, the differ-
ences between comparators were small, and all confidence intervals for the 
incremental costs and effects were overlapping (Table 6.3). Therefore, it is 
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uncertain which modified fractionation strategy is most cost-effective. Moreover, 
estimated survival after MART was based on only one study with a small num-
ber of patients (N=58). Despite this uncertainty, modified fractionation radio- 
therapy in general is likely (>99%) cost-effective compared with CRT and accel-
erated schemes are likely to be the most effective and cost-effective modified 
fractionation schemes. However, it is unclear which accelerated fractionation 
scheme is deemed optimal. The comparison of MART versus VART resulted in 
a 51% probability for MART and 49% probability for VART of being cost-
effective (Appendix 6.4). Additionally, in the individual patient meta-analysis, 
heterogeneity in the relative treatment effect between the different radiotherapy 
schemes was not demonstrated.7 In this paper we examined patient heteroge-
neity based on differences in baseline risk, and found that there was relatively 
little value to individualize care (i.e. to provide different treatments to different 
patients). Instead, it would be more valuable to perform further research to 
reduce parameter uncertainty, specifically for primary treatment costs of MART 
and cancer mortality after VART and MART. 
Our study was the first to assess the cost-effectiveness of several modified 
radiotherapy schemes in NSCLC. In one prior analysis, also using a Markov 
model, an ICER of €11,576 was estimated for continuous hyperfractionation 
accelerated radiotherapy (CHART) compared to CRT; concluding that CHART 
is likely cost-effective in Belgium.21 This CHART trial was included in the VART 
arm in our study. The comparison in our study of VART and CRT would result in 
a slightly more beneficial ICER for VART of €7,592.  
The present study limitations were, firstly, that the health care perspective was 
used instead of the societal perspective. Therefore, productivity losses at work 
were not incorporated. Since 48% of the study population was at treatment start 
above the Dutch pensionable age, no large differences between the perspec-
tives are expected. Secondly, all MAR-LC trials compare modified radiotherapy 
and CRT (Appendix 6.1). Hence, the comparisons between different modified 
fractionated radiotherapy schemes are based on indirect evidence. Although 
synthesis of head-to-head comparisons of RCTs provides the most valid evi-
dence of treatment effectiveness, it has been recommended to consider indirect 
treatment comparisons if direct evidence is unavailable.22,23 The comparisons 
were stratified by trial, comparing patients only within each trial (preserving 
randomization), to obtain unbiased estimates.14 Thirdly, concomitant chemo-
radiotherapy is the current standard while this was administered in two out of 
the ten included trials. Only one study used cisplatin-doublet chemotherapy 
during radiotherapy (NCCTG 94242), which is at present considered to be the 
standard concurrent schedule. We were therefore unable to examine the impact 
of concomitant chemo-radiotherapy. Nevertheless, compared with CRT the 
benefit of modified radiotherapy with chemotherapy on overall survival 
(HR=0.92, 95% CI 0.77-1.10) was not significantly (interaction p=0.57) lower 
than for modified radiotherapy without chemotherapy (HR=0.87, 95% CI 0.78-
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0.97).7 Additionally, although this was not observed in a recent phase II study,24 
modified radiotherapy delivered concurrently with chemotherapy may increase 
acute side effects opposed to concurrent chemotherapy with conventional 
radiotherapy. In case of increased toxicity when providing concomitant chemo-
radiotherapy, the incremental costs for modified radiotherapy compared with 
CRT might on the one hand increase due to potentially increased toxicity man-
agement costs. On the other hand, it might result in lower incremental costs for 
instance due to interrupting and stopping both chemotherapy and radiotherapy 
(before finishing all chemotherapy cycles and radiotherapy fractions). Thus, if 
chemotherapy was added to all included trials, the incremental effects are 
expected to be similar and the impact on incremental costs is unclear. This 
issue should be addressed in future (economic) studies. Fourthly, to avoid 
unnecessary complexity in the model, it was decided not to incorporate over-
lapping toxicities (as described in the model description section). Despite this 
simplification of the model, the total occurrence of the acute and late toxicities in 
the present model would be equal to a more complex model incorporating 
‘overlap’ between toxicities. Also, as described in the methods section, overlap 
between available toxicities in the MAR-LC database was small. Therefore, 
considering this low proportion of overlap between toxicities and the equiva-
lence between total occurrence of toxicity, this model assumption is unlikely to 
have a large impact on the study results. Finally, the applied survival of six 
months after recurrence, to calculate the disutility for cancer mortality, could be 
criticized in view of the 10-12 months median survival in newly diagnosed stage 
IV NSCLC.25 Nevertheless, this was a conservative assumption, i.e. longer 
survival after recurrence and thus a higher disutility, will favor the modified 
radiotherapy treatments since these have less NSCLC deaths (and thus fewer 
disutilities). 
It is likely that with recent advancements in radiotherapy techniques, the same 
level of acceleration can be given safely in fewer fractions, e.g. 24 fractions 
instead of 38 fractions (as for VART and MART).26,27 This could reduce the 
costs (due to the lower number of fractions) while maintaining the survival 
benefit of accelerated radiotherapy. HRTI, the third most cost-effective option in 
our analysis, applies split-course radiotherapy. Although this was not observed 
in the individual patient meta-analysis,7 it is widely believed to be less efficient 
than continued radiotherapy schemes. As a result, split-course radiotherapy is 
rarely used nowadays.28 Also, concurrent chemotherapy and CRT is nowadays 
the treatment of choice for good performance patients with locally advanced 
NSCLC.29 However, as many patients are not eligible for concomitant chemo-
radiotherapy treatment,30 sequential chemotherapy and accelerated radiothera-
py seems a promising treatment option. In the present analysis we were unable 
to examine the role of chemotherapy in combination with modified fractionation 
radiotherapy. Although the benefit of modified radiotherapy with and without 
chemotherapy did not differ significantly,7 the results of RTOG 9410 and RTOG 
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0617 caution against assuming that modifying conventional concomitant 
chemo-radiotherapy will improve the therapeutic ratio.31,32 For sequential chem-
otherapy and radiotherapy, there are no indications that there would be an 
interaction between both modalities for toxicity. Hence, the present study results 
are probably most applicable to patients not receiving concomitant chemo-
radiotherapy. Studies examining the role of modified fractionation radiotherapy 
combined with concomitant chemotherapy are warranted. This includes examin-
ing for instance whether it is safe to provide chemotherapy concurrently with 
accelerated radiotherapy, whether the benefits of modified fractionation are 
preserved in case of concurrent chemo-radiotherapy and whether other well-
studied27 types of accelerated once-daily high-dose radiotherapy are cost-
effective. 
In conclusion, it remains uncertain which modified scheme is most cost-effective 
and it is unclear whether the study results can be extrapolated to modified 
radiotherapy combined with concomitant chemotherapy. Hence, further re-
search comparing the cost-effectiveness of different types of modified radio-
therapy and examining the role of chemotherapy might be valuable. Neverthe-
less, implementing accelerated radiotherapy is almost certainly more cost-
effective than current practice (CRT) for patients treated with sequential chemo-
radiotherapy or radiotherapy alone. Hence, waiting for more evidence before 
implementing accelerated radiotherapy (without concomitant chemotherapy) 
would lead to health benefits forgone. In addition, if future evidence would show 
that accelerated radiotherapy is not the most cost-effective radiotherapy type, 
the forgone implementation costs (sunk costs) are expected to be low. There-
fore, despite available uncertainty, it is encouraged to adopt accelerated radio-
therapy for the curative treatment of unresected NSCLC patients who do not 
receive concurrent chemo-radiotherapy and examine its role in the context of 
concurrent chemo-radiotherapy. 
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Appendix 6.1: Classification of MAR-LC trials 
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Abbreviation: BED = biologic effective dose (average in case of multiple trials) 
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Appendix 6.2: Input parameters for survival 
The Weibull models were constructed according to the intention-to-treat princi-
ple using the following covariates: treatment arm (CRT; VART; MART; HRTI; 
HRTH), sex (male; female), age (≤59; 60-69; ≥70), performance status (mild; 
good), histology (SCC; non-SCC) and disease stage (I/II; IIIA; IIIB). All variables 
were included in the initial model as categorical variables. Selection of covari-
ates was performed as described by Hosmer et al,1 except for the treatment 
arm variable. This variable was not included in the equation to predict non-
cancer mortality, and was always included in the model for cancer mortality. 
The parameterization of the Weibull model is as follows: 
1) 
α
λt)( −= etS  
Where S(t) = survival probability at time t. The shape parameter (α) could be 
retrieved from the analysis output. Lambda (λ) the event rate parameter was 
calculated by the sum of all coefficients multiplied by the accompanying covari-
ates (X):  
2) λ = βIntercept + βTreament arm XTreatment arm + βAge 60-69X Age 60-69 + βAge 70+X Age 70+ 
+ βFemaleX Female + βPerformance status goodXPerformance status good  
+ βHistology Squamous cellXHistology Squamous cell + βDisease Stage IIIAXDisease Stage IIIA  
+ βDisease Stage IIIBXDisease Stage IIIB 
The coefficients (β) for all covariates were retrieved from the analysis output. 
The coefficient for the intercept was calculated based on the shape (α) and 
scale parameters from the R output: 
3) βIntercept = -Ln(scale) × shape 
One essential statistical technique when analyzing multiple trials is stratification 
by trial, which guarantees that patients are compared within each trial and not 
across trials.2 The Weibull model was stratified by trial, which resulted in sepa-
rate scale and shape parameters for each trial. The different scale and shape 
parameters were pooled using a random effects model.3 Subsequently, all 
coefficients were multiplied by the accompanying average covariates to calcu-
late λ. For instance the proportion of female patients XFemale was multiplied by 
the coefficient for female ßFemale. The time-dependent transition probability 
between two cycles (between t1 and t2), was then calculated using the following 
formula (derived from equation 1): 
4) 
)t(t
12
21)(
αα
λ −−
=− ettS  
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Estimated regression coefficients for survival probabilities 
Parameter Equation 1: probability of cancer 
mortality (1644 events) 
Equation 2: probability of non-cancer 
mortality (205 events) 
 Estimated value Se Estimated value Se 
Model characteristics  
Model distribution Weibull*  Weibull*  
Shape (α) 1.093 0.200 0.920 0.372 
Ln(scale) 6.635 0.053 8.389 0.147 
Intercept† -7.252  -7.722  
  
Explanatory baseline characteristics§  
Treatment arm      
VART  -0.176 0.064   
MART -0.169 0.276   
HRTI -0.137 0.128   
HRTH -0.022 0.119   
Age (year)     
      60-69 -0.123 0.061 0.378 0.219 
      70+  -0.149 0.070 0.688 0.223 
Sex      
      Female -0.149 0.059 -0.372 0.188 
Performance status      
      Good -0.237 0.053 -0.508 0.160 
Disease stage      
      IIIA 0.242 0.081   
      IIIB 0.384 0.083   
     
Mean 2Y probability‡     
CRT 62% 18% 
VART  56% 18% 
MART 56% 18% 
HRTI 57% 18% 
HRTH 61% 18% 
Source MAR-LC MAR-LC 
Abbreviation: Se = standard error, 2Y = 2-year 
* Included in the probabilistic sensitivity analysis using a multivariate normal distribution which was 
constructed using Cholesky decompositions (multivariate normal distribution)4 
†Calculated using the following formula: -Ln(scale) × shape 
‡This probability represents the mean 2-year probability for the separate Weibull models (not the 2-
year probability as in the Markov trace) 
§ Histology was excluded (according to the purposeful selection of covariates algorithm by Hosmer 
and Lemeshow).1,5 
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Appendix 6.3: Input parameters for acute toxicity 
The included covariates and subsequent selection procedure were the same for 
acute pulmonary and esophageal toxicity as described for the Weibull models 
(Appendix 6.2). This was also the case for hematological toxicity, except that 
the treatment arm was excluded as covariate since it is caused by chemothera-
py and independent of radiation fractionation scheme. The parameterization of 
the logistic model is as follows: 
1) 
z
z
e
e
P
+
=
1  
  
Where P is the toxicity probability and z was calculated by the sum of all coeffi-
cients multiplied by the accompanying covariates (X):  
2) z = βIntercept + βTreatment arm XTreatment arm + βAge 60-69X Age 60-69 + βAge 70+X Age 70+ 
+ βFemaleX Female + βPerformance status goodXPerformance status good  
+ βHistology Squamous cellXHistology Squamous cell + βDisease Stage IIIAXDisease Stage IIIA 
+ βDisease Stage IIIBXDisease Stage IIIB 
As for the Weibull models, the logistic regression models were stratified by trial. 
However, no coefficient for the intercept is given if the logistic regression mod-
els are stratified by trial in SAS, thus absolute toxicity probabilities based could 
not be calculated based on this logistic regression model. Therefore, separate 
logistic regression models were constructed for each trial using the covariates 
as selected in the above described logistic regression model stratified by trial. 
The obtained coefficients for each trial were pooled using a random effects 
model.3 To calculate the acute toxicity probabilities using the logistic regression 
models, individual characteristics were needed. For this purpose, a hypothetical 
cohort of individual patients with individual characteristics was replicated based 
on the average characteristics and their correlations from the MAR-LC-
database. For each patient, the individual z values and toxicity probabilities 
were calculated. To obtain the toxicity probabilities for the whole cohort, the 
individual probabilities were averaged. This was done separately for each 
comparator. 
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Estimated regression coefficients for acute toxicity (≥ grade 3) probabilities* 
Parameter Equation 1: probability 
of acute pulmonary toxicity  
(77 events)† 
Equation 2: probability 
of acute esophageal toxicity  
(304 events) 
Equation 3: probability 
of acute hematological 
toxicity (202 events) 
 Estimated  
value 
Se Estimated  
value 
Se Estimated  
value 
Se 
Explanatory baseline characteristics‡ 
Intercept -2.856 0.273 -2.429 0.268 -1.892 1.418 
Trial arm        
VART  -0.625 0.324 1.281 0.216   
MART/HRTH 0.086 0.405 0.428 0.539   
HRTI 0.016 0.839 -0.157 0.314   
Age (year)       
      60-69 0.360 0.323   0.364 0.560 
      70+  0.737 0.354   1.033 0.374 
Sex        
      Female   0.672 0.204 0.963 0.313 
       
Mean probability§       
CRT 7.8% 9.8% 24.7%|| 
VART  4.4% 27.8% 24.7%|| 
MART/HRTH 8.5% 14.3% 24.7%|| 
HRTI 8.0% 8.6% 24.7%|| 
Source MAR-LC MAR-LC MAR-LC 
Abbreviation: Se = standard error 
* Included in the probabilistic sensitivity analysis using a multivariate normal distribution which was 
constructed using Cholesky decompositions(multivariate normal distribution).4 
† To handle the occurrence of zero events in 2x2 tables between dependent and independent 
variables (leading to quasi-complete separation), the Firth’s penalized maximum likelihood estima-
tion method 6,7 was used for four logistic regression models. 
‡ A combined estimate was calculated for HRTH and MART. This was done because acute toxicity 
was not reported in the MART trial and the overall treatment time and total treatment dose are 
similar for these two comparators In addition, performance status, histology and disease stage were 
excluded (according to the purposeful selection of covariates algorithm by Hosmer and 
Lemeshow).1,5 
§It was assumed that acute toxicity increased from start radiotherapy to 3 months thereafter to the 
total probability (reported in the table). The monthly probability was then calculated from the total 
probability using the following formula:4 
P(1 month) = 1- e (ln (1- P(total)) * 1/3) 
|| Hematological toxicity is mainly caused by the administration of chemotherapy rather than the 
radiotherapy treatment scheme and was therefore assumed to be independent of the radiotherapy 
scheme (and thus equal for all comparators). The calculated probability (24.7%) was conditional on 
that patients received chemotherapy and has to be multiplied by the proportion of patients who 
received chemotherapy (29.5%; assumed equal among all comparators) to calculate the average 
probability of acute hematological toxicity per comparator (7.3%). 
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Appendix 6.4: Cost-effectiveness planes corresponding to the 
comparisons in Table 6.3 
 
HRT
H
 versus CRT* 
 
 
HRT
I
 versus CRT* 
 
 
HRTH versus CRT % simulations  HRTI versus CRT % simulations 
North-West quadrant 44.0%  North-West quadrant 14.5% 
North-East quadrant 56.0%  North-East quadrant 85.5% 
South-West quadrant 0.0%  South-West quadrant 0.0% 
South-East quadrant 0.0%  South-East quadrant 0.0% 
     
HRTH cost-effective 35.2%  HRTI cost-effective 80.7% 
CRT cost-effective 64.8%  CRT cost-effective 19.3% 
* The diagonal line represents the ceiling ratio which was adopted in our analyses (€80,000 per 
QALY gained).  
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VART versus CRT* 
 
 
MART versus CRT* 
 
 
VART versus CRT % simulations  MART versus CRT % simulations 
North-West quadrant 0.4%  North-West quadrant 27.3% 
North-East quadrant 99.6%  North-East quadrant 82.6% 
South-West quadrant 0.0%  South-West quadrant 0.0% 
South-East quadrant 0.0%  South-East quadrant 0.1% 
     
VART cost-effective 99.1%  MART cost-effective 69.7% 
CRT cost-effective 0.9%  CRT cost-effective 30.3% 
* The diagonal line represents the ceiling ratio which was adopted in our analyses (€80,000 per 
QALY gained). 
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VART versus HRT
I* 
 
 
MART versus VART* 
 
 
VART versus HRTI % simulations  MART versus VART % simulations 
North-West quadrant 2.1%  North-West quadrant 50.3% 
North-East quadrant 0.0%  North-East quadrant 39.0% 
South-West quadrant 38.5%  South-West quadrant 0.0% 
South-East quadrant 59.4%  South-East quadrant 10.7% 
     
VART cost-effective 60.6%  MART cost-effective 51.0% 
HRTI cost-effective 39.4%  VART cost-effective 49.0% 
* The diagonal line represents the ceiling ratio which was adopted in our analyses (€80,000 per 
QALY gained). 
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The overall aim of this dissertation, as introduced in Chapter 1, was twofold: 1) 
to examine recommendations in pharmacoeconomic guidelines on acknowledg-
ing patient heterogeneity in economic evaluations (Part I) and; 2) to explore 
innovative methodology to acknowledge patient heterogeneity in economic 
evaluations in two case studies; in case comparative studies are lacking and in 
case individual patient data are available (Part II). This chapter summarizes the 
main findings, presents methodological considerations, implications for policy, 
implications for clinical practice and finally this chapter ends with concluding 
remarks and future perspectives.  
Summary of main findings 
In Chapter 2 a systematic review was presented considering guidance from 
national pharmacoeconomic guidelines on handling patient heterogeneity in 
economic evaluations. In total, 26 pharmacoeconomic guidelines were included 
of which 20 advised to identify patient heterogeneity. With regards to the first 
aim of this thesis, it was concluded based on this review that, although the 
importance of acknowledging patient heterogeneity in economic evaluation was 
internationally recognized, it was less clear when and how patient heterogeneity 
should be acknowledged. This includes which inputs or sources are considered 
relevant to acknowledge in economic evaluations, whether stratified analysis 
should be prespecified and how subgroups should be defined. Finally, it was 
unclear how the results should be presented to inform individualized reim-
bursement decisions. Based on these findings, we recommend that future 
pharmacoeconomic guidelines provide specific guidance on the identification of 
patient heterogeneity, methods to acknowledge patient heterogeneity and 
presenting the results. The presented checklist may help guideline authorities to 
formulate their guidance. This could facilitate the systematic and transparent 
handling of patient heterogeneity in economic evaluations worldwide.  
The subsequent three chapters considered the first case study that compared 
proton and photon radiotherapy for head and neck cancer patients. The aim of 
this case study was to acknowledge patient heterogeneity in an economic 
evaluation in case comparative studies are lacking (aim 2a). Chapter 3 synthe-
sized and compared available evidence considering the effectiveness of car-
bon-ion, proton and photon radiotherapy for head and neck cancer. For this 
purpose, a systematic review and meta-analyses were performed. In total, 86 
observational studies (74 photon, 5 carbon-ion and 7 proton) and eight compar-
ative in-silico studies were included. Since the overall quantity and quality of 
data regarding carbon-ion and proton therapy was poor and considering the risk 
of bias in comparisons between (small) observational studies, no definite con-
clusions were drawn. Despite the scarcity of data, it was suggested that a 
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clinically relevant benefit of proton therapy in patients with head and neck 
cancer probably lies in reducing treatment toxicity. To achieve definite conclu-
sions in the future, it was recommend to construct an international particle 
therapy register to facilitate definitive comparisons on both survival and treat-
ment toxicity. 
Chapter 4 presented an analysis of the impact of late treatment-related xero-
stomia and dysphagia on generic health-related quality of life (HRQOL) in head 
and neck cancer patients after radiotherapy. A multi-center cross-sectional 
survey (N=396) was performed. It was found that both xerostomia and dyspha-
gia diminished HRQOL substantially, with dysphagia having the strongest 
impact on HRQOL. This finding emphasizes that next to the expected length of 
survival, also treatment toxicity and its impact on HRQOL should be considered 
when treatment choices are made. The results presented in this chapter can be 
used to assist this trade-off between length and quality of survival. In considera-
tion of this trade-off, xerostomia was more prevalent than dysphagia, whereas 
dysphagia has a higher impact on HRQOL than xerostomia. Therefore, prevent-
ing xerostomia could benefit more patients, whereas preventing dysphagia 
might result in a larger benefit per patient. 
The results of the two previous chapters were used in Chapter 5 to perform a 
model-based economic evaluation to explore the effectiveness and cost-
effectiveness of proton radiotherapy compared with radiotherapy with photons 
for head and neck cancer patients. Proton radiotherapy is a promising radio-
therapy modality with a superior dose distribution compared with radiotherapy 
with photons. However, proton radiotherapy is also associated with higher costs 
than photon radiotherapy, which are mainly irrecoverable investment costs. As 
described above, comparative effectiveness research was sparsely available for 
proton radiotherapy in head and neck cancer. This made it challenging to exam-
ine its effectiveness and cost-effectiveness as well as to acknowledge patient 
heterogeneity in this economic evaluation. To bridge this gap of evidence, 
normal tissue complication probability (NTCP) models were combined with 
comparative planning studies in an integrated model. NTCP models estimate 
the probability of toxicity based on the expected radiation dose to healthy tis-
sues. Comparative planning studies compare the dose-distributions in patients 
for different radiotherapy techniques. Hence, NTCP models and comparative 
planning studies can be used in economic evaluations to estimate the expected 
benefit of innovative radiotherapy techniques for individual patients. This meth-
odology was explored in the presented economic evaluation to handle the lack 
of comparative effectiveness research and acknowledge patient heterogeneity. 
It was concluded that proton radiotherapy was on average not cost-effective. 
However, when considering individual cost-effectiveness estimates, it became 
clear that proton radiotherapy was potentially worthwhile for individually select-
ed patients. Thus, in this case it was considered valuable to acknowledge 
patient heterogeneity and examine on the individual level for which patients 
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proton radiotherapy is cost-effective and for which patients it is not. Further-
more, value of information analysis indicated that further research to obtain 
more data on utility scores after xerostomia and NTCP models to predict xero-
stomia and/or dysphagia was most valuable. Also, it would be valuable to 
explore which radiotherapy technique makes the most optimal use of the dosi-
metric advantages of proton therapy. For instance, the comparative planning 
studies used in the present analysis primarily focused on reducing the radiation 
dose to the swallowing structures.1 It might be of interest to examine the cost-
effectiveness based on comparative planning studies primarily focused on 
reducing the radiation dose to parotid glands to reduce the occurrence of xero-
stomia. Additionally, tumor control probability (TCP) models can be employed to 
consider strategies wherein the total dose to the tumor is increased to improve 
the probability of tumor control. 
The economic evaluation for the second case study (aim 2b) was presented in 
Chapter 6. This economic evaluation assessed the cost-effectiveness of modi-
fied fractionation radiotherapy as opposed to conventional fractionation radio-
therapy in the curative treatment of unresected non-small cell lung cancer 
patients. In contrast with the previous chapter, where comparative evidence 
was lacking, individual patient data from 10 randomized controlled trials were 
available for this case study. Based on available evidence, it was found that 
accelerated radiotherapy was on average the most cost-effective treatment 
strategy for all patients. The expected value of individualized care (EVIC) indi-
cated that, in this case, individualized treatment allocation is probably not 
worthwhile. Thus accelerated radiotherapy was the most cost-effective strategy 
for all patients and it seemed not valuable to provide individualized treatments 
with regard to type of radiotherapy fractionation scheme. However, these results 
are probably most applicable to patients not receiving concomitant chemo-
radiotherapy as concomitant chemo-radiotherapy is provided in only two of the 
ten trials and it is unclear whether the benefits of modified radiotherapy are 
preserved when provided concurrently with chemotherapy. Also, the differences 
between treatments in terms of effectiveness were small and it was uncertain 
which type of accelerated radiotherapy scheme was most cost-effective. Never-
theless, implementing any accelerated radiotherapy was almost certainly more 
efficient than current practice. Therefore, waiting for more evidence before 
implementing accelerated radiotherapy would lead to health benefits forgone. In 
addition, if future evidence would show that accelerated radiotherapy is not the 
most cost-effective radiotherapy type, the forgone implementation costs (sunk 
costs) are expected to be low. Therefore, it was encouraged to adopt accelerat-
ed radiotherapy as standard treatment for the curative treatment of unresected 
non-small cell lung cancer patients not receiving concomitant chemo-
radiotherapy. Furthermore, value of information analysis indicated that research 
to obtain more data on the primary treatment costs for and cancer mortality after 
different types of accelerated radiotherapy would be most valuable. Additionally, 
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further research is required to examine for instance whether it is safe to provide 
chemotherapy concurrently with accelerated radiotherapy, whether the benefits 
of modified fractionation are preserved in case of concurrent chemo-
radiotherapy and whether other well-studied types of accelerated once-daily 
high-dose radiotherapy are cost-effective. 
Methodological considerations 
In the first case study, an integrated model was developed to overcome the lack 
of comparative effectiveness research. This integrated model consisted of 
individual patient characteristics, a dose-response model (e.g. NTCP model) 
and an economic model to assess the cost and consequences. In this case 
(Figure 7.1), patient-specific radiation dose to the swallowing structures and 
parotid glands was estimated (model 1) and linked to dose-response models 
which predict the probability of dysphagia and xerostomia (model 2). Subse-
quently, these patient-specific complication probabilities were combined with 
HRQOL and cost data to estimate the effectiveness and cost-effectiveness for 
individual patients (model 3).  
This integrated model could also act as a decision support tool to facilitate 
individualized decision-making both for individualized treatment decisions in 
clinical practice (micro-level) and for individualized reimbursement decisions 
(macro-level). This methodology is based on surrogate outcomes and assump-
tions about reality and thus cannot be considered as a substitute for prospective 
clinical studies, rather a supplement. The methodology offers a solution if it is 
not desirable to wait or postpone decisions until clinical data become available. 
This can be the case for example in an early stage of a technology or if random-
ized trials are considered unethical or unfeasible. Moreover, as with decision-
analytic modelling in general, the integrated model might be employed to enrich, 
extrapolate and broaden the results from available evidence by combining 
various evidence sources and types of analytical models.2 Hence, even if com-
parative effectiveness research is available, the integrated modelling methodol-
ogy might be used to address policy questions.3  
As with most novel methodologies, the presented methodology is not yet vali-
dated. Moreover, the validity of the integrated modelling methodology heavily 
relies on the validity of the employed dose-response models. To critically ap-
praise the validity of these dose-response models, the following dimensions of 
validity should be considered: face validity, internal validity, external validity and 
clinical validity.4 As part of the external validity, it was unclear in the first case 
study whether the NTCP models validated with photon studies can be used to 
predict toxicity after proton radiotherapy. Next to the dependence on the validity  
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Figure 7.1: Integrated model to predict patient-specific effectiveness and cost-effectiveness 
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of available NTCP models, two fundamental methodological challenges con-
cerning the internal validity are still to be overcome before the integrated model-
ling methodology can be implemented on a broader scale. This involves exam-
ining 1) how valid and uncertain the individual predicted outcomes are for 
individuals; and 2) whether this methodology can be applied beyond radiothera-
py. Firstly, the integrated model is partly based on population-specific data (e.g. 
Model 2) and does only reflect uncertainty surrounding specific model parame-
ters (parameter uncertainty). It is questionable how these population-specific 
data should be incorporated to produce valid outcomes and appropriately reflect 
all existing uncertainty for individual patients. For example, additional uncertain-
ty arises because population estimates are used to predict outcomes for specif-
ic individuals. One possible solution might be to incorporate unexplained be-
tween-subject variance in the integrated model to estimate the uncertainty of 
(sub)group predictions for individuals. Secondly, since dose-response models 
are not specific to radiotherapy, the wider applicability of this methodology, for 
instance in pharmacology, is an area for further research. In pharmacology for 
instance, population pharmacokinetic modelling5-8 can be used to optimize drug 
dosing for antibiotics.9 Additionally, dose-response models can be used to 
predict the probability of an event or disease (‘response’) based on biomarker 
values (‘dose’). These prediction models can be used to facilitate personalized 
medicine. For instance, biomarkers related to thrombosis might be considered 
in the integrated model to select optimal thresholds when the risk of thrombosis 
becomes ‘too high’ and antithrombotic medication should be initiated. However, 
the feasibility and wider applicability of this methodology beyond radiotherapy 
should be confirmed in further research.  
The second case study illustrated that if individual patient data are available, 
patient heterogeneity can be incorporated by using regression models to esti-
mate input parameters dependent on patient characteristics. Individual patient 
data as available in the second case are preferred above surrogate (dosimetric) 
outcomes as in the first case study as these contain final outcomes and the 
highest grade of evidence.10 Additionally, individual patient data provide more 
opportunities to identify subgroups to be considered in the analysis, to explore 
patient heterogeneity based on identified subgroups, to examine for which 
subgroups additional research is valuable and to determine the optimal number 
of subgroups.11 Thus, to acknowledge patient heterogeneity and move towards 
personalized medicine, access to individual patient data is essential. Ideally, 
trial data should be made available to the public for this purpose. It can be 
questioned who should have the right to access the individual patient data. Data 
on what works in clinical practice can be considered a public good, inde-
pendently of the entity (public or private) responsible for collecting the data.12 
When considering the massive amount of public money and public trust which 
are placed in medical products that are adopted in clinical practice, it seems 
reasonable to request access to the full data.13 It may even be argued that 
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society should have access to these data since the society indirectly pays for 
industry-funded trials through patents. To stimulate this openness of data, 
governments should establish laws that go beyond current legislation to de-
mand access to the individual patient data behind any analyses used to license 
or reimburse a medical product.13 Additionally, scientific journals may facilitate 
this by using “open data” policy as for instance now applies to Nature journals: 
“authors are required to make materials, data and associated protocols prompt-
ly available to readers without undue qualifications”.14 Ultimately, as put forward 
by others, this procedure should become the norm: “required by journals and 
accepted by the scientific community as mandatory”.15 An “open data” approach 
is considered essential to maximize the benefits of research.15,16 
In addition to “open data” policies, Performance-Based Risk Sharing Agree-
ments (PBRSA) might provide opportunities to achieve data necessary for 
individualized decisions. Decision-makers often face considerable uncertainty 
about effectiveness and cost-effectiveness of novel medical products, and 
growing financial risks (due to the increasing costs of medical interventions). 
Partly in response to these concerns, the interest in PBRSA is substantial and 
rising.12 PBRSA are arrangements, often between the payer and producer of a 
medical product, mainly aimed at reducing the uncertainty through investing in 
the collection of evidence while a technology is temporarily adopted within 
clinical practice. These agreements concern a specified period of time and the 
(future) price and/or utilization of the product is dependent on the outcomes 
achieved.12,17 In this way, PBRSA may lead to value based pricing and facilitate 
patient access to (high cost) drugs or technologies. Part of the decision uncer-
tainty aimed to resolve in PBRSA may originate from patient heterogeneity. 
These arrangements may thus provide an excellent opportunity for decision-
makers to request the collection of data necessary to examine the effectiveness 
and cost-effectiveness for subgroups of patients for instance identified in previ-
ous trials or based on biological plausibility. This may lead to ex ante reim-
bursement schemes, where the treatment is only reimbursed for a selection of 
individual patients for instance based on a biomarker or a diagnostic test.12 As 
an example: gefitinib for the treatment of non-small cell lung cancer is only 
recommended by National Institute for Health and Clinical Excellence for pa-
tients with a positive epidermal growth factor receptor mutation status and 
based on an agreed price.18 Alternatively, if it is not possible to identify sub-
groups before treatment initiation, PBRSA schemes focused on ex post reim-
bursement might prove valuable. This may involve schemes as “outcomes 
guarantees” meaning that the product will only be (fully) reimbursed for patients 
who respond to treatment or “conditional treatment continuation” meaning 
reimbursement for the continued use of a treatment based on intermediate 
outcomes.12 These arrangements seem promising as they potentially result in a 
number needed to treat of one. However, these ex post schemes require a 
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measure for response or an intermediate outcome that is feasible, valid and can 
be measured relatively shortly after treatment initiation.  
The data gathered through “open data” policy or PBRSA schemes may facilitate 
the acknowledgement of patient heterogeneity in decision-analytic models. This 
may involve complex methods19-23 and as reimbursement decision-makers are 
often not specialized in health economics, the cost-effectiveness results might 
become increasingly difficult to communicate. Therefore, to communicate the 
potential value of stratified or individualized decision-making and influence 
reimbursement policy, these complex methods should be translated to less 
complex outcomes. In the first case study, the EVIC was translated by using an 
additional comparator next to “proton radiotherapy for all patients” and “photon 
radiotherapy for all patients”. This additional strategy was named “proton radio-
therapy if efficient” and implies that patients for whom proton radiotherapy is 
expected to be cost-effective receive proton radiotherapy, while the remaining 
patients receive photon radiotherapy. The results of this strategy were present-
ed as a ‘normal’ comparator using less complex outcomes such as the incre-
mental cost-effectiveness ratio. Next to communicating outcomes to decision-
makers, the outcomes should also be properly communicated to clinical prac-
tice. For instance, the decision support tool as developed for the first case study 
can be converted to highly accessible smartphone apps or web-based applica-
tions. These applications can support physicians in their decisions without 
confronting them with the complexity of the decision-analytic model.  
Implications for policy 
Acknowledging patient heterogeneity may result in efficiency gains.23-26 Despite 
this potential efficiency gain, patient heterogeneity is currently frequently ne-
glected in economic evaluations and subsequent policy decisions.27 Patient 
heterogeneity might be neglected in case it is considered unethical or contro-
versial to exclude subgroups from treatment reimbursement based on certain 
characteristics. For instance, it may be considered unethical to discriminate 
patients and restrict access to treatment reimbursement based on differences in 
life expectancy (i.e. between younger and older patients). These considerations 
contain a normative trade-off between efficiency and equity. This also includes 
issues as whether subgroups should be excluded if a treatment is more effec-
tive but not cost-effective compared with current practice, or only when a treat-
ment is not effective at all compared with current practice. These moral dilem-
mas should be handled in the technology appraisal by decision-makers and 
health authorities. Health authorities should provide guidance to researchers, 
for instance in the pharmacoeconomic guideline, when patient heterogeneity 
should (not) be acknowledged, how it should be acknowledged and what should 
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be presented. Health authorities may consult the checklist presented in Chapter 
2 to formulate guidance on acknowledging patient heterogeneity in their phar-
macoeconomic guidelines.  
To enable the acknowledgement of patient heterogeneity based on individual 
patient data, policy makers should stimulate the openness of data. This can for 
instance be part of the process to obtain a license or reimbursement for a 
medical product. Alternatively, in case individual patient data or comparative 
effectiveness research are not available, policy makers may consider other 
sources of evidence to acknowledge patient heterogeneity and inform their 
decisions (see for instance the first case study). 
Implications for clinical practice 
Personalized medicine might be enhanced if patient heterogeneity is acknowl-
edged in economic evaluations and subsequent reimbursement decisions. 
Therefore, it is encouraged that acknowledging patient heterogeneity in eco-
nomic evaluations becomes standard practice. In this way, economic evalua-
tions might inform the development of clinical decision support tools. These 
tools can be used to examine which treatment is expected to be most (cost-
)effective for a specific patient. For instance, the first case study showed that 
proton therapy was only cost-effective in selected HNC patients for whom 
proton radiotherapy leads to a substantial reduction in the probability of treat-
ment-related toxicity. The developed decision support tool may be used on the 
micro-level in clinical practice to select patients for treatment as well as on the 
macro-level to select patients for reimbursement. The second case study indi-
cated that it is probably not valuable to individualize treatment decisions regard-
ing radiotherapy fractionation scheme of NSCLC. Instead, it was encouraged to 
provide accelerated radiotherapy to all patients who do not receive concomitant 
chemo-radiotherapy. 
Concluding remarks and future perspectives 
To increase the efficiency of healthcare and bridge the gap between individual-
ized decisions in clinical practice and population-based reimbursement deci-
sions, it is encouraged that acknowledging patient heterogeneity becomes 
standard practice in future economic evaluations. Although this is preferably 
based on individual patient data, the unavailability of these data does not justify 
neglecting patient heterogeneity. It was demonstrated that acknowledging 
patient heterogeneity in economic evaluation is both feasible and informative, 
even if comparative effectiveness research is scarcely available. The interna-
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tional health economic community should develop consensus on how available 
methods such as stratified analysis,23 regression techniques,19-21 and the ex-
pected value of individualized care22 should be used to acknowledge patient 
heterogeneity in the economic assessment of technologies. Particularly interna-
tional societies such as the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) are encouraged to adopt a leading role in this 
process. On the other hand, national decision-makers are encouraged to pro-
vide specific recommendations in their pharmacoeconomic guideline when it is 
(ir)relevant (e.g. which characteristics can potentially be used for policy deci-
sion) to acknowledge patient heterogeneity in economic evaluations and what is 
required to inform their appraisal process. 
One frequently mentioned barrier to acknowledging patient heterogeneity, a 
lack of appropriate data (e.g. if comparative clinical data or individual patient 
data are lacking), can be overcome by an integrated model using dose-
response models or over a longer period of time by risk sharing agreements 
and/or “open data” policy for scientific journals. Additionally, entities (public and 
private) responsible for collecting data are encouraged to make their data 
available to the public. This seems reasonable when considering the massive 
amount of public resources and trust that are placed in medical products adopt-
ed in clinical practice. Governments may facilitate this process by requesting 
openness of data for submissions during the licensing and reimbursing process 
of medical products. Additionally, future efforts should be aimed at further 
developing and validating the integrated modelling methodology, reaching 
consensus on how to acknowledge patient heterogeneity in the economic 
assessment and formulating specific guidance in pharmacoeconomic guide-
lines. This would increase population health gains and stimulate that health 
technology assessment practice and national reimbursement decisions are 
better aligned with the development towards personalized medicine in clinical 
practice. 
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Hoewel de mensheid als soort wordt gedefinieerd door een groot aantal gelijke-
nissen, bestaat er een aanzienlijke diversiteit tussen individuele patiënten. Alle 
patiënten zijn individuen en reageren vaak verschillend op identieke behande-
lingen ondanks een vergelijkbare diagnose. Deze natuurlijke variatie tussen 
patiënten kan worden gedefinieerd als variabiliteit. Helaas kunnen we deze 
variabiliteit vaak maar voor een klein deel voorspellen. Het deel van deze 
variabiliteit dat verklaard kan worden door bepaalde patiëntkenmerken wordt 
gedefinieerd als patiënt heterogeniteit. Deze patiëntkenmerken kunnen demo-
grafische gegevens, voorkeuren en klinische kenmerken omvatten. In de klini-
sche praktijk wordt deze patiënt heterogeniteit steeds meer erkend door te 
anticiperen op voorspelbare verschillen in behandelrespons en hiermee te 
streven naar geïndividualiseerde behandelingen; 'de juiste behandeling voor de 
juiste persoon'. De belofte van geïndividualiseerd behandelen is dat het zal 
resulteren in een verbeterde effectiviteit en een vermindering van bijwerkingen 
en kosten. Evenals het erkennen van patiënt heterogeniteit in de klinische 
praktijk, kan het erkennen van patiënt heterogeniteit in economische evaluaties 
gunstig zijn. Dit kan potentieel resulteren in verbeteringen van de doelmatigheid 
en/of de effectiviteit van de gezondheidzorg. Patiënt heterogeniteit wordt echter 
vaak genegeerd in economische evaluaties en dus ook in het hierop gebaseer-
de beleid zoals besluiten omtrent het wel of niet vergoeden van bepaalde zorg. 
Dit proefschrift richt zich op de rol van patiënt heterogeniteit in economische 
evaluatie(s). De hypothese van dit proefschrift is dat het haalbaar en informatief 
is om patiënt heterogeniteit te erkennen in economische evaluaties. 
In Hoofdstuk 2 wordt een systematische review gepresenteerd van aanbeve-
lingen uit nationale farmaco-economische richtlijnen betreffende het erkennen 
van patiënt heterogeniteit in economische evaluaties. In totaal werden 26 far-
maco-economische richtlijnen geïncludeerd waarvan er 20 adviseren om patiënt 
heterogeniteit te identificeren. Op basis van deze review kon worden geconclu-
deerd dat het belang van het erkennen van patiënt heterogeniteit in de econo-
mische evaluatie internationaal wordt bevestigd. Echter, het is minder duidelijk 
wanneer en hoe patiënt heterogeniteit precies moet worden erkend in economi-
sche evaluaties. Dit heeft onder andere betrekking op welke parameters of 
welke patiëntkenmerken relevant worden geacht om te erkennen in economi-
sche evaluaties, of gestratificeerde analyses vooraf moeten worden gespecifi-
ceerd en hoe subgroepen moeten worden gedefinieerd. Tot slot was het ondui-
delijk hoe de resultaten moeten worden gepresenteerd voor het informeren van 
geïndividualiseerde vergoedingsbesluiten. Gebaseerd op deze bevindingen, 
raden we aan dat toekomstige farmaco-economische richtlijnen specifieke 
aanbevelingen geven met betrekking tot het identificeren van patiënt heteroge-
niteit, methoden om patiënt heterogeniteit te erkennen en de presentatie van de 
resultaten. De gepresenteerde checklist kan autoriteiten ondersteunen om hun 
aanbevelingen te formuleren. Dit kan wereldwijd het erkennen van patiënt 
heterogeniteit in economische evaluaties faciliteren. 
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De hierop volgende drie hoofdstukken hebben betrekking op de eerste casus 
waarin patiënt heterogeniteit wordt erkend. Het betreft een vergelijking van 
radiotherapie met protonen en radiotherapie met fotonen voor hoofd-halskanker 
patiënten. Het doel van deze casus was het erkennen van patiënt heterogeniteit 
in een economische evaluatie, in het geval vergelijkende studies met betrekking 
tot effectiviteit ontbreken. Hoofdstuk 3 betreft een synthese en vergelijking van 
het beschikbare bewijs omtrent de effectiviteit van radiotherapie met koolstof-
ionen, protonen en fotonen voor hoofd-halskanker. Hiervoor werd een systema-
tische review en meta-analyse uitgevoerd. In totaal werden 86 observationele 
studies (74 fotonen, 5 koolstof-ionen en 7 protonen) en acht vergelijkende in-
silico studies geïncludeerd. Aangezien de kwantiteit en de kwaliteit van de 
gegevens met betrekking tot radiotherapie met koolstof-ionen en protonen over 
het algemeen slecht was en gezien het risico op bias in vergelijkingen tussen 
(kleine) observationele studies, werden er geen definitieve conclusies geformu-
leerd. Ondanks deze tekortkomingen, kon er gesuggereerd worden dat een 
klinisch relevant voordeel van protonentherapie bij patiënten met hoofd-
halskanker waarschijnlijk ligt in het verminderen van de bijwerkingen van de 
behandeling. Om in de toekomst definitieve conclusies te kunnen formuleren 
werd aanbevolen een internationaal register op te zetten voor het verzamelen 
van gegevens betreffende de effectiviteit van radiotherapie met koolstof-ionen 
en protonen. 
Hoofdstuk 4 betreft een analyse van de impact van late behandeling gerela-
teerde xerostomie (droge mond) en dysfagie (slikklachten) op generieke ge-
zondheidsgerelateerde kwaliteit van leven (KvL) bij hoofd-halskanker patiënten 
behandeld met radiotherapie. Een multicenter cross-sectioneel onderzoek (N = 
396) werd uitgevoerd. Het optreden van zowel xerostomie als dysfagie was 
geassocieerd met een substantieel verminderde KvL; waarbij dysfagie de 
sterkste invloed had op KvL. Deze bevinding benadrukt dat het belangrijk is om 
naast de verwachte duur van de overleving, ook behandel-toxiciteit en het effect 
hiervan op KvL moet worden meegenomen wanneer behandelkeuzes worden 
gemaakt. De resultaten gepresenteerd in dit hoofdstuk kunnen worden gebruikt 
om deze afweging tussen de lengte en kwaliteit van de overleving te faciliteren. 
In deze overweging dient mee te worden genomen dat xerostomie vaker voor-
komt dan dysfagie, terwijl dysfagie een grotere impact heeft op de KvL dan 
xerostomie. Daarom kunnen meer patiënten profiteren indien xerostomie kan 
worden vermeden, terwijl het vermijden van dysfagie misschien resulteert in 
een groter voordeel per patiënt. 
De resultaten van de voorgaande twee hoofdstukken werden gebruikt in 
Hoofdstuk 5 om een modelmatige economische evaluatie uit te voeren om de 
effectiviteit en kosteneffectiviteit van protonentherapie te verkennen in vergelij-
king met radiotherapie met fotonen voor hoofd-halskanker patiënten. Protonen-
therapie is een veelbelovende radiotherapie modaliteit met een superieure 
dosisverdeling in vergelijking met radiotherapie met fotonen, maar is ook geas-
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socieerd met hogere kosten dan radiotherapie met fotonen. Deze kosten be-
staan voornamelijk uit onomkeerbare investeringskosten. Zoals hierboven 
beschreven, was vergelijkend effectiviteitsonderzoek slechts beperkt beschik-
baar voor radiotherapie met protonen bij hoofd-halskanker. Dit maakte het een 
uitdaging om de effectiviteit en kosteneffectiviteit te onderzoeken en het be-
moeilijkte ook het erkennen van patiënt heterogeniteit in deze economische 
evaluatie. Om deze kloof van bewijsmateriaal te overbruggen werden dosis-
respons modellen gecombineerd met vergelijkende planning studies in een 
geïntegreerd model. Dosis-respons modellen schatten de waarschijnlijkheid van 
het optreden van toxiciteit gebaseerd op de verwachte stralingsdosis in gezon-
de weefsels. Vergelijkende planning studies vergelijken voor verschillende 
radiotherapie technieken de verwachte stralingsdosis voor individuele patiënten. 
Daarom kunnen dosis-respons modellen en vergelijkende planning studies 
worden gebruikt in economische evaluaties om het te verwachten voordeel van 
innovatieve radiotherapie technieken te schatten voor individuele patiënten. 
Deze methode werd toegepast om patiënt heterogeniteit te erkennen in de 
gepresenteerde economische evaluatie bij gebrek aan vergelijkend effectivi-
teitsonderzoek. Er kon worden geconcludeerd dat protonentherapie gemiddeld 
niet doelmatig is. Echter, gekeken naar de individuele kosteneffectiviteit is 
protonentherapie mogelijk doelmatig voor individueel geselecteerde patiënten. 
Daarom werd het erkennen van patiënt heterogeniteit in deze casus als waar-
devol beschouwd voor het informeren van behandelbeslissingen op individueel 
niveau; dus voor het selecteren van patiënten voor wie protonentherapie doel-
matig is en voor welke patiënten niet. Bovendien, gaf de “value of information” 
analyse aan dat verder onderzoek voor het verkrijgen van meer gegevens 
betreffende KvL na xerostomie en dosis-respons modellen om xerostomie en/of 
dysfagie te voorspellen het meest waardevol is. Verder zou het waardevol zijn 
om te verkennen welke bestralingstechniek het meest optimaal gebruik maakt 
van de dosimetrische voordelen van radiotherapie met protonen. De vergelij-
kende planning studie die gebruikt is in de huidige analyse was vooral gericht 
op het verminderen van de geschatte stralingsdosis in de slikstructuren. Het 
zou informatief kunnen zijn om de kosteneffectiviteit te schatten op basis van 
vergelijkende planning studies gericht op het verminderen van de geschatte 
stralingsdosis in de speekselklieren om het optreden van xerostomie te vermin-
deren. Bovendien kunnen dosis-respons modellen ook gebruikt worden om 
strategieën te overwegen waarbij de verwachte totale dosis in de tumor wordt 
verhoogd om de kans op tumorcontrole te verbeteren. 
De economische evaluatie van de tweede casus werd gepresenteerd in Hoofd-
stuk 6. Deze modelmatige economische evaluatie schat de kosteneffectiviteit 
van radiotherapie met alternatieve fractionering in vergelijking met conventio-
neel gefractioneerde radiotherapie voor patiënten met een niet-kleincellig long-
carcinoom, die curatief behandeld worden zonder chirurgische resectie. In 
tegenstelling tot het vorige hoofdstuk, waar vergelijkend effectiviteitsonderzoek 
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ontbrak, waren individuele patiëntengegevens van tien gerandomiseerde stu-
dies beschikbaar voor deze casus. In deze casus werd vastgesteld dat geacce-
lereerde radiotherapie gemiddeld de meest kosteneffectieve behandelingsstra-
tegie was voor alle patiënten. De “expected value of individualized care” gaf aan 
dat, in deze casus, het nemen van beslissingen op individueel niveau waar-
schijnlijk niet waardevol is. Dus geaccelereerde radiotherapie was de meest 
doelmatige strategie voor alle patiënten en het leek niet waardevol om behan-
delbesluiten te individualiseren met betrekking tot het type fractioneringssche-
ma. Echter, zijn deze resultaten waarschijnlijk het meest van toepassing op 
patiënten die met radiotherapie behandeld worden zonder gelijktijdige chemo-
therapie. Dit omdat deze gelijktijdige behandel combinatie in slechts twee van 
de tien studies werd gegeven en het onduidelijk is of de voordelen van radiothe-
rapie met alternatieve fractionering worden behouden indien radiotherapie 
gelijktijdig wordt gegeven met chemotherapie. Daarnaast zijn de verschillen in 
effectiviteit tussen de behandelingen klein en was het onzeker welk type geac-
celereerde radiotherapie het meest doelmatig is. Niettemin is geaccelereerde 
radiotherapie vrijwel zeker doelmatiger dan de huidige praktijk (conventioneel 
gefractioneerde radiotherapie). Wachten op meer bewijs voordat geaccelereer-
de radiotherapie wordt geïmplementeerd zou daarom leiden tot een minder 
hoge gezondheidswinst. Bovendien, wanneer toekomstig onderzoek zou aanto-
nen dat geaccelereerde radiotherapie niet het meest kosteneffectieve type 
radiotherapie zou zijn, zijn de onomkeerbare investeringskosten naar verwach-
ting laag. Daarom wordt aanbevolen om geaccelereerde radiotherapie te im-
plementeren als standaard behandeling voor de curatieve behandeling van 
patiënten met een niet-kleincellig longcarcinoom die behandeld worden zonder 
chirurgische resectie en gelijktijdige chemotherapie. Verder gaf de “value of 
information” analyse aan dat verder onderzoek naar kosten van de initiële 
radiotherapie behandeling en kanker gerelateerde sterfte het meeste waardevol 
is. Daarnaast is verder onderzoek vereist om bijvoorbeeld te onderzoeken of de 
voordelen van alternatieve fractionering worden behouden bij gelijktijdige che-
motherapie en om de doelmatigheid van andere geaccelereerde radiotherapie 
types te bestuderen.  
Hoofdstuk 7 betreft de algemene discussie die eindigt met een slotbeschou-
wing en toekomstperspectieven. Hierin wordt gepleit voor het erkennen van 
patiënt heterogeniteit als standaard praktijk in toekomstige economische evalu-
aties. Dit zal de doelmatigheid van de gezondheidszorg verbeteren en de kloof 
verkleinen tussen geïndividualiseerde beslissingen in de klinische praktijk en 
populatie-gebaseerde vergoedingsbeslissingen. Hoewel dit bij voorkeur wordt 
gedaan op basis van individuele patiëntgegevens, is het niet gerechtvaardigd 
patiënt heterogeniteit te negeren omdat deze gegevens niet beschikbaar zijn. In 
dit proefschrift wordt aangetoond dat het erkennen van patiënt heterogeniteit in 
de economische evaluatie haalbaar en informatief is, zelfs als vergelijkend 
effectiviteitsonderzoek nauwelijks beschikbaar is. De internationale gezond-
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heidseconomische gemeenschap zou tot een consensus moeten komen over 
hoe beschikbare methoden zoals gestratificeerde analyse, regressie technieken 
en de “expected value of individualized care” moeten worden gebruikt om 
patiënt heterogeniteit te erkennen in economische evaluaties. Vooral internatio-
nale gemeenschappen, zoals de International Society for Pharmacoeconomics 
en Outcomes Research (ISPOR), worden aangemoedigd om hierin een leiden-
de rol te nemen. Aan de andere kant worden nationale beleidsmakers aange-
spoord om specifieke aanbevelingen te geven in hun farmaco-economische 
richtlijnen wanneer het (ir)relevant is om patiënt heterogeniteit te erkennen in 
economische evaluaties (bijvoorbeeld welke kenmerken eventueel gebruikt 
kunnen worden voor beleidsbeslissing) en wat nodig is om hun beslissingen te 
ondersteunen. 
Een vaak genoemde belemmering voor het erkennen van patiënt heterogeniteit 
is een gebrek aan geschikte gegevens (bijvoorbeeld als vergelijkende klinische 
gegevens of gegevens van individuele patiënten ontbreken) en kan verholpen 
worden door een geïntegreerd model met behulp van dosis-respons modellen 
of over een langere periode door “risk sharing” overeenkomsten en/of "open 
data" beleid voor wetenschappelijke tijdschriften. Daarnaast worden organisa-
ties (publieke en private) die verantwoordelijk zijn voor het verzamelen van 
gegevens uitgenodigd om hun gegevens beschikbaar te maken voor de maat-
schappij. Dit lijkt redelijk gezien de enorme hoeveelheid publieke middelen die 
geïnvesteerd worden in medische producten en het grote vertrouwen dat in 
deze producten gesteld wordt. Overheden kunnen bijdragen aan dit proces door 
te vragen naar openheid van gegevens tijdens het proces voor het verkrijgen 
van de licentie en de vergoeding van medische producten. Hiernaast is verder 
onderzoek noodzakelijk voor het verder ontwikkelen en valideren van de geïn-
tegreerde modelleringsmethodologie, het bereiken van consensus over de wijze 
waarop patiënt heterogeniteit zou moeten worden erkend in economische 
evaluaties en het formuleren van specifieke aanbevelingen in farmaco-
economische richtlijnen. Dit zou resulteren in een toegenomen gezondheids-
winst op populatieniveau en het zou bevorderen dat economische evaluaties en 
nationale vergoedingsbesluiten beter worden afgestemd op de ontwikkeling in 
de klinische praktijk richting gepersonaliseerde geneeskunde. 
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Het is zover, het boekje is af! Maar dat heb ik natuurlijk niet alleen gedaan. Er 
waren veel mensen en organisaties betrokken bij de totstandkoming van dit 
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vertrouwen die jullie mij hebben gegeven, maar bovenal voor het enthousiasme 
voor onderzoek dat jullie op mij hebben overgebracht. Beste Janneke, aan jouw 
kritische blik ontgaat niets, naast jouw deskundigheid en zorgvuldigheid is dit 
een essentiële kwaliteit als onderzoeker. Hoewel ik af en toe wel eens baalde 
na een van onze meetings omdat ik een stap terug moest, was het erg leer-
zaam en resulteerde het vaak in een sterk verbeterd eindresultaat. Nu ik terug-
kijk op het avontuur dat ze promoveren noemen, denk ik dat ik zelfs een deel 
van deze kritische blik heb overgenomen. Beste Manuela, ik heb veel bewonde-
ring voor jouw capaciteit om snel te schakelen en conceptuele manier om naar 
zaken te kijken. Hier kan ik nog veel van leren. Op die momenten dat ik graag 
te snel in de details duik, wees jij mij vaker op het grotere plaatje. Ik ben je ook 
zeer dankbaar voor de kans die jij mij hebt geboden om de laatste puntjes op 
de ‘i’ te zetten voor mijn proefschrift en me verder te ontwikkelen als onderzoe-
ker na mijn promotie. Beste Madelon, jouw kennis, betrokkenheid en motive-
rende houding zijn erg waardevol geweest. Je hebt me altijd de ruimte en 
vrijheid gegeven om mijn eigen weg te zoeken. Alhoewel ik jullie alle drie erg 
dankbaar ben voor bovenstaande, is mij een vreemd verband opgevallen dat ik 
toch even met jullie wil delen. Nadat ik bij MAASTRO CLINIC startte aan mijn 
onderzoek, waar Madelon mijn 1e aanspreekpunt was, verwisselde Madelon na 
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Dr. Thea van Asselt, Dr. Frank Hoebers en Prof. dr. Yolande Lievens wil ik 
graag bedanken voor het kritisch lezen en beoordelen van mijn proefschrift. 
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Gedurende het promotietraject zijn er veel personen geweest waarmee ik 
prettig heb samengewerkt of gewoon regelmatig een leuk praatje mee kon 
maken. De eerste 2 jaar van mijn onderzoek heb ik bij MAASTRO CLINIC ge-
werkt. Ik wil graag de collega’s van het DCM bedanken: Ann, Annette, Cary, 
Chantal, Merel, Ria, Ruud, Sylvia en later ook Iverna. Ook wil ik Bianca en 
Claudia bedanken voor de gezelligheid in de kantoortuin. Verder ben ik Piet van 
den Ende, Jos de Jong en Dirk De Ruysscher dankbaar voor hun klinische input 
en bijdrage als medeauteurs. Tevens wil ik ook de overige medewerkers (o.a. 
laboranten, onderzoekers, promovendi, artsen (in opleiding), fysici) van 
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maakte of die hebben meegewerkt aan de kwaliteit van leven studie graag 
bedanken.  
 
Fons, bedankt voor de ondersteuning in het ‘foetelen’ met data (andere mensen 
zouden het meta-analyse noemen), dit heeft mede mijn enthousiasme voor de 
kwantitatieve kant van onderzoek aangewakkerd. 
 
Hans Langendijk, Ivo Beetz en Miranda Christianen wil ik graag bedanken voor 
de Maastricht-Groningen samenwerking.  
 
Het tweede deel van mijn promotietraject was ik bij de Universiteit Maastricht 
werkzaam. Hier waren Anil en Mitchel mijn ‘roommates’. Vooral met laatstge-
noemde heeft dit tot eindeloze tafelvoetbal sessies en VVV – Ajax discussies 
geleid. Hierbij werd Mitchel meermaals (noodzakelijkerwijs natuurlijk) bijgestaan 
door mede Ajacied Arno. Ik ben nog steeds van mening dat je niet naar de 
absolute plaats op de ranglijst maar naar de relatieve prestaties van een voet-
balclub moet kijken en dat deze ook nog eens afgezet dienen te worden tegen 
de begroting. Doordat afgelopen seizoen zelfs de relatieve prestaties van VVV 
onder de maat zijn geweest, Voetballen we Voorlopig op Vrijdag in Venlo, 
echter zie ik geen Reden om ervan Uit te gaan dat dit Langer dan Een Seizoen 
duurt. Verder, Anil nu ik je weer tegenkom bij KEMTA, kunnen we definitief een 
‘Dutch Day’ invoeren. Hiernaast waren ook de bezoeken aan het ‘meidenhok’ 
van DUB30 bevolkt door: Reina, Janneke, Arianne en Cindy gezellig. Natuurlijk 
wil ik ook alle andere oud-collega’s, het zijn er te veel om op te noemen, be-
danken voor de prettige informele en/of formele samenwerking. 
 
During the 3rd year of my PhD, I visited Institut Gustave-Roussy in Paris and I 
would like to thank Béranger Lueza, Julia Bonastre, Jean-Pierre Pignon and 
Cecile Le Pechoux for the opportunities and fruitful collaboration which I hope to 
continue for many years.  
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Verder wil ik ook mijn huidige collega’s bij KEMTA bedanken voor de koffie 
momenten, inhoudelijke discussies en inspiratie de ik nodig had om mijn proef-
schrift af te ronden. 
 
Het zijn eigenlijk te veel collega’s en medeauteurs om op te noemen, maar ik 
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Een van de leuke dingen aan een avontuur is dat je het kunt delen; de (span-
nende) verhalen kunt vertellen aan familie en vrienden. Daarom wil ik ook mijn 
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steun en vertrouwen in mij. Daarnaast wil ik alle familie en vrienden bedanken 
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mogen beleven. 
Tenslotte lieve Jennifer, bedankt voor je steun, begrip en liefde zodat ik dit 
avontuur, waarin voor jou ook een grote rol was weggelegd (kijk maar o.a. naar 
de kaft), heb kunnen beleven.  
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